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ABSTRACT
Nitric oxide (NO) is a ubiquitous signaling molecule that diffuses freely
across the cell membrane to activate several cellular signaling pathways.
S-nitrosothiols (RSNO), the storehouse of NO and protein disulfide isomerase
(PDI) catalyze release of NO from RSNO under physiological conditions. The
objectives of the present study are to determine the role of NO signaling in
hypoxic vasodilatation and to develop methods for detecting NO signaling.
We studied the role of red blood cell (RBC) PDI in hypoxic vasodilation. The
data presented demonstrate that nitrite support S-nitrosation of PDI under
oxygenated conditions; also PDI has high affinity for RBC surface under
oxygenated conditions. We show interaction of PDI with hemoglobin and RBC
resident proteins like band 3 and Glutl supporting the hypothesis that PDI can
act as an acceptor of NO-equivalents from NOx-modified RBC resident proteins.
We have shown that sinapinic acid can denitrosate RSNO generating a free
thiol but it does not reduce disulfide bridges thus can be used for detecting
S-nitrosated proteins. Furthermore, we have shown that sinapinic acid detects
basal protein S-nitrosothiols and produces nearly identical S-nitrosoprotein
patterns as ascorbate in the biotin switch analysis.
Thiols are susceptible to NO-dependent and independent oxidative
modification. In this work we present a RFP-PDI-construct as a probe to monitor
thiol redox status at the cell surface. Our results show increase in RFP-PDI
fluorescence with oxidative stress. Also, RFP-PDI forms covalent mixed
disulfides with cell surface protein thiols that are susceptible to extracellular
reductants.
The decrease in synthesis and availability of NO in endothelial cells is one
of the risk factors leading to endothelial dysfunction. Our next objective was to
investigate the possible link between endothelial dysfunction and ER stress. Our
results show that under conditions of ER stress, neutral sphingomyelinase
(NSMase2) the enzyme that control plasma membrane cholesterol levels was
dysfunctional as a result of nitration of its tyrosine residues.

V

We also studied plasma membrane cholesterol and effect of ticagrelor
(AZD6140) on platelet P2Y12 receptor. Herein, we show that ticagrelor disrupts
P2Y12 receptor clustering in lipid rafts and inhibits platelet aggregation.
Interestingly, we found that differential effect of ticagrelor in normal and type-2
diabetic (T2D) platelets correlates to the differences in cholesterol levels of
platelets.
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MAP OF THE THESIS:
Nitric oxide is an endogenously produced gas that diffuses across cell
membranes and acts as a signaling molecule. One of the key mechanisms by
which NO regulates the function of various target proteins is through the coupling
of a nitroso moiety from NO-derived metabolites to a reactive cysteine leading to
the formation of a S-nitrosothiol (SNO), a process commonly known as Snitrosylation. Protein S-nitrosylation is an important post-translational modification
altering protein function. The first objective of our study was to improve currently
available method for detection of protein S-nitrosothiols i.e. biotin switch assay. In
this study, we provide an important modification that eliminates false positives in
the widely used biotin switch assay for detecting the S-nitrosoproteome.
NO signaling in hypoxic vasodilation is based on S-nitrosylation of
hemoglobin and also on RBC membrane proteins. Protein disulfide isomerase
(PDI) is the ER residing protein that functions as a redox catalyst involved in
oxidation, reduction and isomerization of disulfide bonds. Several studies have
shown association of PDI with cell surfaces (csPDI) including RBCs. However,
the physiological role of RBC surface PDI is unknown. Previous studies from our
lab have shown csPDI-catalyzed NO released from S-nitrosothiols. Given the role
of csPDI in transfer of NO, our next objective was to address whether RBC-csPDI
plays a role in transfer of NO bioactivity from RBCs. In the present study we show
S-nitrosylation of PDI and its role in hypoxic vasodilation.
Protein thiols are susceptible to oxidative modifications by reactive oxygen
species. The cell membrane thiols are more exposed to redox acting molecules
thus play key role as environmental redox state sensor. It is well established that
PDI associates with the cell surfaces and performs reduction of disulfide bonds.
The next objective was to determine whether PDI binding to mammalian cells
depend on the redox state of the extracellular thiols. Using a red fluorescence
protein tagged PDI, we demonstrated that PDI is able to sense the cell surface
redox state.
The decrease in biosynthesis and the bioavailability of NO in endothelial
cells is an important factor leading to endothelial dysfunction. Previous study from
1

our lab has also shown that NSMase2, a plasma membrane residing protein
known to regulate cellular cholesterol homeostasis becomes dysfunctional during
ER stress by S-nitrosylation. Our next objective was to determine if ER stress in
endothelial cells could lead to increase in plasma membrane cholesterol. We
observed that ER stress elevates plasma membrane cholesterol and NSMase2
becomes dysfunctional under ER stress by tyrosine nitration and S-nitrosylation.
In extention of the cholesterol studies, we also investigated the effect of
platelet cholesterol on anti-thrombotic drug (AZD6140) mediated inhibition of
P2Y12 signaling in healthy and T2D subjects. We observed differential effect of
AZD6140 on platelet P2Y12 receptor correlates to the differences in cholesterol
levels in normal and T2D subjects.

2

CHAPTER-1

General Introduction

3

1. Nitric Oxide (NO)
Several research groups in mid 1980s identified nitric oxide (NO) as
endothelial derived relaxation factor (EDRF) (Moncada et al 1986; Palmer et al
1987;lgnarro et al 1987). NO is a small lipophilic molecule that diffuses through
the cell membranes and reacts with various intracellular targets to mediate its
biological effects. It is well established that NO is a cellular signaling molecule
that regulates various cellular processes in vasculature, immune response and
neurotransmission (Bredt efa/1999; Bloodsworth etal 2000).

1.1 NO biosynthesis
Endogenous NO is synthesized by nitric oxide synthases (NOS). There are
three isoforms of NO synthase, neuronal NOS (NOS1 or nNOS), endothelial
NOS (NOS3 or eNOS) and inducible NOS (NOS2 or iNOS). All NOS isoforms
catalyze oxidation of the terminal guanidium nitrogen of L-Arginine to yield
citrulline and NO. The overall reaction requires two moles of oxygen and 1.5
moles of NADPH to generate one mole of NO (Ignarro et al 2000; Stuehr et al
1991b) (Figure 1).

H2N
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m/-OH

1 NADPH NADP*
NH
\ y
.
0,
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H,0
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0

X :
0,
K,0
coo-

N^-hydroxy-L-arginine
(NOHA)

NH2
]
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•HsN

-no

COO-

L-citrulline

Figure 1: NO synthesis from L-Arginine (Image taken from Ignarro et al

2000).
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The three isoforms of NOS exists as homodimers. Each monomer in turn
consists of N-terminal oxygenase domain and C-terminal reductase domain. The
oxygenase domain contains heme, tetrahydrobiopterin (BH4) and the arginine
binding site and the reductase domain has binding sites for calmodulin (CaM),
flavin mononucleotide (FMN), flavin adenine dinucleotide (FAD) and nicotinamide
adenine dinucleotide phosphate (NADPH) (Masters et al 1996) (Figure 2). The
binding of CaM to the reductase domain initiates transfer of electrons from
NADPH, FAD and FMN to the heme iron and BH4 in oxygenase domain
(Gachhui et al 1998). nNOS and eNOS are constitutively expressed and their
activity is dependent on Ca2+/CaM binding (Mayer et al 1989; Moncada et al
2006; Bredt et al 1990,1999). iNOS is produced in response to cytokines; since
CaM is tightly bound to iNOS, it is a Ca2+ in sensitive form and produces large
quantities of NO (Stuehr et al 1991b; Cho efa/1992).

Oxygenase domain

NH,

BHJFe/Arg

NH,"

NH,

BHJFe/Arg

BHj/Fe/Arg

Reductase domain

-COOH Neuronal NOS
161kDa

-COOH Inducible NOS
131kDa

-COOH Endothelial NOS
133kDa

Figure 2: Domain structure of NOS isoforms (Image modified from Ignarro
et al 2000).
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1.2. Vascular NO
Endothelial cells express eNOS to generate NO. The NO generated from
endothelial cells can diffuse to the vascular lumen as well as to smooth muscle
cells. However, it is suggested that the majority of NO is taken up by the vascular
lumen (Lancaster et al 1997; Butler et al 1998). NO activates soluble guanyl
cyclase (sGC) in smooth muscle cells by binding to the heme group of the
enzyme. Activated soluble guanyl cyclase (sGC) catalyzes conversion of
guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP)
(Arnold et al 1977; McNamara et al 1980). cGMP is the secondary messenger
that initiates signaling for smooth muscle relaxation by activating protein kinases
and calcium dependent potassium channels (Lincoln et al 1993; Bolotina et al
1994).
Most of the NO produced is taken up in the vascular lumen by hemoglobin (Hb) in
the red blood cells (RBC) suggesting that RBC hemoglobin acts as a sink for NO.
The higher concentration of Hb (~23mM) therefore would severely compromise
the NO mediated activation of cGMP signaling (Lancaster et al 1994). In the
vascular lumen, NO may also be oxidized to nitrite as in reaction (1)
(Ford et al 1993).

(1)

4NO + 02 + 2H20

4 N02" + 4H+

NO reacts with oxyhemoglobin (Hb-Fe(ll)-02) to form nitrate (NO3) and
methhemoglobin (Hb-Fe(lll)) as shown in (2) (Doyle et al 1981).

(2)

Hb-Fe(ll)-02 + NO

Hb-Fe(lll) + N03"

NO also rapidly reacts with deoxyhemoglobin (Hb-Fe(ll)) to form nitrosyl-Hb (HbFe(ll)NO) as shown in (3) (Eich et al 1996).

(3)

Hb-Fe(ll)+ NO * Hb-Fe(ll)-NO
6

Previous studies therefore assumed that RBCs scavenge and reduce NO
availability for vasodilation. However, later studies have suggested that the
reaction of NO with RBC-encapsulated Hb is much slower due to RBC
membrane acting as a barrier and also the RBC-free zone in the lumen would
increase NO availability for vasodilation (Butler et a/1998; Vaughn etal 2000).

1.3. RBCs and hypoxic vasodilation
The classical role of the RBC is to carry oxygen from lungs to body tissues,
which is guided by the allosteric properties of the hemoglobin inside them. The
Hb molecule exists as a tetramer composed of two a and two (3 subunits that
contain heme groups responsible for oxygen binding. The Hb tetramer exists as
two quaternary structures in equilibrium, the R-state (relaxed) and T-state
(tensed). In lungs, the blood is saturated with oxygen and Hb is in R-state or
oxygenated state whereas, when blood enters microcirculation the oxygen is
unloaded from Hb and Hb assumes T-state or deoxygenated state. Hypoxic
vasodilation is the relaxation of the vascular smooth muscle in low tissue oxygen
area to enhance oxygen delivery (Allen et al 2006). Recent work has implied that
RBCs not only sense the tissue oxygen status by deoxygenation of the Hb but
also could couple this to the release of vasodilatory molecules such as NO, Snitrosothiols and ATP to increase the blood flow in tissues under hypoxia (Jia et
al 1996; Ellsworth et al 1995; Cosby et al 2003). Three main hypotheses were put
forward for RBC mediated hypoxic vasodilation and common to all of them is
deoxygenation of Hb: 1- ATP release from RBC (Ellsworth et al 1995, 2000) 2The release of NO from S-nitrosylated hemoglobin (SNO-Hb) (Jia et al 1996) and
3- Reduction of nitrite to NO (Cosby et al 2003; Huang et al 2005).

1.3.1. ATP release from RBCs
Previous studies have reported that RBCs contain millimolar quantities of
ATP and, in response to hypoxia, RBCs release ATP (Miseta et al 1993;
Ellsworth et al 1995; Sprague et al 1996). ATP once released into the vascular
lumen binds to P2Y receptor on endothelial cells and activates eNOS leading to
7

vasodilation via NO production (Ellsworth et al 2000, 2004) (Figure 3). It has
been shown in rabbit and human erythrocytes that release of ATP is by activation
of heterodimeric G-proteins that activates adenyl cyclase (Olearczyk et al 2004).
Further studies have shown that release of ATP from RBCs is by a signal
transduction pathway mediated by cAMP-dependent protein kinase A (PKA) in
RBC surface. The increased levels of cAMP activate PKA that in turn
phosphorylates and activates cystic fibrosis transmembrane conductance
regulator (CFTR) that facilitate the movement of ATP out of RBCs (Sprague et al
1998). It was also shown that when deoxy Hb binds to band 3 protein, the
glycolytic regulatory subunits are dislodged increasing glycolysis (Campanella et
al 2004). Thus, stimulation of glycolysis causes accumulation of ATP in RBCs.
Increased skeletal muscle blood flow was coupled to elevated plasma ATP in
exercising humans, further suggesting that ATP release is coupled to Hb oxygen
saturation for inducing vasodilation (Gonzalez-Alonso et al 2002).

A
Smooth Muscle

RBCs

Endothelial Cell
Layer

8

B

Deoxy RBC

T

Figure 3: RBC mediated hypoxic vasodilation by ATP release (Image
modified from Halpen eta/2011).
A-The diagram shows cross section of blood vessel. The lumen contains plasma,
RBC and other blood components; the inner layer surrounding the lumen consists
of endothelial cells followed by smooth muscle cells. B- Under hypoxic conditions
deoxygenated RBC release ATP. The released ATP binds to P2Y receptor on
endothelial cells and induces Ca2+ influx that in turn activates eNOS. The
activated eNOS synthesizes NO that diffuses to smooth muscle cell and cause
vasodilation.

1.3.2. S-nitrosothiols
Thiols readily react with NO in vivo to form S-nitrosothiols (RSNO). Previous
studies have shown that RSNO are more stable than NO itself and therefore act
as storehouse for NO (Girard et al 1993). Moreover, it has also been shown that
9

RSNO are vasorelaxants like NO, and can react with protein thiols under
physiological conditions to form S-nitrosoproteins. S-nitrosoalbumin accounts for
~82% of plasma S-nitrosoproteins suggesting that serum albumin serves as
reservoir for NO (Stamler et al 1999a, 1999b). The formation of S-nitrosoalbumin
is via N2O3 that is a strong nitrosating agent. RSNO synthesis in vitro is by
reaction of thiols (RSH) with nitrous acid (HNO2) at lower pH (<3).

(4)

RSH +HN02-» RSN0+H20

However, protein nitrosothiols can be synthesed in vivo by transnitrosation
reaction involving transfer of an NO moiety from one intracellular thiol to another.

(5)

RSNO+R'SH (Protein) *R'SNO (Protein)+ RSH

N2O3 is the primary nitrosating agent under physiological conditions. As

suggested by Liu et al (1988a) both NO and O2 are concentrated in the
hydrophobic compartments of the cell, significantly accelerating NO oxidation and
N2O3 formation.

(6)

2NO +02

2N02

N02 is capable of reacting with other NO molecule forming N2O3 or it may react
with NO2 forming dinitrogen tetroxide (N2O4) (Fukuto et al 2000).
(7)

NO +N02

N2O3

(8)

NO2+NO2

N2O4

Both N203 and N2O4 are nitrosating agents that can transfer an NO moiety to
nucleophilic species such as thiols as in reactions (9-10) (Keshive et al 1996).
However, in aqueous conditions N203 and N204 are hydrolysed and therefore
nitrosation reactions compete with hydrolysis of water (11-12) (Gobert et al 1999;
Fukuto et al 2000).
(9)

N2O3+RSH

RSNO + N02" + H+
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RSNO + NOa" + H+

(10)

N204+RSH

(11)

N2O3+H2O * 2N02" + 2H+

(12)

N204+H20* N02" + N03"+ 2H+

Previous studies have suggested three possibilities for S-nitrosoalbumin
mediated NO transfer (Figure 4). (1) Albumin is the abundant protein in the
vasculature and acts as sink for NO (Stamler et al 1994). (2) NO and O2 in the
hydrophobic pockets of the albumin leads to the formation of N2O3. (3) The
albumin N2O3 can transfer NO+ directly to the low molecular weight thiols or via its
Cys34 or Try 214 residue by transnitrosation. Thus the NO bioactivity in
vasculature is preserved and transferred to other thiol containing proteins via
transnitrosation reaction (Rafikova et al 2002).
RS-NO RSH

RS-NO

albumin

Figure 4: Albumin N203 mediated RSNO formation and preservation of NO
bioactivity in vasculature (Image taken from Rafikova eta!2002).
Albumin N203 can transfer NO+ to low molecular weight thiols (RSH) by l-Direct
transnitrosation of RSH, II- Transfer of NO+ and transnitrosation of RSH from
Cys24, Ill-Transfer of NO+ and transnitrosation of RSH from Try214.

1.3.3. SNO-Hb Hypothesis
SNO-Hb Hypothesis is the first theory that directly connects the allosteric
properties of Hb with oxygen sensing and vasoactivity of RBC. According to this
theory, Hb assumes the R-state upon oxygenation in lungs and a fraction of
HbNO is transferred from heme to the Cys93 residue on the p-chain of Hb to form
11

SNO-Hb. Upon transition of Hb from the R-state to the deoxygenated T-state, the
NO bioactivity is released from SNO-Hb (Stamler et al 1994; Jia et al 1996)
(Figure 5). X-ray crystallography studies have demonstrated that the formation of
(3cys93-SNO disrupts the intra-subunit salt bridge between Hisp-146 and Aspp94
(Gow et al 1998).
In the R-state the pCys93 residue is in hydrophobic pocket and protected
from solvent hence it is highly stable. However, upon R- to T-state transition the
NO group is reoriented to the solvent phase and available for transnitrosation of
thiol-containing proteins. Further studies demonstrated that the export of NO
bioactivity from RBC is via interaction of deoxy Hb with the aminoterminal
cytoplasmic domain of band 3/AE1. This domain of band 3 has two cysteine
residues surrounded by amino acids that constitute the S-nitrosylation motif. The
interaction of deoxy Hb with band 3 allows transfer of NO group from SNO-Hb to
the reactive cysteine of band 3 at RBC membrane. The preferential transfer of
NO bioactivity by transnitrosylation to the RBC membrane cytosol interface was
demonstrated (Pawloski et al 2001, 2002). From the RBC membrane, NO
bioactivity could be transferred to glutathione (GSH) via transnitrosation. The
transit of NO bioactivity from either nitrosogluthathione or nitrosated band 3 into
the vessel wall could mediate vasodilation (Jia etal 1996; Sonveaux et al 2007).
Biochemical studies further confirm the NO transfer from heme to pCys93
resulting in SNO-Hb formation and mutation of Cys-Ala at (393 resulted in
nitrosylated heme accumulation (Gow et al 1998). However, a recent study in
transgenic mice expressing human wild type Hb or human Hb where (3Cys93 was
mutated to Ala showed that pCys93 is not essential for hypoxic vasodilation. The
animals with pCys93 to pAla93 mutation develop normally and induce hypoxic
vasorelaxation ex-vivo (Isbell et al 2008).
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Figure 5: Proposed

SNO-Hb

pathway

for

RBC mediated

hypoxic

vasodilation (Image modified from Halpen et al 2011).
Blood is oxygenated in lungs and Hb assumes the R-state, NO from heme
groups is transferred to f3Cys93 residue to form SNO-Hb. In the R-state SNO-Hb
is highly stable and protected in the hydrophobic pocket. Transition from the Rstate to the T-state, promote SNO-Hb interaction with thiols in RBC membrane
proteins such as band 3 and NO bioactivity is exported via transnitrosation. Small
molecular weight thiols such as GSH or albumin could transport the NO
bioactivity from band 3 to the vessel wall and induce vasodilation.

1.3.4. Nitrite reduction hypothesis
The nitrite reduction hypothesis couples the oxygen sensing by RBCs with
reduction of nitrite to generate NO. Both oxy and deoxy Hb can react with nitrite,
however, the reaction of deoxy-Hb with nitrite produces NO for vasodilation. The
nitrite-induced vasodilation involves transport of nitrite to RBCs, reaction of nitrite
with deoxy-Hb, transport of NO bioactivity from RBCs and finally vasodilation
(Doyle et al 1981; Cosby et al 2003; Nagababu et al 2003) (Figure 6).

(13)

4Hb-Fe(ll)-02 + 4N02' + 4H+

(14)

Hb-Fe(ll) +N02" +H+

(15)

Hb-Fe(ll) + NO

4Hb-Fe(lll) + 4N03"+2H20+02

Hb-Fe(lll) + NO + OH'

Hb-Fe(ll)-NO

Nitrite enters the RBC by a mechanism probably involving diffusion through
a channel or as nitrous acid (HNO2). Inside RBCs the concentration of nitrite is
regulated by its reaction with oxy-Hb, establishing a diffusion gradient across the
membrane (13). Under deoxygenated conditions accelerated consumption of
nitrite results in NO bioactivity (14). It is also suggested that deoxy-Hb binds to
band 3 and exports the NO bioactivity at the RBC membrane-cytosol interface
(Vitturi et al 2009). Further studies have shown that the nitrite reductase activity is
under allosteric control and maximum nitrite reduction occurs at 50% oxygen
saturation (Huang et al 2005; Crawford et al 2006). It is also reported that the
nitrite reductase pathway leads to the formation of N203 via the reaction of nitrite
bound methemoglobin with NO to generate N203. The strong nitrosating and
lipophilic agent N203 can nitrosate thiols and NO bioactivity is exported outside
RBCs (Robinson et al2005;Gladwin ef a/2006; Basu etal2007).
Experiments with nitrite infusion in humans support the nitrite induced
vasodilation hypothesis and escape of NO bioactivity from RBCs (Cosby et al
2003; Maher et al 2008). Proteins such as xanthine oxidoreductase were shown
to reduce nitrite to NO there by contributing to physiological nitrite-induced
vasodilation (Webb et al 2008).
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Deoxy RBC

Figure 6: RBC nitrite reduction pathway and hypoxic vasodilation (Image
modified from Halpen eta/2011).
Nitrite entering RBCs reacts with both oxy- and deoxy-Hb. The reaction with OxyHb generates nitrate and met-Hb. The reaction of deoxy-Hb with nitrate is favored
at 50% oxygen saturation generating NO and met-Hb. The generated NO
escapes out of RBCs and induces vasodilation. NO may also react with nitritemet-Hb intermediate generating N2O3 that further nitrosate thiols or release NO.
The formation of N203 explains NO bioactivity efflux pathway from RBCs.
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2. Protein disulfide Isomerase (PDI)
Protein disulfide isomerase was first isolated and characterized from bovine
liver microsomes (Goldberger et al 1963; De Lorenzo et al 1966). PDI is primarily
localized in the lumen of endoplasmic reticulum (ER) (Akagi et al 1988). In ER,
PDI is involved in protein folding, and in disulfide bond formation, cleavage and
rearrangement. PDI is also reported in non-ER locations on the surface of various
cell types where its function is associated with its redox properties (Turano et al

2002).
2.1. Domain structure of PDI
PDI is a multi-domain protein composed of four thioredoxin like domains (a,
b, b', a') and a c-domain (Figure 7). The a and a' domains show homology to
thioredoxin domains and contain the catalytically active sequence Cys-Gly-HisCys (Darby et al 1996; Ferrari et al 1999). The b and b' domains resemble
thioredoxin modules but do not contain the active sequence and thus lack activity
(Ferrari et al 1998; Kemmink et al 1999). The c-domain is located at the carboxy
terminus of the protein. It contains a negatively charged sequence and
contributes to the Ca2+ binding properties of PDI. Following the c-domain is the
KDEL sequence that is the ER retention signal of PDI (Macer et al 1988;
Kemmink et al 1997).
The crystal structure of yeast PDI revealed that the molecule exists in a
twisted U-shape. The a and a' domains are at the end of 'U' with the catalytic
sites of the domains facing each other and b and b' domains occupy the base of
'U'. The interaction of misfolded protein is facilitated by the hydrophobic residues,
which are towards inner surface of 'U\ The active sites separated by 28A° can
accommodate ~100 residues of a protein (Tian et al 2006).
The NMR and crystal studies of b and b' domains of the human and yeast
PDI have shown that these domains have hydrophobic patches. These
hydrophobic patches in the b and b' domains along with the a and a' domain
hydrophobic residues form a surface/platform for binding of misfolded proteins
(Kemmink et al 1996, 1997). Further studies on the b and b' domains have shown

the key role of the b' domain in substrate binding; and mutations of this site were
associated with reduced binding affinity for small petides. The b domain is
proposed to play a structural role such as ensuring the right orientation of
catalytic and substrate binging sites in the other three domains (Pirneskoski et al
2004; Koivunen et al 2005; Tian et al 2006). Previous studies on the c-domain of
PDI have revealed that it is not essential for the enzymatic functions of PDI
(Koivunen et al 1999).

2.2. Physiological role of PDI
PDI is one of the most abundant proteins in ER and constitutes up to ~0.8%
of the total cellular protein (Freedman et al 1994). The redox state of the ER is
more oxidizing compared to the cytosol. The ratio of GSH to GSSG in the ER is
around 2:1 whereas the ratio is 100:1 in the cytosol (Hwang et al 1992). Thus,
PDI equilibrates between oxidized and reduced forms. Based on its redox state,
PDI is capable of catalyzing oxidation, reduction and isomerization. PDI in a
reduced state can perform reduction or isomerization of disulfide bonds. In the
isomerization reaction, there is no net change in the redox state of PDI. Oxidized
PDI catalyzes the oxidation of protein thiols (Wilkinson et al 2004) (Figure 8).
PDI-catalyzed isomerization converts misfolded disulfide bonds to their properly
folded forms. The reaction is initiated by the active site (CGHC) cysteine of PDI at
its N-terminus resulting in formation of a mixed disulfide between PDI and its
substrate (Schwaller et al 2003).
PDI promotes the folding of nascent proteins and refolding of misfolded
proteins thus the PDI chaperone system reduces protein aggregation. PDI
chaperone activity does not require the CGHC active sequence and is
independent of its isomerase activity. The C-terminal peptide-binding site
mediates the chaperone activity of PDI. Studies in E.coli expressing a mutant
form of PDI with C-terminal deletion have shown no chaperone or peptide binding
abilities. PDI is a chaperone for a variety of target proteins such as Dglyceraldehyde-3-phosphate dehydrogenase (GAPDH), lysozyme and acidic
phospholipase A2 (Dai et al 1997; Wang et al 1998).
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Figure 7: Domain structure of PDI (Image taken from Gruber et al 2006)
(a) Schematic overview of PDI domain structure: PDI has five domains and a
linker sequence organized in the order abb'xa'c. Domain boundaries indicated
are based on the yeast crystal structure. Shown in a separate box are the active
site domains and border residues of human (top) and yeast (bottom).
(b) Ribbon diagram of PDI: PDI has twisted U-shape. The b (dark blue) and b'
(light blue) domain are at the bottom of the 'U' and a (orange) and a' (yellow) at
the end of 'U\ The active sites CxxC (green) on a and a' domains face each other
but are separated by a large cleft. The a and a' domains are more flexible
compared to the b and b' domains that form a rigid platform. The linker region (x)
between domains b' and a' is shown in black. The C-domain with ER retention
signal (KDEL) is in red.
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Reduction

Oxidation
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Figure 8: Redox reactions driven by PDI (A) Reduction (B) Oxidation
(C) Isomerization.
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2.3. Cell Surface PDI
PDI is located primarily in the ER lumen, as it contains the carboxyl-terminal
ER retention sequence. However, several studies have shown PDI on the surface
of wide variety of cell types including pancreatic cells (Akagi et al 1988;
Yoshimori et al 1990), B cells (Kroning et al 1994; Tager et al 1997), hepatocytes
(Terada et al 1995), platelets (Chen et al 1995; Essex et al 1995), endothelial
cells (Hotchkiss et al 1998), leukocytes (Bennett et al 2000) and platelet derived
microparticles (Raturi et al 2008). Proteomic studies in RBCs have identified
membrane associated PDI but the physiological role of PDI in RBCs is largely
unknown (Alloisio et al 1996; Low et al 2002; Essex et al 1995; Goodman et al
2007).
The association of PDI with cell membranes is through electrostatic
interactions (Terada et al 1995, Yoshimori et al 1999). Although PDI has an ER
retention signal, a possible mechanism by which it escapes ER is by its
association with other secretary proteins or removal of the ER retention signal
(Johnson et a/2001). The cell surface localization of PDI implies that it could play
a role in variety of physiological process.
2.4. Identified roles of cell surface PDI (csPDI)
csPDI is reported to control the redox state of exofacial thiols. It was shown
in HT1080 fibrosarcoma cells that over expression or under expression of PDI
correlates with an increase or decrease in cell surface PDI, respectively. The cell
surface PDI levels affect the expression of thiol containing proteins on the cell
surface (Jiang et al 1999). However, inhibition of PDI by anti-PDI antibodies
correlates with an increase in cell surface thiols in B cell chronic lymphocytic
leukemia (B-CLL) cells. The increased levels of exofacial thiols were reported in
conditions like lymphocyte activation and leukemia (Lawrence et al 1996; Tager
et al 1996).
The cell surface thiols are also involved in cellular adhesion and a direct role
for csPDI in regulating leukocyte cell adhesion has been reported. L-selectin is a
cell membrane protein involved in leukocyte recruitment to inflammatory sites.

Upon leukocyte activation, the L-selectin undergoes proteolytic cleavage resulting
in loss of L-selectin dependent adhesive properties. csPDI maintains the reduced
state of L-selectin and is resistance to proteolytic cleavage. Blocking of csPDI
with anti-PDI antibodies or phenyl arsenic oxide (PAO) promotes L-selectin
shedding independent of leukocyte activation (Bennett et al 2000). Similarly,
reduced activity of csPDI was also reported in the case of the thyroid stimulating
hormone receptor on thyrocytes. csPDI catalyzed reduction of disulfide bonds
between a and (3 subunit of the receptor resulted in shedding of a subunit (Couet
et al 1996).
Previous studies have shown the crucial role of csPDI in the transport of
RSNO-bound NO to intracellular compartments. It was also shown in the same
study with human erythroleukemia (HEL) cells that a decrease in csPDI
correlated with decreased surface thiol levels, supporting the notation that csPDI
maintains the redox state of exofacial thiols (Zai et al 1999). Later studies have
shown that csPDI catalyzes release of NO from RSNO. It was shown in HT1080
fibrosarcoma cells that transport of extracellular RSNO-bound NO correlated with
csPDI levels. A model was proposed for PDI-mediated nitrosation of intracellular
thiols. csPDI catalyzes release of NO from RSNO that accumulates at the cell
membrane and reacts with 02 to form N203 that in turn can nitrosate intracellular
thiols (Liu et al 1998; Nedospasov et al 2000).
In

support

of

this

hypothesis

pretreatment

of

cells

with

a-

tocopherol decreased the transfer of RSNO-bound NO in human umbilical vein
endothelial cells (HUVECs), suggesting accumulation of N203 (Ramachandran et
al 2001) (Figure 9). Further studies have confirmed csPDI-mediated transfer of
NO from extracellular S-nitrosoalbumin to the endothelial metal-binding protein
metallothionein. Transnitrosation of metallothionein by SNO-albumin was shown
to be sensitive to csPDI inhibition (Zhang et al 2006; Li et al 2011). A similar role
of csPDI in NO delivery from extracellular RSNO was shown in a megakaryocyte
cell line (MEG-01) and the effect was blocked by treatment with PDI inhibitors
(Shah et al 2007).
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Figure 9: Proposed mechanism for csPDI mediated NO transport from
extracellular RSNO (Image taken from Ramachandran ef a/2001)
csPDI catalyzes release of NO from RSNO. The released NO accumulates in the
membrane and reacts with 02 to produce N203. Intracellular thiols get nitrosated
at membrane-cytosol interface by N203.
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The role of csPDI in pathological events is well documented. Human
immunodeficiency virus (HIV) entry is mediated by binding of viral glycoproteingp120 to the CD4 receptor of the cell. The conformational change in gp120
followed by gp41 insertion into the cell membrane results in fusion of viral
envelope to the host cell. csPDI interact with gp120 at CD4 binding site and
reduces disulfide bonds (Figure 10). The PDI dependent reduction of gp120
disulfides was shown to be crucial for viral entry. Inhibition of virus entry by
inhibiting PDI was also demonstrated. Carbohydrate binding agents (CBAs) and
auranofin that inhibit Thioredoxin (TrxR1) were also reported to inhibit gp120
disulfide reduction and viral entry (Barbouche et al 2003; Reiser et al 2012).
Similarly, csPDI has been shown to reduce disulfide bonds of diphtheria toxin
resulting in chain separation and increased cytotoxicity in host cells (Mandel et al
1993). Cholera toxin disassembly was also mediated by PDI (Taylor et al 2011).
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(a)

(b)

PDI-induced conformational changes in gp120
Figure 10: csPDI mediated disulfide reduction of gp120 (Image taken from
Ryser et al 2005)
a) csPDI binds to the D3 domain of CD4 receptors on the cell membrane. CD4
receptor also binds to gp120 via its D1 domain. The disulfide bonds of gp120 are
intact and gp41 in its native conformation, b) PDI in contact with gp120 at CD4gp120 binding site reduces the disulfide bond resulting in conformational change
of gp120 and gp41 followed by the N-terminal fusion peptide (Fp) of gp41 being
inserted to host cell membrane.
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3. Sphingomylinases
Sphingomyelin (SM) accounts for approximately 10-15% of total cellular
phospholipids and is the major building block of the plasma membrane of
mammalian cells. Sphingomyelin is also present in subcellular sites such as
lysosomes, mitochondria, microsomes and nuclei. The majority of sphingomyelin
is on the outer leaflet of the plasma membrane in tight hydrophobic association
with cholesterol (Simons et al 1997; Kallen et al 1994). The biochemical
synthesis of sphingomyelin is catalyzed by sphingomyelin synthase (SMS) that
transfers the phosphocholine moiety of phosphatidylcholine to ceramide
producing sphingomyelin and diacylglycerol (Ullman et al 1974; Marggraf et al
1984). Two isoforms (SMS 1 and SMS 2) of sphingomyelin synthase exists that
are associated with the trans-Golgi apparatus and the plasma membrane,
respectively (Futerman et al 1990; Kallen et al 1994). Sphingomyelinases
(SMases) hydrolyze membrane sphingomyelin to ceramide and phosphocholine
(Figure 11). The hydrolysis of sphingomyelin to ceramide results in disruption of
sphingomyelin and cholesterol interaction and creation of ceramide rich
microdomains. Ceramide is a second messenger that mediates various cellular
functions such as proliferation, differentiation and apoptosis (Hannun et al 1999).
SMS regulates signal transduction pathways at the level of plasma membrane by
decreasing ceramide levels. Thus both SMS and SMases act as switches
regulating cell-signaling pathways (Van Blitterswijk et al 2003; Milhas et al 2010).
Different isoforms of SMases have been reported that are classified
depending on their localization, optimum pH and cation dependence. The five
different isoforms are: acidic SMases that are Zn2+ independent and dependent,
alkaline SMase and neutral SMases that are Mg2+ independent and dependent
(Mizutani et al 2001; Goni et al 2002). Alkaline SMases are expressed in the
intestine and are Mg2+ independent and their deficiency is related to colon
carcinogenesis. Acid and neutral SMases are expressed in endosomal-lysosomal
compartments and the plasma membrane respectively (Wiegmann et al 1994).
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3.1. Acid Spingomyelinases (ASMases)
Based on their localization, ASMase are further divided into secretory
sphingomyelinase (S-SMase) and lysosomal sphingomyelinase (L-SMase). LSMase as the name indicates is a lysosomal enzyme with optimum activity at pH
4-5 and deficiency causes Niemann-Pick disease characterized by accumulation
of sphingomyelin (Horinouchi et al 1995; Goni et al 2002).
Previous studies have shown that the TNF receptor or CD95 triggers
translocation of ASMase the to extracellular leaflet of cell membrane via direct
fusion of lysosomes to the plasma membrane of cell. The ASMase at plasma
membrane results in ceramide-rich platform from sphingomyelin and triggers
apoptosis (Gulbins et al 2003; Jin et al 2008). Both L-SMase and S-SMase are
zinc-dependent enzymes. S-SMase is implicated in the aggregation of lowdensity lipoprotein (LDL) particles through metabolism of sphingomyelin bound to
lipoprotein (Schissel et al 1998; Devlin etal 2008).

3.2. Neutral Sphingomyelinases (nSMase)
Neutral sphingomyelinases require millimolar concentration of Mg2+ or Mn2+
for their activity and have a pH optima near 7. Currently, three different NSMase
isoforms are reported: nSMasel (SMPD2), nSMase2 (SMPD3) and nSMase3
(SMPD4) that posses in vivo NSMase activity (Goni et al 2002; Wu et al 2010).

3.2.1.Neutral Sphingomyelinase 1 (nSMase 1)
NSMasel was first cloned and identified in 1998 as a Mg2+ dependent
enzyme that is localized in the nucleus, ER and Golgi. Human nSMasel is a 47.6
kDa protein containing 423 amino acid residues. nSMasel is an integral
membrane protein with two adjacent transmembrane domains at its C-terminus.
(Tomiuk et al 1998, 2000). Further studies have shown that reactive oxygen
species (ROS) reversibly inhibit the enzyme activity and NO-derived oxidant
peroxynitrite irreversibly inactivates NSMasel (Fensome et al 2000; Josephs et
al 2002). It was also shown that nSMasel generates ceramide in response to
stress. Consistent with this, it was shown in T-cell hybridoma (3DO) cells that
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inhibition of nSMasel resulted in decreased ceramide levels and reduced T-cell
receptor mediated apoptosis (Tonnetti et al 1999).

nSMase 1, 423 AA
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TM TM
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Figure 12: Domain architecture of human NSMase isoforms (Image taken
from Wu ef al 2010)
HD-hydrophobic domain; MB- Mg2+ binding domain; PR-Proline rich doman; TMtransmembrane domain; ER-Endoplasmic reticulum localization motif.
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3.2.2. Neutral Sphingomyelinase 2 (nSMase 2)
Human nSMase2 was first cloned in 2000; it is a 655 amino acid protein
with a predicted molecular weight of 71kDa. nSMase2 is an integral membrane
protein located in the inner leaflet of plasma membrane.(Hofmann et al 2000;
Tani et al 2007). It has two N-terminal hydrophobic segments integrated into the
plasma membrane, a C-terminal catalytic domain and a 200-residue collagen-like
triple helices between N- and C- terminus. nSMase2 was reported to be
palmitoylated at two cysteine clusters, one cysteine clusters was located in
catalytic domain and the other between the two hydrophobic segments (Figure
12). The palmitoylation was important for plasma membrane localization and
stability of nSMase2 (Tani et al 2007). Increased in vivo enzyme activity with
overexpression of nSMase2 was shown in primary hepatocytes and MCF-7 cells
as evidenced by a decrease in cellular sphingomyelin levels and a concomitant
increase in ceramide (Marchesini etal 2003; Karakashian et al 2004).
Recent studies in human airway epithelial cells have shown that nSMase2 is
the only SMase that is activated under oxidative stress where nSMase2 protein
stability and expression levels are regulated by phosphorylation (Filosto et al
2012). nSMase2 plays a major role in stress induced ceramide production. It has
been shown in human airway epithelial cells that nSMase2 is upregulated by
H202 leading to formation of ceramide and induction of apoptosis (Levy et al
2006). Previous studies in MCF-7 cells have shown confluence induced
upregulation and translocation of nSMase2 to the plasma membrane. The
upregulation of nSMase2 resulted in hypophosphorylation of retinblastoma tumor
suppressor protein and regulation of cyclin dependent kinases, leading to cell
cycle arrest in G0/Gi phase (Marchesini et al 2004).
nSMase2 is activated in response to TNF-a suggesting a role in the
inflammatory response. nSMase2 is activated exclusively through TNF receptor-1
(TNFR-1). The nSMase activation domain (NSD) in TNFR-1 serves as a binding
site for factor associated with neutral sphingomyelinase activation (FAN) that is
an adaptor protein. FAN binds to the TNFR1 cytoplasmic domain and recruits
RACK1 (Adam-Klages et al 1996; Tcherkasowa et al 2002). TNF induces

translocation of embryonic ectoderm development (EED) from nucleus to plasma
membrane where it binds to RACK1 and the catalytic C-terminal domain of
nSMase2. The activation of nSMase2 induces sphingomyelin hydrolysis and
ceramide production (Philipp et al 2010). Activation of nSMase2 was suggested
to participate in the execution phase of apoptosis in response to TNFR signaling.
Further studies in scrambling-competent Jurkat T and deficient Raji B cells have
shown that ceremide generated from sphingomyelin that is initially located in the
outer leaflet of the plasma membrane. Upon flipping of plasma membrane in the
lipid scrambling process, the sphingomyelin flips to the inner leaflet of plasma
membrane in a manner parallel to phosphatidylserine exposure to the outer cell
leaflet followed by phagocytosis by macrophages (Tepper et al 2000). Studies
with TNF-a induced activation of mutant TNFR1 have shown that the role of
nSMase2 in activating caspase-3 and subsequent induction of apoptosis is
dependent on FAN adaptor protein (Neumeyer et al 2006).
TNF-a increased nSMase2 activity in various cell types including smooth
muscle cells, A549 lung epithelial cells and HUVECs. In A549 cells TNF-a not
only increased nSMase2 activity but also induced relocalization of nSMase2 to
the plasma membrane in a manner in a manner dependent on p38 MAPK (Clarke
et al 2007, 2008).
3.2.3. Neutral Sphingomylinase 3 (nSMase 3)
nSMase 3 was isolated from cytosol of HL-60 cells and does not require
Mg2+ for the enzyme activity. It is a 53-kDa protein that possesses very little
homology to nSMasel and nSMase2 (Okazaki et al 1994). Previous studies have
shown that NSMase3 posseses both in vitro and in vivo enzyme activity. In MCF7 cells it was shown that transient or stable expression of nSMase3 modulates
levels of sphingomyelin and ceramide (Krut et al 2006). nSMase3 is a Cterminally-anchored membrane protein with an N-terminal proline rich region that
mediates protein-protein interactions and an ER retention signal at the Cterminus.
TNF-a was reported to activate nSMase3 in MCF-7 cells. FAN is an adaptor
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protein that binds to the TNF receptor cytoplasmic domain and activates nSMase.
The activation of nSMase3 was completely impaired by expression of dominant
negative FAN in MCF-7 cells, suggesting that nSMase3 acts downstream of the
TNF-a signaling pathway (Corcoran et al 2008).

3.3. Cholesterol
Several studies have shown that cholesterol and sphingomyelin are
enriched in the plasma membrane of mammalian cells. A large proportion (6080%) of the cellular unesterified cholesterol is in the plasma membrane of cells
and cholesterol constitutes 30-40% of the total lipid molecules in the plasma
membrane (Lange et al 2000; Maxfield et al 2002). The molecular structure of
cholesterol has four fused hydrocarbon rings, a flexible iso-octyl hydrocarbon
chain at carbon 17 and a hydroxyl group located at carbon 3. Plasma membrane
cholesterol is unesterified and the free C-3 hydroxyl group of cholesterol is
involved in hydrogen bonding with the sphingosine moiety of sphingomyelin in the
plasma membrane (Cremesti et al 2002; Olsen et al 2009).
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Figure 13: Structure of cholesterol (Image taken from Olsen et al 2009)
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3.3.1. Cholesterol biosynthesis
Cholesterol is synthesized from acetyl-CoA and acetoacetyl-CoA in a
series of steps involving various intermediates and enzymes. The first step in
cholesterol biosynthesis is the thiolase-catalyzed condensation of two molecules
of acetyl-CoA to form acetoacetyl-CoA. HMG-CoA synthase catalyses the
condensation of acetoacetyl-CoA with a third acetyl-CoA to yield the 6 carbon
compound (3-hydroxy-acetyl-|3-methylglutaryl-CoA (HMG-CoA). In the next step
HMG-CoA is reduced to mevalonate by HMG-CoA reductase, an anchored
membrane protein of ER. The reaction catalyzed by HMG-CoA reductase is the
rate-limiting step in cholesterol biosynthesis. Previous studies have shown that
inhibiting cholesterol biosynthesis at the rate-limiting step can induce cell death.
The cells deficient in HMG-CoA reductase do not survive even when supplied
with exogenous cholesterol, indicating that mevalonate and subsequent
intermediates are essential (Mosley ef a/1983; Liscum ef a/2002).
Mevalonate is converted into activated isoprene units in the second step.
Mevalonate is phosphorylated by mevalonate kinase and phosphomevalonate
kinase yielding 5-pyrophosphomevalonate. ATP dependent decarboxylation of 5pyrophosphomevalonate by mevalonate-5-pyrophosphate decarboxylase gives
the

first activated

isoprene

molecule isopentenyl

pyrophosphate

(IPP).

Isopentenyl diphosphate delta isomerase catalyzes the conversion of IPP to the
more reactive isoprene dimethylallyl pyrophosphate (DMPP).
In the third step, six 5-carbon isoprene units condense to form 30-carbon
squalene. One molecule of IPP condenses with one DMPP to generate the 10carbon geranyl pyrophosphate (GPP). GPP further condenses with one IPP
molecule to generate the 15-carbon intermediate farnesyl pyrophosphate (FPP).
Squalene synthase catalyzes condensation of two molecules of FPP to generate
the 30-carbon squalene. Squalene cyclization occurs in two steps. Squalene
monooxygenase catalyses addition of molecular oxygen to squalene generating
2,3 squalene epoxide followed by oxidosqualene cyclase-mediated cyclization to
yield lanosterol. Finally, the conversion of lanosterol to cholesterol is a multistep
process (Nelson and Cox, 2008).
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3.3.2. Cholesterol homeostasis
Although cholesterol is primarily synthesized in the ER, the ER cholesterol
content is only 0.5-1.0% of total cellular cholesterol. Cholesterol biosynthesis is
regulated at number of points and is sensitive to the existing intracellular
cholesterol levels (Lange et al 1999). Cholesterol homeostasis is maintained by
complex mechanisms involving synthesis, storage, uptake and efflux (Maxfield et
al 2005). In normal cells, cholesterol is rapidly distributed after synthesis with the
highest cholesterol content in plasma membrane and the lowest in ER. Golgi has
intermediate cholesterol content to ER and plasma membrane with an increase in
cholesterol content from the cis to trans Golgi compartments (Blanchette-Mackie
et al 2000). The transport of de novo synthesized cholesterol from ER to plasma
membrane is energy dependent with a half time of ~10min (DeGrella et al 1982;
Kaplan etal 1985).
Cholesterol homeostasis is controlled by a protein regulatory system that
senses the cellular cholesterol content. The best-studied protein sensor is sterol
regulatory element binding protein (SREBP) that is embedded in the ER
membrane. SREBP have three domain N- and C-terminal domains facing the
cytosol and a central membrane-spanning domain separated by a hydrophilic
loop that extends into the lumen. SREBPs are involved in activating genes that
upregulate cholesterol synthesis and uptake. SREBPs are released from
membrane following two proteolytic cleavages by site-1 protease (S1P) and site2 protease (S2P). The cleavage of SREBP by S1P is dependent on SREBP
cleavage activating protein (SCAP) that contains a sterol-sensing domain. When
cholesterol levels are high, the SREBP-SCAP complex remain in the ER
membrane and is not proteolyzed to mature SREBP. However, when cellular
cholesterol levels fall, the SREBP-SCAP complex translocates from the ER to the
Golgi where it is cleaved by S1P and S2P proteases to produce mature SREBP.
The mature SREBP translocates to the nucleus and binds to sterol regulatory
element (SRE) sequences there by enhance target gene transcription (Nohturfft
et al 2000; Liscum et al 2002).
Lipid rafts are liquid-ordered sphingomyelin and cholesterol-enriched
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microdomains within plasma membrane of cells. Any change in the ratio of
cholesterol:SM (1:1) or SM content in plasma membrane alters cholesterol
synthesis and transport. An increase in cholesterol concentration in rafts would
result in increased cholesterol in liquid disordered-phase. The excess of
cholesterol moves back to the ER thus increasing cholesterol esterification and
blocking the

translocation of SREBP-SCAP

complex

to Golgi thereby

downregulating cholesterol synthesis (Slotte etal 1988; Scheek et al 1997).
Apart from de novo synthesis, cellular cholesterol is also derived from
uptake by lipoproteins: specifically, low-density lipoprotein (LDL). Lipoproteins are
complex aggregates made of soluble protein with lipids to facilitate transport of
cholesterol to peripheral tissues. Lipoproteins contain various combinations of
phospholipids,

free

cholesterol,

cholesteryl

esters

and

triacylglycerols.

Lipoproteins are classified based on the density/ lipid content as well as their
lipoprotein association. Different combinations of lipid and protein give rise to
various sizes of lipoproteins such as low-density lipoproteins (LDL), very lowdensity lipoproteins (VLDL) and high-density lipoproteins (HDL). The LDL
receptor (LDLR) plays a key role in the maintenance of cholesterol homeostasis.
LDL receptor mediated internalization of LDL supplies the cells with exogenous
cholesterol. LDL down-regulates expression of LDLR in various cell types that
including hepatocytes, lymphocytes and fibroblasts. It is also shown that
exogenous cholesterol downregulate both LDLR and SREBP2. Cells with low
levels of exogenous cholesterol have been reported to upregulate LDLR
expression (Brown et al 1981; Chen et al 2001).
An excess of cholesterol in the cell is effluxed by reverse cholesterol
transport. The HDL binds to cell surface scavenger receptor (SRB1). SRB1
accepts cholesterol thus facilitating the HDL receptor mediated cholesterol efflux
and maintains cholesterol homeostasis (Fielding et al 1995; Ji et al 1997). ATP
binding cassette transporter 1(ABC1) is a ubiquitously expressed membrane
associated protein that mediates cholesterol efflux from cells to apo-AI or HDL
(Lawn etal 1999; Langmann et al 1999).
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3.3.3. Interactions between cholesterol and sphingomyelin
The interactions between cholesterol and sphingomyelin are of high
biological

significance

mainly

because

the

formation

of

ordered

lipid

microdomains in the plasma membrane is driven by molecular association
between the two. It is proposed that these rafts act as platforms for attachment of
different proteins and control several cellular signal transduction pathways
(Simons et al 1997). The interaction of cholesterol with sphingomyelin is
demonstrated in model membranes and this preferred association was shown
due to hydrogen bonding between the amide linkage in sphingomyelin and the 3hydroxyl group of cholesterol (Ridgway et al 2000). As cholesterol is present both
in the inner and outer leaflets of the plasma membrane it functions as spacer
filling up the void spaces associated with sphingolipids (Simons et al 1997).

3.3.4. Cholesterol and sphingomyelin: coordinate regulation
A constant ratio of cholesterol to sphingomyelin is maintained in the cell
membrane in order to support the lipid raft mediated cellular signaling pathways.
The cell may sense the change in cholesterol and sphingomyelin and alter
synthesis or catabolism of either in order to maintain appropriate amounts (Okwu
et al 1994; Ridgway et al 2000).
The first evidence of SMase-stimulated transport of cholesterol from the
plasma membrane to the ER was shown in fibroblasts. The catabolism of
sphingomyelin in plasma membrane by exogenous bacterial SMases resulted in
increased Acyl-CoA:cholesterol acyltransferase (ACAT) activity resulting in rapid
esterification of

cholesterol and downregulation of its de novo synthesis by

inhibition of HMG-CoA reductase (Slotte et al 1988; Gupta et al 1991). The
movement of cholesterol from the plasma membrane is because of decreased
capacity of the plasma membrane to solubilize cholesterol as evidenced by
decreased incorporation of exogenous [3H] cholesterol in sphingomyelin-depleted
cells (Slotte et al 1988). Conversely, addition of exogenous sphingomyelin to
human skin fibroblast resulted in enhanced synthesis of cholesterol by increasing
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HMG-CoA reductase activity and decreased acyl-CoA:cholesterol acyltransferase
(ACAT) activity resulting in flow of cholesterol from intracellular sites to the
plasma membrane (Kudchodkar et al 1983; Slotte et al 1988).
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4. Platelets
Platelets are small, disc-shaped and anucleated cellular structures
measuring 2-4 pm in diameter and 0.5 pm in thickness that are derived from
megakaryocytes (Patel et al 2005). The average life span of human platelets is
around 8-10 days. They are removed from blood circulation by phagocytes from
spleen and liver. Platelets play a major role in hemostasis and wound repair. In
blood vessels, erythrocytes occupy the lumen of the blood vessels pushing
platelets nearer to the endothelial walls to sense and adhere rapidly following
vascular injury (Ruggeri et al 2009).
The main function of platelets is to sense vascular injury by adhering to the
site and forming a platelet plug there by preventing further blood loss. Vascular
injury exposes platelets to sub-endothelial matrix thrombogenic proteins leading
to adhesion, activation and aggregation. Agonists activating platelets in vivo
include collagen, thromboxane A2 (TXA2), serotonin, thrombin and adenosine
diphosphate (ADP) (Zucker et al 1985). Platelet activation by agonists initiates
morphological and cytoskeleton changes leading to remodeling of cytoskeleton
and formation of filopodia and lamellipodia. a-granules and dense granules are
released by activated platelets, a-granules store adhesive proteins such as Von
Willebrand factor (VWF), fibrinogen and fibronectin that support adhesion
between platelets and the endothelial cell matrix. The dense granules store ADP,
adeniosine triphosphate (ATP), Ca2+ and serotonin (Harrison et al 1993; GunayAygun et al 2004; Hartwig et al 2006; Italiano et al 2009). The releasates at the
site of vascular injury attract and activate more platelets and play important roles
in platelet plug formation and wound repair.
Platelet plug formation upon vascular injury follows a specific series of
events. In the initiation phase, platelets adhere and spread to form a monolayer
at the sub-endothelium collagen matrix. In the extension phase, the releasate
from the secretory granules (a- and dense granules) of the platelets such as
ADP, ATP, Ca2+, serotonin, VWF, fibrinogen and fibronectin activates more
platelets and recruits them to the site of injury. During the final aggregation stage,
platelets further stabilize and increase the platelet plug thus preventing premature
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disaggregation and eventually leading to wound healing (Brass et a12003).

4.1. Platelet purinergic receptors (ADP receptors)
ADP is important mediator of platelet aggregation. ADP is released by
dense granules of activated platelets and by injured vascular endothelium.
Platelets express two G-protein coupled receptors-P2Y1 and P2Y12 (Figure 14).

4.1.1. P2Y1 Receptor
The P2Y1 receptor is widely expressed in platelets, endothelial cells,
leucocytes, heart, ovary and neural cells. Platelets express around 150 copies of
P2Y1 receptor. P2Y1 is coupled to Gaq, which activates phospholipase C
resulting in inositol trisphosphate formation and calcium mobilization. The P2Y1mediated Ca2+ mobilization results in platelet shape change and weak-transient
aggregation. P2Y1 receptor is crucial in ADP induced shape change and
aggregation. Inhibition or genetic deficiency of this receptor abolishes Ca2+
signalling. However, cAMP inhibition via ADP is preserved. The P2Y1 receptor
also participates in platelet aggregation mediated by collagen (Gachet et al 2005;
Gachet et al 2006; Hechler et al 2011). Apart from calcium mobilization induced
by ADP, no other signaling molecules downstream of P2Y1 receptor activation
have been implicated in fibrinogen receptor activation (Kim et al 2011).

4.1.2. P2Y12 Receptor
The P2Y12 receptor was first cloned in 2001. Human P2Y12 contains 342
amino acid residues and is selectively expressed in platelets, brain, endothelial
cells, smooth muscle cells and glial cells (Hollopeter et al 2001; Hechler et al
2011). Platelet ADP-induced aggregation is mediated primarily by the P2Y12
receptor signaling pathway. P2Y12 receptor signaling results in calcium
mobilization, secretion of dense granule, thromboxane A2 (TXA2) and fibrinogen
receptor activation resulting in amplification of platelet aggregation (Gachet et al
2001;Turner et al 200; Shankar et al 2006).
P2Y12 receptor coupled to Gai subunits inhibits adenyle cyclase resulting in
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decreased intracellular cAMP. However lowering of cAMP is not sufficient for
platelet aggregation. Decrease in cAMP by Gai further facilitates inhibition of
cAMP-dependent protein kinase mediated phosphorylation of vasodilatorstimulated phosphoprotein (VASP). VASP is a known negative modulator of
allbp3 integrin activation. P2Y12 receptor inhibition or activation is assessed by
VASP phosphorylation or dephosphorylation status. The Gpy-subunit coupled
P2Y12 receptor activates phosphatidylinositol-3-kinase (PI3K), which is important
for sustained aggregation. P2Y12 activates GTPase Raplb in a PI3K dependent
manner. PI3K also promotes the phosphorylation and activation of protein Kinase
B (PKB; also known as Akt1) that is involved in optimal activation of allbp3
(Angiolillo et al 2010). Thus, P2Y12 receptor plays a pivotal role in sustaining
platelet aggregation by activating several intracellular pathways.
Activation of both the P2Y12 and P2Y1 receptors is essential for ADPmediated aggregation; inhibition/deficiency of either of them was shown to
decrease aggregation (Jin et al 1998; Savi et al 1998). Both receptors are
indirectly involved in P-selectin exposure on platelets and platelet-leucocyte
conjugate formation that leads to leucocyte tissue factor exposure (Leon et al
2003, 2004). The contribution of P2Y12 receptor in ADP mediated aggregation
was studied in P2Y12 receptor deficient mice. P2Y12 receptor deficient platelets
fail to inhibit adenylyl cyclase and do not aggregate in response to ADP.
However, they remain sensitive for P2Y1 mediated shape change and calcium
mobilization (Foster et al 2001; Jantzen et al 2001).

4.1.3. P2X1 Receptor
The P2X1 receptor is an ATP-gated purinergic receptor of platelets,
involved in platelet shape change. Binding of ATP to P2X1 opens up the
receptor-channel pore and mediates calcium entry. The P2X1 receptor has two
transmembrane domains, a large extracellular loop and N- and C- terminal
intracellular

domains.

P2X1

receptors

desensitize

quickly.

However,

desensitization is prevented by apyrase that hydrolyzes ATP (Mahaut-Smith et al
2004). Cooperative interplay between P2X1 and P2Y1 has been reported and

may contribute to platelet activation, implying the initial role of P2X1 receptor in
subsequent activation of P2Y1 (vital et al 2003). P2X1 receptor are unable to
induce platelet aggregation on their own, however they are reported to be
involved in collagen and shear induced platelet aggregation (Oury et al 2001;
Hechler et al 2003).
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Figure 14: Platelet purinergic receptors (Image taken from Ibanez et al 2006)
The P2Y1 and P2Y12 receptors are responsible for ADP mediated aggregation.
P2Y1 receptor coupled to Gq subunit mediates intracellular calcium mobilization,
shape change and transient aggregation. Binding of ADP to Gq-coupled P2Y1
activates phospholipase C (PLC) resulting in diacylglycerol (DAG) and inositol
triphosphate (IP3) from phosphatidylinositol biphosphate (PIP2). IP3 leads to
intracellular calcium mobilization and DAG activates protein kinase C (PKC)
resulting in phosphorylation of myosin light chain kinase (MLCKP).
Gi-coupled P2Y12 receptor is responsible for stabilization of the ADP-induced
aggregation. The Gai subunit inhibits adenylyl cyclase (AC) there by reduces
cyclic adenosine monophosphate (cAMP) levels that in turn inhibit cAMPmediated phosphorylation of vasodilator-stimulated phosphoprotein (VASPP).
VASPP is critical for allb(33 receptor inhibition. The subunit-py activates the
phosphatidylinositol 3-kinase (PI3K) involved in dense granule secretion. It also
activates allb(33 receptor mediated by protein kinase B (PKB/Akt) and Raplb
GTP binding proteins. ATP bound P2X1 receptor is responsible for calcium influx
and platelet shape change.
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4.2. P2Y12 Receptor Antagonists
Platelet activation is important under physiological and pathphysiological
conditions. The formation of pathogenic thrombi by platelet activation promotes
atherothrombotic diseases such as ischaemic stroke, acute coronary syndrome
and peripheral artery disease (Mackman et al 2008; White et al 2011). Platelet
inhibition is thus the primary target to treat/prevent pathological thrombotic events
leading to disease. The selective tissue distribution of P2Y12 makes it an
excellent target for various antithrombotic agents (Hollopeter et al 2001; Hechler
et al 2011; Kim et al 2011).
ADP plays a crucial role in haemostasis and development of arterial thrombosis.
It is the key agonist acting on P2Y1 and P2Y12 receptor on platelets. Upon
vascular injury, the dense granules of activated platelets release ADP. Through
autocrine and paracrine mechanisms, ADP further amplifies platelet activation
(Figure 15). Finally, ADP signaling through P2Y12 receptors leads to sustained
aggregation (Born et al 1985; Gurbel et al 2010; Marczewski et al 2010).
Currently, the P2Y12 receptor has been the target for antithrombotic compounds
such as clopidogrel, prasugrel, ticlopidin, ticagrelor (AZD6140) and elinogrel.

4.2.1. Ticlopidin
Ticlopidin is the first generation thienopyridine that irreversibly inhibits
P2Y12 receptor. It is a pro-drug that requires hepatic biotransformation (Figure
16, 17). Around 20 different metabolites of ticlopidine were reported and only one
active metabolite is formed via CYP-dependent pathway (Yoneda et al 2004).
Ticlopidine therapy is associated with hepatic toxicity, unfavourable hematologic
side effects including neutropenia and thrombotic thrombocytopenic purpura
(Klepser et al 1997; Patrono et al 2004).

4.2.2. Prasugrel
Prasugrel is a pro-drug that is administered orally and requires hepatic
biotransformation to irreversibly inhibit P2Y12 receptor. Prasugrel is hydrolyzed
by carboxyesterases in intestine to a thiolactone followed by hepatic CYP
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Figure 15: Central role of P2Y12 receptor in platelet aggregation (Image
taken from Becker et al 2010)
ADP, thromboxane (TXA2) and collagen activate platelets. Upon activation,
platelets release more TXA2 and ADP that bind to their respective receptors
further amplifying the response. The activation of GPIIb/llla receptors leads to
irreversible platelet aggregation. The commonly used anti-platelet drugs
clopidogrel, prasugrel and ticagrelor inhibit ADP binding to P2Y12 receptor thus
attenuating

platelet

aggregation

and

pro-coagulatory

and

inflammatory

responses.
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Figure 16: Emerging and currently available P2Y12 receptor antagonists
(Image taken from White et al 2010)
Clopidogrel, Ticlopidine and prasugrel are P2Y12 antagonists belonging to the
thienopyridine family. All three of them require hepatic biotransformation to form
their respective active metabolites. The thienopyridine active metabolites
irreversibly block the P2Y12 receptor. Ticagrelor is a direct acting, high affinity,
ADP analogue that leads to reversible P2Y12 receptor inhibition in a
noncompetitive manner. Elinogrel is a competitive, direct acting and reversible
P2Y12 receptor antagonist.
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dependent conversion to generate its active metabolite (Figure 17). It is more
effectively converted to its active metabolite thus provides rapid onset and
greater platelet inhibition profiles (Wiviott et al 2007; Angiolillo et al 2008). The
active metabolite covalently binds to P2Y12 receptor similar to clopidogrel. The
disulfide bond formed between prasugrel and extracellular cysteine residues of
P2Y12 receptor irreversibly blocks ADP binding to the receptor (Ding et al 2000;
Sugidach et al 2000). Prasugrel therapy was associated with greater incidence
of major and life-threatening bleeding compared to clopidogrel (Wiviott et al
2007).

4.2.3. Clopidogrel (Plavix)
Clopidogrel is the second-generation, orally administered thienopyridine and
most widely used antithrombotic drug. Clopidogrel is a prodrug that requires
hepatic biotransformation via cytochrome P450 enzymes to generate its active
metabolite (savi et al 1992). Clopidogrel is oxidized to 2-oxo-clopidogrel an
intermediate metabolite that is further oxidized to active metabolite containing a
reactive thiol group (Figure 17). The active metabolite of clopidogrel was isolated
and characterized.

It is highly unstable and contains a free thiol group; the

biological activity of the active metabolite is due to irreversible binding of the thiol
group of the active metabolite to a cysteine residue of the platelet P2Y12
receptor. The activity of clopidogrel's active metabolite was lost when the thiol
group was derivatized (Savi et al 2000; Pereillo et al 2002).
It has been shown that P2Y12 receptor exists as homooligomers in lipid
rafts, and oligomerization is essential for its biological activity. The active
metabolite of clopidogrel irreversibly binds and disrupts the oligomers to dimers
and monomers that are shuttled out of lipid rafts (Savi et al 2000). The cysteine
residue in the first extracellular loop of P2Y12 receptor was suggested to be
involved in disulfide bond formation with the active metabolite of clopidogrel
resulting in disruption of receptor oligomers (Savi etal 2006).
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Figure 17: Structures of P2Y12 receptor antagonists and their active
metabolites (Image taken from Nishiya et al 2009)
All three thienopyridines require hepatic biotransformation to form their respective
active metabolites and irreversibly block the P2Y12 receptor. Ticagrelor is
converted to its active metabolite by CYP, cytochrome P450. Clopidogrel under
goes two steps of oxidative biotransformation. It is first converted to 2-oxoclopidogrel by CYP followed by hydrolysis to generate the active metabolite.
Prasugel displays greater and more rapid platelet inhibition compared to
clopidogrel as it requires only one hepatic CYP450 oxidation step to generate its
active metabolite.
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The disadvantages associated with clopidogrel therapy are as follows: in
vivo esterases inactivate more than 85% of clopidogrel the remaining 15% is
converted to its active metabolite. Clopidogrel displays relatively slow on-set with
respect platelet inhibition thus a higher loading dose is administered to achieve
rapid platelet inhibition (Matsagas et al 2003; Wiviott et al 2007; Wallentin et al
2008). The irreversible inhibition of the P2Y12 receptor as well as large interindividual variability is associated with clopidogrel response among patients
(Angiolillo et al 2007).

4.2.4. Ticagrelor (AZD6140)
Ticagrelor is a cyclopentyltriazolopyrimidine (CPTP) and is the first
reversible, oral P2Y12 receptor antagonist (Figure 5). Ticagrelor is not a pro
drug, thus does not require metabolic biotransformation for it activity.

Unlike

clopidogrel, ticagrelor provides more consistent and greater platelet inhibition with
no increase in major or minor bleeds. One active metabolite (ARC124910XX) of
ticagrelor

is

rapidly

formed by

cytochrome P450 and display

similar

pharmacokinetics as ticagrelor itself (Husted et al 2009; Kowalczyk et al 2009).
Ticagrelor binds to the P2Y12 receptor at a site independent from ADP binding
site and inhibit platelet aggregation via non-competitive mechanism (Giezen et al
2009).
Ticagrelor has a longer half-life (~12hr) and rapid-onset, with greater platelet
inhibition achieved in 2-3hr following single dose. It is also shown that ticagrelor
resulted in rapid, more effective and reversal anti-thrombotic effects as compared
to clopidogrel. The normal function of platelets is restored in 2-3 days after
discontinuation of ticragrelor treatment thus confirming in-vivo reversibility of drug
(Gurbel et al 2009). Recent studies have also shown that ticragrelor resulted in
greater platelet aggregation in clopidogrel pre-treated patients, suggesting further
blockade of P2Y12 receptor. Therefore, ticragrelor therapy could overcome
platelet high reactivity in clopidogrel patients (Storey et al 2007).
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Figure 5: Structure of P2Y12 receptor antagonist-Ticagrelor (Image taken
from Angiolillo etal2010)
Ticagrelor (Cyclo-pentyl-triazolo-pyrimidine) is the first oral, reversible, directacting anti thrombotic drug. It binds to P2Y12 receptor and inhibits ADP mediated
platelet aggregation in a non-competitive manner.
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Ticragrelor

side

effects

are

different

from

those

displayed

by

thienopyridines. Increase in dyspnea, bradycardia and uric acid levels that are
caused by ticagrelor mediated blocking of adenosine reuptake by red blood cells.
However, the reduced adenosine uptake is also associated with protection
against reperfusion, improved coronary flow and reduced blood pressure
(Serebruany et al 2006, 2007; Giezen et al 2009).

4.2.5. Elinogrel
Elinogrel is a sulphonylurea derivative, direct acting and reversible P2Y12
blocker in phase III clinical trails.

Elinogrel can be administered both

intravenously and orally (Marczewski et al 2010). This drug is reported to produce
more rapid anti-platelet action and minor bleeds compared to clopidogrel (Yousuf
et al 2011). This drug has been reported to compete with ADP for binding on
P2Y12 receptor, thus it is associated with decrease in major bleeding in low-flow
and shear environment of the bleed (Leonardi et al 2010).
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CHAPTER-2
Sinapinic acid can replace ascorbate in the biotin switch assay

Published as original research as Kallakunta et al. 2009
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1. Introduction
Protein S-nitrosation is an important post-translation modification that
affects various proteins involved in number of cellular processes, mediated by
Nitric Oxide (NO) through redox-dependent conversion of cysteine thiols of
proteins to S-nitrosothiols (Hess et al 2005; Liu et al 2004; Stamler et al 1994;
2001). Earlier studies have shown that modifying cysteine residues of proteins
may result in altered protein function thus nitrosothiols play major roles in human
health and disease (Foster et al 2003).
A major contribution to the field of S-nitrosothiols is the biotin switch assay
was introduced by Jaffrey et al 2001. In this assay, proteins are denatured by
sodium dodecyl sulfate (SDS) in the presence of methyl methane thio-sulfonate
(MMTS) to block free thiols. Thiols present in the interior of the protein are
exposed when they are incubated with SDS at 50°C. After acetone precipitation
to remove excess of MMTS, 1 mM ascorbate and biotin-HPDP are added to
maintain the Cu (l)-catalyzed reduction of the nitrosothiols and to label the
reduced thiol with biotin. Proteins are separated by non-reducing SDS-PAGE
followed by immunoblotting. Biotinylated proteins are detected using streptavidinHRP or anti-biotin HRP and chemiluminescence detection system. This assay
was the first method to identify S-nitrosated proteins on a gel, which enables their
subsequent

isolation

and

identification

by

techniques

like

mass

spectrophotometry.
Many researchers have modified the biotin switch assay either by altering
the concentration of ascorbate or the incubation times for the various steps, or
adding metals or metal chelators. Several reports indicate that the high levels of
ascorbic acid utilized for denitrosation can also reduce disulfide bonds in proteins
thus leading to "false" biotinylation of proteins that have no S-nitrosothiols
(Landino et al 2006; Huang et al 2006). A recent article by Gladwin and
coworkers indicated that the extent of biotin labeling depends upon factors such
as buffer composition and choice of the metal-ion chelators. Other modifications
of the biotin switch method include the addition of trace amounts copper to
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increase the sensitivity of the assay without compromising its specificity (Wang et
al 2008).
Sinapinic acid (3, 5-dimethoxy-4-hydroxy cinnamic acid) is widely used as
matrices

in

matrix-assisted

laser

desorption/ionization

(MALDI)

mass

spectrometry (Burton et al 1997). Previous studies with sinapinic acid have
shown that it reacts with peroxynitrous acid at neutral pH to yield a red product,
O-nitrososinapinic acid. The O-nitrososinapinic acid is a direct analog of Snitrosothiols and was shown to be capable of trans nitrosating thiols (Akhter et al
2003). However, O-nitroso intermediates were unstable, which would lead to their
dimerization via the formation of mono-lactone like products at pH 7.4 (Leis et al
1998; Niwa et al 1999).
The objectives of our study were to determine if sinapinic acid could: 1)
denitrosate S-nitrosothiols and 2) to test if sinapinic acid could replace ascorbic
acid as the denitrosating agent in biotin switch assay.
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2. Experimental Methods

Synthesis of S-nitrosothiol
S-nitrosoglutathione

(GSNO)

and

S-nitrosocysteine

(CysNO)

were

synthesized as described previously (Akhter et al 2002). Briefly, GSH was
dissolved in ice-cold 0.5 M HCI. Equimolar sodium nitrite was added, and the
reaction was carried out in the dark at 4°C for 40 min. The pH of the reaction
mixture was adjusted to 7.4. The concentration of GSNO was determined by UVVis spectrophotometer by measuring absorbance at 334nm (extinction coefficient
of 920 M"1cm"1). CysNO was synthesized as described previously and
concentration was determined using extinction coefficient of 900 M"1cm"1 (Greco
et al 2006). S-nitroso-BSA was synthesized by incubating BSA with GSNO at
room temperature for 1h, and purified on a G25 sephadex column (Huang et al
2006). The yield of S-nitroso-BSA was calculated from the typical S-nitrosothiol
absorbance spectra, using the reported molar absorption coefficients 3869 M"
1cm"1

(Akhter et al 2003; Wang et al 2001).

Nitric Oxide detection using NO analyzer (NOA)
Amount of NO formation was determined using Sievers® Nitric Oxide
Analyzer (NOA 280i) based on gas-phase chemiluminescence reaction between
NO and ozone. NO (NaN02+Nal) standard was used to calibrate the NOanalyzer. GSNO (20-1000 pmol) were injected into purge vessel at room
temperature containing either ascorbate (1 mM) at pH 7.4 or sinapinic acid
(30 mM) at pH 7.0, 8.0 and 8.5.

Cell culture and treatment
RAW 264.7 cells were purchased from ATCC. Cells were cultured in
Dulbecco's modified eagle's media (DMEM) supplemented with streptomycin
(200 pg/ml), penicillin (200 pg/ml) and 10% fetal bovine serum. All cells were
maintained in a humidified incubator at 37°C with 5% CO2 and 95% air. Cell
culture and treatments were performed as previously described (Zhang et al
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2005). Briefly, cells were seeded in 100mm dishes and grown to 70-80%
confluence. Media was removed and washed thrice with PBS, followed by
incubation with CysNO for 1hr in Hank's balanced salt solution (HBSS) with
10 mM Hepes. Cells were washed thrice with PBS and 900 pi of lysis buffer
containing 250 mM Hepes pH7.7, 1 mM phenylmethylsulfonyl flouride and 50 mM
NEM was added. Cells were scraped and sonicated (550 sonic Dismembrator
from Fisher scientific, power level 2 for 15s) followed by centrifugation at 12000g
for 5min. Supernatant was used for detection of S-nitrosothiol by biotin switch
assay and sinapinic acid technique.

Detection of protein S-nitrosothiols by the biotin switch assay with
ascorbic acid vs. sinapinic acid as the denitrosating agents
Biotin switch assay was performed as previously described (Jaffrey et al
2001; Wang et al 2008). Briefly, SDS (2.5%) was added to cell lysate in NEM
containing lysis buffer, followed by incubation at 50°C for 1h with frequent
vortexing. Excess of blocking agent was removed by precipitating the proteins
with 2 volumes of prechilled (-20°C) acetone. After incubation for 1h at -20°C,
samples were centrifuged at 8000g for 10min at 4°C. The protein pellets were
then washed with acetone to remove the excess NEM.
Protein pellets were dissolved in PBS pH 7.4 with 1%SDS, followed by
addition of 1 mM ascorbic acid and 1 mM biotin-maleimide for the normal biotin
switch assay procedure, and incubated in dark at room temperature for 1h. For
the sinapinic acid modification, after removing excess of blocking agent as
described above protein pellets were dissolved in PBS pH 7.0, 30 mM sinapinic
acid and 1 mM biotin-maleimide were added and incubated at room temperature
in dark for 1h. After incubation, proteins were precipitated by adding prechilled
acetone and resuspended in PBS. Samples were resolved on non-reducing SDSPAGE gel followed by immunoblotting. The blots were incubated with
streptavidin-HRP (1/100,000 dilution) antibody for 2h and visualized by
chemiluminescence substrate.

54

Griess assay
Determination of nitrite formed by reaction of GSNO with sinapinic acid at
pH 8.5 and 7.0 was based on griess reaction (Wang et al 2002). Nitrite containing
sample was mixed with equal volume of griess reagent (0.1% (w/v) N-(1naphthyl)-ethylenediamine dihydrochloride, and 1% (w/v) sulphanilamide in 5%
(v/v) phosphoric acid) and incubated at room temperature for 5min to form a
purple azo dye, and absorption was determined at a wavelength of 546nm
(Marzinzing et al 1997).

DTNB Assay
The Ellman's reagent (DTNB, 0.4 mM) was used to test if sinapinic acid
(30mM) reduces disulfide bridges. The thiol reagent DTNB bears an aryl-disulfide
bond and once reduced possesses a strong absorbance at 410nm wavelength
(Giustarini et al 2008). 0.4 mM DTNB was added to 1mM ascorbic acid pH 7.4 or
30 mM sinapinic acid pH 7.0 and formation of the thiol (TNB) was determined
spectrophotometrically by measuring the absorbance at 410nm. To determine
free thiol generated by reaction of GSNO with sinapinic acid, 0.2 mM GSNO was
added to 30 mM sinapinic acid at pH 7.0 and DTNB assay was performed.

Kinetic Measurements
The reductive decomposition of GSNO by sinapinic acid was monitored
spectrophotometrically on Agilent 8453 UV-Vis spectrometer. The reaction was
started by addition of 1 mM GSNO to 30 mM sinapinic acid at pH 7.0. Time
dependent spectra were monitored immediately after addition of 1 mM GSNO.
Loss of NO from GSNO was accompanied by decrease in absorption at 334nm.
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Detection of endogenous protein S-nitrosothiols from RAW 264.7 cells
treated with and without NOS inhibitor by the biotin switch assay vs.
sinapinic acid technique
In this study endogeneous NO synthesis is utilised as basis for Snitrosylation for detecting basal levels of protein S-nitrosothiols from RAW 264.7
cells using both biotin switch and sinapinic acid assay (Gao et al 2005). The
murine macrophage cell line RAW 264.7 was exposed to lipopolysaccharide
(LPS) 1 pig/ml for 12h to induce inducible nitric oxide synthase (iNOS). To detect
basal protein S-nitrosothiols the cells were either stimulated with LPS or
unstimulated in control samples followed by treating with or without NOS-specific
inhibitor NG-monomethyl-L-arginine (L-NMMA, 1 mM) (Zhang et al 2004; Ranjan
et al 2004). After incubation for 12h, cells were washed and resuspended in NEM
containing lysis buffer. Cells were scraped, sonicated followed by and
centrifugation at 12000g for 5min. Supernatant was used for detection of Snitrosothiol by biotin switch assay and sinapinic acid technique as described
before.

Detection of S-nitroso-BSA by biotin switch assay vs. sinapinic acid
technique
For these experiments, S-nitrosated BSA was biotin labelled using either
ascorbate or sinapinic acid as denitrosating agents, followed by SDS-PAGE and
immunoblotting as described earlier (Wang et al 2008). The blots were incubated
with streptavidin-HRP (1/100,000 dilution) antibody for 2h and visualized by
chemiluminescence substrate.
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3. Results

Denitrosation S-nitrosothiols by sinapinic acid
We first sought to determine whether or not sinapinic acid had ability to
denitrosate S-nitrosothiols. Denitrosation ability of sinapinic acid was studied at
pH 7.0, 8.0 and 8.5 by injecting various concentrations of GSNO (20-1000 pmol)
into glass vessel of a nitric oxide analyzer containing 30 mM sinapinic acid.
Figure 1A shows the amount of NO released by denitrosation of GSNO by
sinapinic acid at varying pH compared to denitrosation of GSNO by 1mM
ascorbic acid at pH 7.4.
The data obtained suggest that the denitrosation ability of sinapinic acid at
pH 7.0 is comparable to that of 1 mM ascorbic acid at pH 7.4. However, the
denitrosation ability of sinapinic acid at pH 8.5 and 8.0 was less as compared to
that observed at pH 7.0. The data obtained with griess assay show that sinapinic
acid yields nitrate at higher pH (Figure 1B).
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Figure 1: Denitrosation S-nitrosothiols by sinapinic acid (A) Comparison of
denitrosation of GSNO by 1 mM ascorbic acid at pH 7.4 and 30 mM sinapinic
acid at pH 7.0, 8.0 and 8.5 analyzed by ozone-based chemiluminescence nitric
oxide analyzer. 20-1000 pmol of GSNO were injected into a glass vessel
containing either 1 mM ascorbic acid or 30 mM sinapinic acid solution at varying
pH. The error bars represent standard error (n=3). (B) Comparison of nitrite
formed by reaction GSNO with 30 mM sinapinic acid at pH 8.5 and 7.0.
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The reductive decomposition of GSNO by sinapinic acid
UV-Vis spectra were recorded for reduction of 1 mM GSNO by 30 mM
sinapinic acid (Figure 2). The spectra were characterized by time dependent
decrease at 334 nm. The pseudo first order rate constant (k0bs) for the
denitrosation of GSNO (1 mM) by sinapinic acid (30 mM) estimated form this data
was 0.0079 ± 0.0005 s"1 corresponding to a half-life of 1.46 ± 0.009 min. The k2
(extracted from kobs) was 0.016 ± 0.001 M"1s"1.
Sinapinic acid mediated decomposition of GSNO
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Figure 2: UV-Vis spectra for decomposition of GSNO by sinapinic acid.

59

Denitrosation of RSNO by sinapinic acid results in a free thiol
The next question was does the denitrosation of RSNOs with sinapinic acid
result in the generation of free thiols? To this end, we added DTNB to solution of
GSNO ± sinapinic acid. Our data with DTNB assay show that free thiols are
generated in the presence but not in the absence of sinapinic acid (Figure 3A).
Our data in Figure 3B indicate that at concentrations employed in the biotin
switch assay procedure sinapinic acid does not reduced disulfide bridges and
hence it is specific for the degradation of S-nitrosothiols. Consistent with the
results of Marzinzing et al 1997, we also observed that ascorbic acid result in the
reduction of the DTNB disulfide Figure 3B.
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Detection of free thiol by DTNB assay by reaction of
GSNO with sinapinic acid
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Figure 3: Denitrosation of RSNO by sinapinic acid results in a free thiol
(A) Detection of free thiol by DTNB assay by reaction of GSNO with sinapinic
acid at pH 7.0.The error bars represent standard error (n=2). (B) Comparison of
DTNB disulfide reduction by 30 mM sinapinic acid or 1 mM ascorbic acid at pH
7.0 and pH 7.4 respectively. The error bars represent standard error (n=2).
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Detection of S-nitrosated proteins
Next, we investigated the potential role of sinapinic acid in replacing
ascorbic acid in biotin switch assay. RAW264.7 cells treated or untreated with
CysNO (250 pM) and S-nitrosothiols were detected by both biotin switch assay
where sinapinic acid replaced ascorbate for S-nitrosoprotein reduction (Figure
4A). Densitometry of the western blots was calculated using Image-J software
(Figure 4B). 32 pmol of SNO/pg of protein were detected in blot. It is evident from
the western blot data that nearly identical S-nitrosoprotein band patterns were
evident when either sinapinic acid or ascorbate was used to reduce the Snitrosoprotein pool. However, the blot densities calculated for ascorbate were
larger than sinapinic acid both in the absence (Figure 4B lanes 2, 5) and
presence (Figure 4B lanes 3, 6) of CysNO.
Protein S-nitrosothiols were measured from RAW 264.7 cells as an index of
NOS induction, using both sinapinic acid and biotin switch assay. LPS induced Snitrosation (Figure 5, Lanes 3 and 7) was inhibited in presence of L-NMMA
(Figure 5, Lanes 4 and 8). Both biotin switch assay and sinapinic acid technique
are used for detecting S-nitroso-BSA (Figure 6, Lanes 3 and 6).
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Figure. 4: Detection of S-nitrosated proteins in RAW 264.7 cell line
(A) Detection of S-nitrosated proteins in murine macrophage- derived RAW
264.7 cell line using biotin switch assay with either sinapinic acid or ascorbic acid
as the denitrosating agent. (B) Densitometry of the western blots in panel A with
Image-J software:
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L-NMMA
LPS

Lanes 1-4: Sinapinic acid,
Lanes 5-7: Biotin switch assay
Figure 5: S-nitrosothiols measured in cells as an index of NOS induction.
Western blot of protein S-nitrosothiols in control and LPS-treated with and without
L-NMMA in RAW 264.7 cells detected by both sinapinic acid assay and biotin
switch assay.
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Figure 6: S-nitroso-BSA detected by both sinapinic acid assay and biotin
switch assay.
(A) Western blot of S-nitroso-BSA detected by both sinapinic acid assay and
biotin switch assay. (B) Coomassie staining of S-nitroso-BSA as loading control.
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Figure 7: Proposed mechanism for denitrosation of S-nitrosothiols by
sinapinic acid. (A) Proposed mechanism for denitrosation of S-nitrosothiols by
sinapinic acid at pH 7.0. (B) Proposed mechanism for the formation of nitrite at
pH 8.5 and 8.0 from O-nitroso sinapinic acid.
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4. Discussion
Previous studies had shown that sinapinic acid could get O-nitrosated with
nitrite at acidic pH (Akhter et al 2003; Leis et al 1998). Furthermore, Onitrososinapinic acid could transnitrosate the free thiol of bovine serum albumin
(BSA) forming S-nitroso-BSA at pH 7.0. Here we tested whether sinapinic acid
could also be utilized to denitrosate S-nitrosothiols, with the goal of using it
instead of ascorbate in the biotin switch assay.
Our data shows that the reactions of sinapinic acid (30 mM, pH 7,0) or
ascorbic acid (1 mM, pH 7.4) with GSNO resulted in the release of similar
amounts of NO as detected by ozone-chemiluminescence (Figure 1A). However,
at pH 8.0 and 8.5 sinapinic acid yielded ~ 64 % less (500 pmol GSNO) or -56%
less (1000 pmol GSNO) NO respectively than at pH 7.0 (Figure 1A). We believe
a plausible explanation for our observations is that at pH 7.0, sinapinic acid
releases NO as shown in the proposed mechanism in Figure 7A: when an Snitrosothiol comes into contact with sinapinic acid at pH 7.0, the hydroxyl oxygen
performs a nucleophilic attack on the nitrogen of the nitroso group. The oxygen of
the nitroso group would abstract electrons from the double bond to help stabilize
the nitrosothiol-sinapinic acid adduct. Upon interaction of the hydroxyl proton with
the nitrosothiol sulphur, a protonated thiol as well as O-nitrososinapinic acid
would be formed. This is similar to mechanism proposed for formation of Onitrososinapinic acid by nitrite and peroxynitrite (Akhter et al 2003). The
intermediate O-nitrososinapinic acid is unstable and would decompose to yield
nitric oxide and O-nitrososinapinic acid radical, which can be stabilized by
resonance as proposed earlier (Leis et al 1998; Niwa et al 1999). However, at pH
8.0 and 8.5 we believe the product of the reaction is nitrite, as proposed in
mechanism shown in Figure 7B: where, a hydroxide anion attacks the Onitrososinapinic acid nitrogen forming O-nitrosinapinic acid which decomposes to
yield nitrite. To test this, we compared the amount of nitrite formed by sinapinic
acid at pH 7.0 and pH 8.5 via the griess reaction which has a detection limit for
nitrite ~1-5 pM (Wang et al 2002). As a result we studied the degradation reaction
at larger [GSNO] (40-100 pM). The data obtained (Figure 1B) does show that
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sinapinic acid yields ~50% more nitrite at the higher pH thus supporting the
proposed mechanism in (Figure 7B).
Our data with DTNB assay indicate that a free thiol is formed as result of
denitrosation of GSNO by sinapinic acid at pH 7.0 (Figure 3A). We tested
whether sinapinic acid, like ascorbate, could also reduce disulfide bridges. To this
end, we employed the thiol reagent DTNB that bears an aryl-disulfide bond
whose reduction can be monitored spectrophotometrically since the reduced
product 2-nitro-5-thiobenzoate has a strong absorbance at 410nm (EM=13,6000
L/mol.cm). Our data indicates that at concentrations employed in the biotin switch
assay procedure sinapinic acid does not reduced disulfide bridges and hence it is
specific for the degradation of S-nitrosothiols. In contrast, ascorbic acid as
previously shown (Marzinzig et al 1997) does result in the reduction of the DTNB
disulfide (Figure 3B).
The data obtained from western blots (Figure 4) indicate that both the
techniques (ascorbate or sinapinic acid) detect same set of S-nitrosated proteins.
However, the blot densities calculated for ascorbate were larger than sinapinic
acid both in the absence and presence of CysNO, likely due to the reduction of
disulfides by ascorbate in biotin switch assay.
Our data from LPS activated RAW cells, indicated that both the techniques
detect basal levels of S-nitrosothiols (Figure 5, Lanes 1&5). The fact that the Snitrosated proteins decreased significantly in the presence of and L-NMMA
(Figure 5, Lanes 4 and 8), an inhibitor of all nitric oxide synthase (NOS) isoforms,
suggests that the LPS induced S-nitrosation (Figure 5, Lanes 3 and 7) is the
result of NOS-dependent NO production.
Taken together, we have shown that sinapinic acid has the ability to
denitrosate S-nitrosothiols at pH 7.0 resulting in generating a free thiol. Also,
sinapinic acid degrades S-nitrosothiols, but it does not reduce disulfide bridges.
The fact that sinapinic acid produced nearly identical S-nitrosoprotein patterns in
comparison to ascorbate, in RAW 264.7 cells and S-nitroso-BSA suggest that it
can readily replace ascorbate in the analysis of the S-nitrosoproteome.
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CHAPTER-3
Protein disulfide isomerase- mediated oxygen and nitrite
dependent efflux of NO-equivalents from red blood cells
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1. Introduction
When RBCs enter a hypoxic region of the vasculature they release
effector(s) that induce vasodilation thus ensuring that the oxygen they release is
effectively distributed. This phenomenon termed hypoxic vasodilation, is highly
conserved and although first reported some 90 years ago (Hilton et al 1925;
Gremels et al 1926; Ross et al 1962), the sensing mechanisms as well as the
vasodilatory substances released by RBCs remain to be clearly identified.
Current research in this area is very controversial and supports either nitric oxide
(NO) and related compounds (NOx) (Jia et al 1996; Cosby et al 2003; Huang et al
2005) or ATP (Ellsworth et al 1995, 2000) as vasodilator triggers released from
RBCs.
The first hypothesis put forward for RBC mediated hypoxic vasodilatation is
through release of ATP upon decrease in Hb02 saturation. The ATP released
diffuses to the endothelium and binds to the purinergic receptors leading to
increase NO production via eNOS activation (Ellsworth et al 1995, 2009; Sprague
et al 1996; Jagger et al 2001). Furthermore, recent studies have shown that
deoxy-Hb interacts with nitrite and dislodges the membrane bound glycolytic
regulatory subunits enhancing intracellular ATP that is released under hypoxic
conditions (Campanella et al 2005; Cao et al 2009; Garcia et al 2010). The ATP
is released from RBC not only when RBC deoxygenates but also in response to
mechanical deformation when RBC travel through narrow vessels (Sprague et al
2001, 2007). Various factors are likely to regulate the role of ATP in
vasodilatation such as the activity of transporters that regulate ATP release,
enzymes that regulate ATP concentrations and purinergic receptor expression
levels (Crawford et al 2006).
The NO (or NOx) based hypotheses can be further subdivided into those
that depend on the scavenging of endothelia-generated NO to yield Snitrosohemoglobin (SNO-Hb) or those that transform nitrite to NO within the RBC
by hemoglobin acting as a nitrite reductase. In the SNO-Hb hypothesis,
deoxygenated Hb in its T-state scavenges the endothelial NO to yield a mixture
of HbFe(ll)-NO and HbFe(lll)-NO. When the RBCs arrive in the lungs the Hb

undergoes a conformational change to the R-state where the 02 displaces the
heme-bound NO to Cys |393 of Hb to form SNO-Hb. When the RBC reach the
hypoxic tissues, Hb then undergoes conformational changes to the T state which
leads to the concomitant release of O2 and transfer the SNO-bound NO
bioactivity to the outside of the RBC possibly via transnitrosation reactions to
induce endothelial vasodilatation (Stamler et al 1994; Jia et al 1996; Pawloski et
al 2001, 2002).
The nitrite/nitrite reductase hypothesis involves transport of nitrite to RBC,
reaction of nitrite with deoxy-Hb, transport of NO bioactivity from RBC and finally
vasodilation (Doyle et al 1981; Cosby et al 2003; Nagababu et al 2003). The
plasma levels of nitrite are reportedly between ~120 nM to 290 nM (Dejam et al
2005; Crawford et al 2006). Recent studies suggest that plasma nitrite can
accumulate to near fxM levels in RBC under hypoxia, via the deoxyHb-mediated
inhibition of the anion transporter (AE1) which is responsible for nitrite efflux from
the RBC (Vitturi et al 2009). Within RBC the nitrite could be converted to NO by
the

previously

demonstrated

nitrite

reductase

activities

of

xanthine

oxidoreductase, hemoglobin (Vitturi et al 2009) and eNOS (Kleinbongard et al
2006; Mikula etal 2009).
The next important question concerns the mechanisms by which
intracellular NO or NO-equivalents exit the RBC which contains ~30 mM Hb. The
amount of NO produced by the SNO-Hb or the nitrite routes are expected to be in
the submicromolar levels. Under these conditions, any NO that is formed can
react with deoxyhemoglobin (Fe2+) and yield heme-nitrosylHb (HbNO) which can
either react with oxygen to form nitrate plus methemoglobin (Fe3+) or react with
RBC-thiols to yield S-nitrosothiols (SNO). The efflux of SNO-bound NO from RBC
could be plausible via a series of transnitrosation reactions where the SNO
moiety would be transferred/shuttled from Hb to other intracellular proteins then
to membrane spanning proteins eventually ending up as cell surface or secreted
SNO-proteins which can deliver their NO into endothelia thus effecting
vasodilation. In fact, several studies have implicated the transmembrane anion
exchanger 1 (AE1) or band 3, one of the most abundant RBC-proteins, of

accepting SNO-Hb-bound NO via transnitrosation (Walder et al 1984; Shingles et
al 1997; Pawloski et al 2001,2002; Vitturi eta! 2009).
Protein disulfide isomerase (PDI) is another enzyme that could potentially
play a role in the efflux of NO equivalents from RBCs for the following reasons:
PDI accounts for ~1% of total cellular proteins in mammalian cells. Although it is
largely an endoplasmic reticulum-(ER)-resident enzyme, it is secreted or leaks
out of cells where it forms weak associations with the cell surfaces of many cell
types including pancreatic cells (Akagi et at 1988; Yoshimori et al 1990), B cells
(Kroning et al 1994; Tager et al 1997), hepatocytes (Terada et al 1995), platelets
(Chen et al 1995; Essex et al 1995), endothelial cells (Hotchkiss et al 1998),
leukocytes (Bennett et al 2000) and platelet derived microparticles (Raturi et al
2008). Several studies in RBCs have identified membrane associated PDI.
However, the physiological role of PDI in RBCs is unknown (Alloisio et al 1996;
Low etal 2002; Essex et a/1995; Goodman etal 2007).
Previous studies have shown that in endothelial cell surface PDI facilitates
the transfer of extracellular SNO to the cytosol (Ramachandran et al 2001) and
that PDI catalyze the release of NO from SNO-PDI as well as other
S-nitrosothiols (Sliskovic et al 2005). In this study, we report the potential
involvement of PDI in a nitrite-dependent and oxygen regulated process for the
efflux of NO (or NO-equivalents) from RBCs.
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2. Experimental Methods

RBCs preparation
RBCs were prepared for experiments under different oxygen saturations
using previously established protocols (Deem et al 2000; Crawford et al 2003;
Vitturi et al 2009). Fresh blood was collected from healthy human volunteers by
venipunture into BD tubes containing anticoagulant. Blood was centrifuged at
1000g for 10min to remove plasma and buffy coat. RBCs were washed with
buffer (pH 7.4) of following composition 6.9 g/L NaCI, 2.28 g/L NaHC03, 0.35 g/L
KCI, 0.136 g/L KH2P04, 0.144 g/L MgS04, 2.0 g/L D-glucose to prevent
hemolysis. Experiments with different oxygen saturations were performed in
septa sealed vials. The buffer used in the experiments was also pre-equilibrated
for 30min at respective oxygen saturations. Isolated and washed RBCs in buffer
(pH 7.4) were held under 16% O2 or hypoxia 4% 02 for 15min (Deem et al 2000;
Vitturi et al 2009). Nitrite stock solution was prepared in PBS with DTPA (100 pM)
and added to RBC suspension to a final concentration of 300 nM using syringe
and further incubated for 10min.

Immunoprecipitation
RBCs membranes were prepared using standard protocol as described
previously (Zhang et al 1998; Crawford et al 2006; Rogers et al 2009; Dejam et al
2005). Briefly, to the RBC pellet (1 mL) 40 volumes of ice-cold 5mM phosphate
buffer containing 0.1mM PMSF, 20 mM NEM and 100 pM DTPA was added.
RBCs were then incubated on ice for 20 min to induce hemolysis. After
centrifugation at 12000g for 10min at 4°C, RBC membranes were washed twice
with the same buffer.
RBC membranes were dissolved as described earlier (Zhang et al
1998,1999). RBC membranes were solubilized in lysis buffer containing Hepes
(50 mM), NaCI (150 mM), EDTA (5 mM), EGTA (5 mM), sodium pyrophosphate
(20 mM), NEM (20 mM), orthovanadate (1mM), NaF (20 mM), K3Fe (CN)6
(10 mM), NP-40(1%), PMSF (0.1 mM) and protease inhibitor (1:200, Sigma). The
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samples (100 pg) was precleared with protein A/G (40 pi) by incubation and
mixing for 1h at 4°C. Samples were then incubated with anti-PDI antibody (1:50
dilution) or mouse anti band 3 antibody (1:100 dilution) or rabbit anti-GLUT 1
antibody (1:100 dilution). After incubation for 2h at 4°C, protein A/G beads (50 pi)
were added to the samples and further incubated for 3h. The beads were washed
three times with lysis buffer. Proteins were eluted from beads using SDS-PAGE
sample buffer devoid of 0-mercaptoethanol by incubating at 95° for 10min and
analyzed by immunoblotting. For experiments with RBC homogenates, RBC
samples (100 pi) were homogenized in PBS with NEM (20 mM), K3Fe(CN)6
(10 mM), DTPA (100 pM), NP-40 (1%), PMSF (0.1 mM) and protease inhibitor
(1:200) (Gladwin et al 2002) followed by immunoprecipitation as described
above.
Detection of S-nitrosated PDI by Immunoblotting
Nitrite supporting PDI-S-nitrosation in-vitro in presence of oxyHb was
determined as follows: Hb(1 mM) was reduced with dithionite(0.1 mM) under
argon in septa sealed vials and transferred to septa sealed vials containing
constant PDI (1 (xM), Hb (0.6 mM) and varying amounts of NO2" (78 nM to 5 (xM)
in PBS. The headspace of the vial contained 20 ppm 02. After incubation for
5 min at room temperature the samples were are subjected to biotin switch assay
as previously described (Gladwin et al 2002; Deem et al 2004; Wang et al 2008).
The supernatant was treated with 100 pM DTPA, 20 mM NEM, 10 mM K3Fe
(CN)6 and 1% SDS and incubated at 50°C for 30min with frequent vortexing. Two
volumes of ice-cold acetone were added to precipitate the proteins. The
precipitant was further washed with 70% acetone. Protein pellets were
resuspended in 100 pi of PBS followed by addition of 1 mM ascorbic acid and
1 mM biotin-maleimide and incubated in dark at room temperature for 1h. Biotinlabeled proteins were precipitated using prechilled acetone and resuspended in
PBS. The concentrations of protein in samples were determined by BCA assay
and protein samples (8 pg) were resolved on non-reducing SDS-PAGE gel
followed by immunoblotting. The membranes were probed with anti- Hb (1:1000),
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mouse anti-PDl (1:1000) and streptavidin-HRP (1:100,000). The blots were then
incubated

with

anti-mouse

secondary

antibodies

and

visualized

using

chemiluminescence substrate.

Preparation of Hb samples for UV Spectroscopy
All reactions were carried out in PBS pH 7.4 at room temperature. Deoxy
hemoglobin was prepared as previously described (Di lorio et al 1987). Briefly,
hemoglobin (sigma) was dissolved in PBS pH 7.4 (8.3 mg/ml) followed by
centrifugation at 12000rpm for 2min. The supernatant was used for preparation
of deoxy hemoglobin. Hb (1 mM) was reduced with dithionite (0.1 mM) under
argon in septa sealed cuvette followed by addition of sodium nitrite (20 pi of
100 pM stock). The concentration of Hb(lll), Hb(ll) and Hb-NO were determined
using the reported millimolar extinction coefficient (van Assendelft et al 1975;
Antonini et al 1975; Romeo et al 2002). Small amount of air was introduced by
the aid of syringe to prepare oxyhemoglobin (Herold et al 2003). Decrease of HbNO with PDI was monitored on Agilent UV spectrophotometer (Agilent, Canada)
in septa sealed cuvette containing 5 pM Hb with 4.5 pM PDI and small volume of
air (500 pi) introduced into the sample-using syringe. The Hb-NO has
characteristic peak at 418 nm. The decrease in Hb-NO was also monitored with
10.8 pM Hb and varying concentration of PDI to give Hb-PDI ratio between 0-10.
Hb-(3cys93 residue of hemoglobin was alkylated using iodoacetamide
(IAC) (Neer etal 1968). Hemoglobin (2mg/ml) was dissolved in Tris buffer pH 7.5.
Iodoacetamide (9.3 mg) was prepared fresh by dissolving in 200mM bicarbonate
buffer pH 8.0 to give 375 mM stock solution. 5 pi of iodoacetamide (375 mM
stock) was added to hemoglobin (200 pg) and incubated in dark. After incubation
for 2h, the excess of iodoacetamide was removed using spin column (Pierce,
Canada).

NO measurements
The gas phase NO was measured using Sievers® Nitric Oxide Analyzer
(NOA 280i). In these experiments, the decrease of Hb-NO with PDI was
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monitored on UV spectrophotometer in septa sealed cuvette containing 5 pM Hb
with 4.5 pM PDI and small volume of air (500 pi) introduced into the sample-using
syringe followed by injecting 100 pi of headspace gas from the reaction to NO
analyzer. The concentration of NO in gas phase was determined from the
standard curve (Gladwin et al 2000). Similarly, NO in gas phase was also
determined from reaction of nitrite (0.1 mM) at acidic pH (citrate buffer pH 5.5)
with PDI (1.2 pM) under aerobic and anaerobic conditions. After incubation for
5min, 100pl of headspace gas was injected into NO analyzer. NO in gas and
iquid phase were also measured in Hb or Hb-IAC (7.4 pM) with PDI (1.2 pM)
under aerobic conditions. Liquid phase NO was measured in Hb or Hb-IAC
samples without addition of l3".

Fluorescence measurements
Fluorescence

measurements

were

performed

on

Cary

eclipse

fluorescence spectrophotometer. The excitation wavelength was set at 280 nm to
limit fluorescence measurements mainly to tryptophan. The PDI concentration
used was 0.75 pM and all measurements were performed in PBS pH 7.4. The
Hb was added from 2 mg/ml stock solution. The PDI intrinsic fluorescence
intensity reported are corrected for Hb.

Flow cytometry
RBCs surface proteins were detected by flow cytometry using previously
established protocols with some modifications (Wang et al 2001; de Isla et al
2003; Beckmann et al 1998). RBCs were isolated and adjusted to 106 cells/ml
and held at different oxygen conditions with and without nitrite as described
above. RBC samples were immediately fixed with 1% paraformaldehyde for
20min, followed by washing with PBS (3X 1 mL). RBCs were incubated with
mouse monoclonal anti-PDI antibody (1:100) for 1h. After washing with PBS (3X
1 mL), RBCs were incubated with sheep anti-mouse IgG-FITC (stressgen
biotechnologies corp) for 30min in dark. RBCs were then washed with PBS (3X 1
mL) and analyzed by flow cytometer. RBCs labeled with only sheep anti-mouse
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IgG-FITC or only anti-PDI antibody were used as controls. Data was collected for
100000 events of RBC population.

Detection of soluble PDI
The buffer of the RBC suspension under 16% O2 and 4% O2 oxygen with
and without nitrite treatment were probed for soluble PDI. The soluble PDI was
isolated as described previously (Mezghrani et al 2000). The supernatant of the
RBC suspension was subjected to two centrifugation steps first at 1000 xg to
remove the cells then at 13000 xg to remove cellular debris. The resulting
supernatant containing soluble proteins was used for immunoprecipitation of PDI.
The supernatant (1 mL) was precleared with protein A/G (40 pi) by incubation
and mixing for 1 h at 4°C. The suspension was centrifuged at 1000 xg for 1min.
10 pg mouse anti-PDI antibodies was immobilized on aminolink plus coupling
resin according to the manufacturers instructions (Pierce) followed by addition of
500 pi of supernatant. After incubation for 2h at 4°C, the suspension was
centrifuged at 1000 xg for 1min. The beads were washed three times with wash
buffer and incubated with 100 pi of elution buffer for 5min. Immunoprecipitated
proteins were collected by centrifugation at 1000g for

2min. Proteins

concentration was determined by BCA assay. 20 pg of protein samples were
resolved on non-reducing SDS-PAGE gel followed by immunoblotting. The
membranes were then incubated with rabbit anti-PDI antibody (1:1000) antibody
for 2h followed by HRP conjugated anti-rabbit secondary antibodies (1:2500) for
1h and visualized using chemiluminescence substrate.
For determining S-nitrosation of

soluble PDI at various oxygen

saturations, 10 pi of imunoprecipitated protein was injected into NO analyzer. The
concentration of NO was determined from standard curve.

Titrations of RBC under different oxygen saturations with RFP-PDI
RBCs were isolated and adjusted to 106 cells/ml and held at 16% and 4%
oxygen saturations as described before. Different concentrations of RFP-PDI
(0-1 pM) were injected into septa sealed vials containing RBCs with the aid of
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syringe. Samples were further held for 10min at 16% and 4% oxygen saturations
and fixed immediately with 1% paraformaldehyde for 20min as described
previously (Wang et al 2001). Fluorescent labeling of RBCs for Glutl was
performed using previously established protocols (Campanella et al 2005;
Kleinbongard et al 2006). Briefly, RBCs titrated at 16% and 4% oxygen
saturations with RFP-PDI were fixed and allowed to attach to coverslips coated
with poly-L-Lysine for 30min. After incubation, coverslips were washed (3X 1mL)
with PBS pH7.4 containing 5 mM glucose to remove unattached RBCs and then
incubated with blocking buffer (1%BSA in PBS with 5 mM glucose) for 1h. After
washing with PBS (3X 1mL), RBCs were incubated with goat anti-rabbit Alexa
488 (1:1000, Molecular Probes, Canada) for 1h. RBCs were then washed 3X
1mL with PBS and mounted on slides with aqua-poly mount (Polysciences,
Canada). The epifluorescence-capable microscope used in these studies was a
Zeiss

Axiovert

200M

inverted

fluorescence

microscope

equipped

with

FITC/TRITC filter cubes. The imaging was performed with an ECPIan-Neofluar
40X oil objective. Images were analyzed with the aid of Northern Exposure 6.0
image analysis software (Empix, Mississauga, ON).
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3. Results

PDI can be S-nitrosated in the presence of Hb plus nitrite under oxygenated
conditions
The nitrite reductase hypothesis requires a significant portion of the RBC
Hb to be in the deoxyHb form (Cosby et al 2003; Nagababu et al 2003; Huang et
al 2005). In addition, the intra RBC nitrite accumulation proposed by Vitturi et al.
(2009) also requires large amounts of deoxyHb to inhibit band3 thereby blocking
the efflux of nitrite. In current study, we first determined if nitrite would support
PDI-S-nitrosation under physiological air oxygenated conditions. The UV-Vis
spectrum of Hb-NO that resulted from nitrite reduction of Hb was monitored with
PDI under physiological air oxygenated conditions. The results indicate time
dependent decrease in Hb-NO absorbance at 418nm with PDI (Figure 1A). The
decrease in absorbance at 418 nm of Hb-NO as a function of Hb/PDI ratio is
shown in FigurelB. To further confirm that the decrease in Hb-NO is dependent
on PDI, we monitored the gas phase NO by NOA analyzer. Nitrite reduction by
deoxyhemoglobin resulted in 563pmol of NO in gas phase. On the other hand,
under the conditions of air oxygenation with PDI in the gas-phase, 265pmol of
NO was detected.
Previous studies have proposed S-nitrosation of Hb at p-cys93 residue to
form S-nitroso-Hb (SNO-Hb) and release of NO during deoxygenation to induce
vasodilation (Jia et al 1996). Here, using iodoacetamide the p-cys93 on Hb was
alkylated, thus Hb-IAC would have less NO to deliver to PDI compared to
unmodified Hb. The Hb and Hb-IAC under aerobic conditions generated 58pmol
and 5.5pmol NO in gas-phase and 30pmol and 46pmol NO in liquid phase
respectively.
Nitrite supporting PDI-S-nitrosation in the presence of oxyHb was also
determined using biotin switch assay. These experiments were performed using
constant PDI (1 ^M), Hb (0.6 mM) and varying amounts of NO2" (78 nM to 5 jxM)
in PBS. The headspace of the vial contained room air. These results indicate that
basal nitrite levels -300 nM under normoxia are sufficient to support PDI-S79

nitrosation in vitro (Figure 1C, D). To this end, S-nitrosation of PDI under aerobic
and anaerobic conditions was investigated with nitrite at acidic pH acting as NO
donor. The NO in gas phase without and with PDI were 229 pmol and 211 pmol
respectively under anaerobic conditions. Whereas, under aerobic conditions the
gas-phase NO detected were 77 pmol and 48 pmol without and with PDI
respectively. The reduction in gas phase NO with PDI suggests formation of
SNO-PDI under aerobic conditions.
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Figure 1: Change in Hb-NO absorption spectrum with PDI
(A) Reaction of Hb-NO and PDI: Absorption spectral changes of Hb(ll) (5 pM) in
presence of nitrite (100 pM), PDI (4.5 pM) under air-oxygenated conditions. UVVIS spectrum was recorded from 250 to 650 nm with a scanning interval of
10min. Decrease in Hb-NO upon exposure to PDI under physiological air
oxygenated conditions was evident by decrease in absorbance at 418 nm. (B)
Reaction of Hb-NO and PDI were monitored at 418 nm with Hb (10.8 |iM) and
varying concentration of PDI to give varying Hb/PDI ratios. The absorbance of
Hb-NO decreased as a function of Hb/PDI ratio is shown. (C) Nitrite supporting
PDI-S-nitrosation in the presence of oxyHb was detected by immunoblotting.
82

Samples containing equal quantities of protein were subjected to SDS-PAGE
under non-reducing conditions followed by probing with (A) streptavidin-HRP, (B)
anti-Hb and (C) anti-PDI antibodies. (D) The graph shows blot densities
determined by using Image J software and normalized with PDI blot. The data
shown is representative of two independent experiments with errors bars
representing the standard deviation.
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intrinsic fluorescence
The structural changes in PDI in presence of Hb were investigated using
intrinsic Trp fluorescence of PDI. PDI has five tryptophan residues in its entire
sequence and quenching of Trp intrinsic fluorescence is assumed to be similar to
that of thioredoxin (Ado et al 2006; Holmgren et al 1972). The intrinsic
fluorescence spectra of PDI were measured with excitation at 280 nm that had a
strong emission at 339 nm originated mainly from the Trp residues. A progressive
decrease of PDI intrinsic fluorescence intensity with increasing Hb concentration
was observed (Figure 2). These results demonstrate the conformational changes
induced in PDI upon interaction with Hb as evidenced by decrease in intrinsic Trp
fluorescence of PDI.
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Figure 2: The effect of Hb on the Trp intrinsic fluorescence of PDI.
The tryptophan intrinsic fluorescence of PDI was taken with excitation at 280 nm
and emission at 339 nm. The change in intrinsic fluorescence of PDI (0.75 pM)
with varying [Hb] (0-5 pM) is shown.
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RBC-PDI can be S-nitrosated in an oxygen-dependent manner
Recent studies indicate that PDI along with several other chaperones are
lost in erythroid progenitor cells as they mature to become RBCs (Patterson et al
2009). Despite this, PDI was detected on the surface of RBCs(Essex et al 1995;
Alloisio et al 1996) as well as in proteomic profiles of RBCs (Low et al 2002;
Goodman et al 2007). Here, we probed the various components of human RBCs
with the aid of anti-PDI antibodies (RL-90). Western blots indicated PDI was
present in RBC homogenates and in the plasma membrane (Figure 3A). In
addition, flow cytometry of intact RBCs, probed with anti-PDI antibodies and then
with fluorescent (FITC) secondary antibodies, indicated the presence of PDI on
the RBC surface (Figure 4). We then explored the ability of RBCs to become Snitrosated upon incubation of intact RBCs with nitrite under 4% O2 or 16% 02
saturations conditions. The S-nitrosation status of PDI was determined by the
biotin switch assay. Our data indicates that RBC-PDI is S-nitrosated under 16%
O2 (Figure 3B, Lane 4), whereas it is not S-nitrosated at 4% O2 saturations
(Figure 3C, Lane 4).
We next determined whether PDI could interact with RBC membrane
proteins like band 3 or Glutl. The role of band 3 in transfer of NO equivalents
from Hb is

well established (Pawloski et al 2001, 2002). By using

immunoprecipitation analysis we show that immunoprecipitation of PDI or band 3
from RBC membrane resulted co-immunoprecipitated of band 3 or PDI
respectively, suggesting interactions of band 3 and PDI in RBC membrane
(Figure 3D, Lanes 1 and 6). By applying the same analysis we also found that
immunoprecipitation of PDI or Glutl

from RBC membrane resulted in

co-immunoprecipitated of Glutl or PDI respectively (Figure 3E, Lanes 2 and 6).
To further examine if band 3 and Glutl interact in RBC membrane, we
immunoprecipitated the membrane fractions with band 3 antibodies. In
agreement with previous studies (Zhang et al 1999), Glutl was not detected in
the band 3 pulldowns, indicating that under these conditions there is no
interaction between the two proteins (Figure 3F, Lanes 3 and 6). We also tested
the ability of PDI to interact with Hb. In these experiments, intact RBCs were

homogenized and immunoprecipitated with PDI and the pulldowns were probed
for Hb. The PDI pulldowns did contain Hb (Figure G, Lane 4).
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Figure 3: PDI S-nitrosation and interactions with RBC membrane proteins.
(A) Detection of RBC PDI by immunoblotting Lanes: 1-RBC membrane, 2-RBC
homogenate, 3-Standard PDI (50 ng). S-nitrosation of PDI under (B) 16% O2 (C)
4% 02 saturations. Lanes: 1&2- Control RBCs without and with nitrite treatment
3&4-S-nitosated proteins without and with nitrite treatment by biotin switch assay.
The data shown are representative of three independent experiments.
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proteins

(D)

Following

immunoprecipitation of 100 pg of RBC membrane protein with anti-PDI antibodies
and SDS-PAGE, the western blot was probed with anti-band 3 antibodies. Lanes:
1- Immunoprecipitation product, 2-Protein A/G agarose beads, 3-PDI antibody
plus Protein A/G agarose beads, 4- RBC membrane protein as positive control
5- PDI antibody plus Protein A/G agarose beads 6- Immunoprecipitation product
7- RBC membrane protein as positive control. (E) Following immunoprecipitation
of 100 pg of RBC membrane protein with anti-PDI antibodies and SDS-PAGE,
the western blot was probed with anti-Glut1 antibodies. Lanes: 1-anti-PDI
antibody plus protein A/G agarose beads, 2-lmmunoprecipitation product, 3Protein A/G agarose beads, 4- RBC membrane protein as positive control 5- antiPDI antibody plus protein A/G agarose beads, 6- Immunoprecipitation product, 7Protein A/G agarose beads. (F) Following immunoprecipitation of 100 pg of RBC
membrane protein with anti-band 3 antibodies and SDS-PAGE, the western blot
was probed with anti-Glut1 antibodies. Lanes: 1- Protein A/G agarose beads, 2anti-band 3 antibody plus protein A/G agarose beads, 3- Immunoprecipitation
product, 4- RBC membrane protein as positive control 5- Protein A/G agarose
beads, 6- Immunoprecipitation product 7) RBC membrane protein as positive
control. (G) Following immunoprecipitation of RBC homogenate with anti-PDI
antibodies and SDS-PAGE, the western blot was probed with anti-Hb antibodies.
Lanes: 1-RBC protein as positive control, 2-anti-PDI antibody plus protein A/G
agarose beads, 3- Protein A/G agarose beads 4) Immunoprecipitation product.
The shown IPs are representative for three independent experiments.
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PDI associates with the RBC surface in an O2 and nitrite-dependent manner
We wanted to determine if the RBC surface PDI content was dependent
on O2 and nitrite levels. To further demonstrate the role of cell surface PDI
(csPDI), RBCs were treated with and without nitrite under 16% O2 and 4% 02
saturations and analyzed. The PDI on the RBCs surface was detected using flow
cytometer (Cytomics FC500, Beckman Coulter, USA) using monoclonal mouse
anti-PDI antibody (primary Ab) and sheep-antimouse IgG-FITC (secondary Ab).
RBCs under 16% O2 with and without nitrite, expressed -8.6% and -0.65%
csPDI respectively (Figure 4A,C). In contrast, RBCs under 4% 02 with and
without nitrite expressed -0.45% and -0.40% respectively (Figure 4B, C). These
results suggest that there is a higher affinity interaction between PDI and the
RBC surface under 16% O2PIUS nitrite in comparison to 4% 02 (± nitrite).
We also probed the buffer in which RBCs were suspended for soluble PDI
by immunoprecipitating the supernatant after it was subjected to centrifugation
steps to remove cells and cellular debris. Interestingly, the amount of soluble PDI
found in RBC suspensions was -11-fold larger under 4% O2

plus nitrite in

comparison to 16% 02 plus or minus nitrite, the exact opposite of the RBC-csPDI
levels (Figure 5A, B).
Next, we determined the S-nitrosation status of soluble PDI by NO
analyzer. These results indicate -274 and ~250pmol of NO per mg protein under
16% O2 with and without nitrite respectively. In contrast, under 4% O2 with and
without nitrite detected 119pmol and 74pmol of NO per mg protein (Figure 5,
Table-1). Taken together, our results indicate that more PDI is secreted from
RBC under hypoxia and the secreted PDI is S-nitrosated.
In order to better characterize PDI interactions with RBCs at various
oxygen saturations, equal number of RBCs were exposed to increasing
concentration of red fluorescence protein tagged PDI (RFP-PDI) (Figure 6A).
The titration of RBC with RFP-PDI showed no further increase in fluorescence
after certain concentration giving a saturation curve (Figure 6B). The apparent
dissociation constant KD was calculated by non-linear regression analysis
(GraphPad, Prism) of saturation curves. The RFP-PDI:RBC apparent dissociation
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constant Kd estimated at 16% and 4% O2 saturations were 0.5|jM and 0.66|jM
respectively. These results indicate increased interaction of RFP-PDI with RBC
surface under 16% O2 saturation compared to 4% O2 as evident by its lower Kp.
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Figure 4: Detection of RBC cell surface PDI at different oxygen saturations
by flow cytometry.
Flow cytometric analysis of cell surface PDI on RBCs. The cells were labeled with
mouse monoclonal anti-PDI antibody followed by sheep anti-mouse IgG-FITC
and analyzed by Beckman coulter cytomics FC500 flow cytometer. The two
histograms show results from the data acquisition of 100,000 events of RBCs at
4% 02 (A) and 16%C>2 (B) with nitrite for cell surface PDI. (C) The graph depicts
percentage of RBCs expressing cell surface PDI at 16% O2 and 4% O2
saturations without and with nitrite respectively. For each sample 100,000 events
were measured on flow cytometer. The data shown is representative-of four
independent experiments with errors bars representing the standard deviation.
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Figure 5:

Detection of soluble PDI from RBC at different oxygen

saturations.
(A) Soluble PDI from RBC at different oxygen saturations with and without nitrite
treatment was recovered by immunoprecipitation followed by SDS-PAGE and
immunoblotting. The blot shows PDI detected from various samples: 1- 4%02
(-N02"), 2- 4%02(+N02"), 3- 16%02(-N02"), 4- 16%02(+N02~), 5- amido link plus
coupling resin plus anti-PDI antibody, 6- amido link plus coupling resin. (B) The
graph represents western immunoblot densities of PDI from samples as
described in (A). Densitometry was performed using Image J software for the
blots and the error bars represent standard deviation (n=4). Table-1 shows the Snitrosation status of soluble PDI determined using NO analyzer. The results are
presented as NO pmol/mg protein from samples at different oxygen saturations
and with and without nitrite treatment. The data shown is representative of four
independent experiments.
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Figure 6: Titration of RBC with RFP-PDI at different oxygen saturations.
(A) Titration of RBC with RFP-PDI (0-1 pM) at 16% and 4% oxygen saturation.
RBCs were imaged with a Zeiss Axiovert fluorescence microscope equipped with
40X oil objective. The images shown are representative of two independent
experiments. (B) Saturation curve of RBC with RFP-PDI: RFP-PDI image data
from Figure 6A from -50 RBCs/treatment were digitized with the aid of ImageJ to
convert the RFP-PDI fluorescence to average gray per unit area. The data shown
is representative of two independent experiments with error bars representing the
standard deviation. The apparent dissociation constants were determined from
the saturation curve using graph pad software.
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4. Discussion
In this study, we have tested the ability of RBC-PDI to participate in the
process of hypoxic vasodilation by facilitating in the efflux of NO-equivalents from
RBCs. In mammalian cells PDI is an ER resident thiol oxidoreductase, which
facilitates the proper arrangement of disulfide bonding in nascent proteins.
However, in many cells PDI is able to leave the ER, cross the plasma membrane
and is associated with the cell surface (Akagi et al 1988; Yoshimori et al 1990;
Kroning et al 1994; Tager et al 1997; Terada et al 1995; Chen et al 1995; Essex
et al 1995; Hotchkiss et al 1998; Bennett et al 2000; Raturi et al 2008). RBCs are
anucleated and lack an ER. Despite this, RBCs do contain PDI (Alloisio et al
1996; Low et al 2002; Essex et al 1995; Goodman et al 2007). We confirmed this
in the present study, with anti-PDI monoclonal antibodies by showing that the PDI
is present on the RBC surface, in the plasma membrane and in total RBC
homogenates (Figures 3A, Figure 4). This suggests that RBCs are able to
accumulate PDI that is secreted by other vascular cells including endothelial
cells, and platelets (Hotchkiss et al 1998; Chen et al 1995; Essex et al 1995).
The fact that it is found in membrane fractions as well as on the RBC surface
suggests that this protein can be taken up and secreted from RBCs.
The nitrite reduction hypothesis involves the reaction of deoxy-Hb with nitrite
and transport of NO bioactivity to induce vasodilation (Doyle et al 1981; Cosby et
al 2003; Nagababu et al 2003). The UV-Vis spectroscopy data showed decrease
in Hb-NO (Hb-NO resulting from nitrite reduction of Hb) with PDI and air
oxygenation (Figure 1A, B). Chemiluminescence analysis of headspace NO also
supported PDI dependent decrease in NO suggesting formation of S-nitrosated
PDI. We further confirmed invitro S-nitrosation of PDI in the presence of oxyHb
and nitrite by immunoblotting (Figure 1C, D).
We also showed that RBC-membrane PDI could be S-nitrosated at 16% O2
saturations with nitrite (Figure 3B). Interestingly, the surface concentrations of
PDI were ~19-fold larger when exposed to nitrite under 16% O2 saturations than
in the absence of nitrite or (±) nitrite under 4% 02 saturations (Figure 4). The fact
that there was ~11-fold larger soluble S-nitrosated PDI found in the soluble

fractions RBC under 4% O2 suggested to us that the RBC surface had a higher
affinity for PDI under 16% 02than under 4% 02 saturation. We tested this with a
fluorescent RFP-PDI and found lower apparent KD at 16% 02 in comparison to
4% O2 (Figure 6B).
The next question is how does PDI get S-nitrosated? Our data with intrinsic
trytophanyl fluorescence of PDI showed decrease in fluorescence as a function of
Hb concentration (Figure 2). PDI has five Trp residues in total, of which Trp-52
and Trp-396 are located nearer to active site (WCGHC) of a and a' domains, Trp128 is in b domain and remaining two Trp-364 and Trp-407 are buried in the a'
domain. The decrease in fluorescence intensity implies conformational changes
occurring in PDI with Hb that could be contributed from the changes in
environment of the Trp residues presumably by both active site and buried Trp
residues (Ado et al 2006). The interactions between PDI and Hb are further
confirmed by PDI pulldowns that contained Hb suggesting that these two proteins
are interacting in the RBC (Figure 3G). This means that PDI free thiols could act
as recipients of SNO-Hb or directly perform a nucleophilic attack on Hb Fe(ll)-NO
getting nitrosated in the process. Here we also show immunoprecipitation
evidence (Figure 3D) for PDI-band3 interaction in RBC plasma membrane.
Therefore, SNO-PDI could be formed as a result of transnitrosation reactions with
SNO-AE1.
Another potential recipient of SNO-Hb bound NO is glucose transporter
protein 1 (Glutl) which mediates Na-independent transport of glucose across the
plasma membrane of mammalian cells (Ismail-Beigi et al 1993; Mueckler et al
1994). Human erythrocyte membrane express high levels of glucose transporter
accounting around ~200,000 copies per cell, that accounts for ~10% of the total
protein content. Each subunit of the tetrameric Glutl has two free thiols
(Helgerson et al 1987; Hebert et al 1992; Mueckler et al 1994). There is some
indirect evidence that Glut 1 is regulated by S-nitrosylation (Kaddai et al 2008.).
The co-immunoprecipitation evidence here between Glutl and PDI could also
mean that PDI could receive NO equivalents from SNO-Glut1 (Figure 3E).
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Based on the results presented here we propose a PDI-based mechanism
for the efflux of NO-equivalents from RBCs. Serum PDI has a high affinity for
RBC surface under normoxic conditions. As a result, the [PDI] builds up on RBCs
as they enter the lungs. PDI can either be transnitrosated by interacting with
either band 3 or GLUT1 on the RBC plasma membrane. PDI can also cross the
plasma membrane and be directly transnitrosated by SNO-Hb. As the RBCs
enter regions of low oxygen tension the affinity of PDI for the RBC surface
decreases releasing SNO-PDI to the blood. Endothelia surface PDI denitrosates
SNO-PDI releasing its NO and inducing vasodilation.

100

CHAPTER-4
RFP-Protein Disulfide Isomerase-Construct as a Cell
Surface Oxidative Stress Sensor
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1. introduction
Thiols (SH) are ubiquitously expressed in cell and cell membranes mainly
as protein thiols (PSH) and as abundant low-molecular thiols in the cell, known as
glutathione (GSH). These thiols can be oxidized to form disulfides in proteins
(PSSG), gluthathione disulfide (GSSG) or mixed disulfides between protein and
gluthathione (PSSG) (Klatt et al 2000; Fratelli et al 2004; Hansen et al 2009;
Wang et al 2006). Thiols are susceptible to oxidative modifications that include
S-thiolation, sulfenic (R-SOH)/sulfinic (R-S02H)/sulfonic acid (R-SO3H) formation
or inter/intra protein disulfide bond formation (Cooper et al 2002; Xu et al 2002;
Kuster et al 2006). Among these oxidative modifications, all but sulfinic and
sulfonic acid modifications are reversible under physiological conditions and are
often viewed as protection against oxidative stress (Huyer et al 1997; Poole et al
2004; Kuster et al 2006; Gallogly et al 2007). The reversible protein modifications
play major role in regulating activity of enzymes and protein structures whereas
the irreversible modification usually result in protein degradation (Thomas et al
2001; Dalle-Donne et al 2007; Yu et al 2008).
The protein thiols in mammalian cells account for ~20-40 mM that are
susceptible to various thiol modifications and the redox state of these thiols
dependent mainly on their location. The cytoplasm has highly reducing
environment due to high GSH ratio hence most cysteine residues of proteins
exist as free thiols whereas extracellular cysteine residues of proteins are mainly
in disulfide forms because of the oxidizing environment. The cell membrane thiols
are in interface between oxidizing and reducing environment hence play key role
as environmental redox state sensor when exposed to exogenous oxidant or
reductants (Lumb et al 2002; Laragione et al 2006; Prakash et al 2009).
It is well established that cancer cells are under persistent oxidative stress
due to increased ROS generation compared to normal cells as a result of
oncogenic transformation, increased metabolic activity, and mitochondrial
malfunction (Behrend et al 2003; Klaunig et al 2004; Halliwell et al 2007; Kumar
et al 2008). The persistent oxidative stress affect several functions such as cell
proliferation, cell sensitivity to anti-cancer agents, promote mutations and genetic
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instability therefore maintaining ROS levels are important for cellular redox
balance and signaling (Toyokuni et al 1995; McCord et al 1995; Martin et al 2002;
Pelicano et al 2004).
Previous studies have shown that thiol oxidation by thiol-disulfide exchange
is catalyzed by several disulfide oxidoreductases that includes glutaredoxin
(GRX)/GRX reductase system, the thioredoxin (TRX)/TRX reductase system and
protein disulfide isomerase (PDI) (Danon et al 2002; Sevier et al 2002; Hogg et al
2003; Kuster et al 2006). Common to all these oxidoreductases is CXXC active
sequence. Based on its redox state, PDI is capable of catalyzing oxidation,
reduction and isomerization. PDI in reduced state can perform reduction or
isomerization of disulfide bonds. In isomerization reaction, there is no net change
in redox state of PDI. Oxidized PDI catalyzes oxidation of protein thiols (Wilkinson
eta! 2004).
Studies with vascular endothelial cells have shown that estrogen-mediated
induced expression of PDI protects cells from oxidative stress. It was also shown
with H202-inactivated glyceraldehyde-3-phosphate dehydrogenase (GAPDH) that
PDI could regenerate, oxidative stress inactivated GAPDH. Moreover, incubation
of H202-inactivated GAPDH with reduced PDI restored GAPDH activity whereas
the oxidized PDI failed to restore the activity (Ejima et al 1999). The reduction of
protein mixed disulfides (dethiolation) by PDI was also shown in hepatocyte
proteins treated with diamide (Jung et al 1996; Ghezzi et a/2005).
Extracellular thiols are oxidized or reduced depending on the redox state of
the extracellular environment. The objective of this study is to determine whether
reduced red fluorescence protein PDI-construct (RFP-PDI) binding to mammalian
cells depend on the redox state of the extracellular thiols. We used diamide and
H202' two thiol-oxidizing agents to promote oxidative thiol modifications and
visualized RFP-PDI binding in cells using fluorescent microscopy.
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2. Experimental Methods
Cell culture and treatment
Bovine aortic endothelial cells (BAEC) were obtained from Coriell Research
Repository. The cells were maintained in DMEM F-12 complete medium
supplemented with 10% FBS (Invitrogen), 100 pg/mL streptomycin, and 100U/mL
penicillin (GIBCO). Cells from passages five to ten were used for all studies. All
cells were maintained in a humidified incubator at 37°C with 5% CO2 and 95%
air. Human breast cancer cell line (HTB126) were obtained from ATCC and
cultured in DMEM supplemented with 10% FBS, 100 pg/mL streptomycin and
100 U/mL penicillin according to manufacturers instructions. Cells were cultivated
at ~80% confluence and treated with oxidants.
The oxidation of thiols was induced using two oxidants: H2O2 and diamide
as described previously (Gilge et al 2008; Baty et al 2005). In most of the
experiments the cells were treated with H202 (20 pM) or H2O2 (200 pM) for 10min
unless otherwise stated (Baty et al 2005). Cells that were mock treated with
culture medium at the corresponding times were taken as control. Cell membrane
thiols were oxidized and reduced using protocol as previously described with
some modifications (Wan ef a/2001; Ghezzi et al2002; Hill et al2010). Briefly, to
oxidize the thiols cells were treated with diamide (0.2 mM) for 5min. In some
experiments, cells were diamide treated followed by incubation with RFP-PDI
(1 pM) for 30min at 37°C in media. The mixed disulfides formed between RFPPDI and cell surface thiols were reduced by subsequent incubation in presence of
DTT (1 mM)for 10min.

Monitoring ceil viability
Cell viability was determined by trypan blue exclusion assay. Cells were
grown to 80% confluence in 6-well plates and treated with H202 or diamide as
described before. Similarly, cells were treated with diamide followed by RFP-PDI
and DTT as described above. After incubation, the media was removed and cells
were trypsinized. The cell viability was assessed by mixing aliquots of cell
suspensions (100 pi) with an equal volume of 0.4% trypan blue solution (Gibco,
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Canada) for 2min. Cells were visualized under a light microscope to determine
the percentage of cells that picked up the trypan blue dye.

Immunofluorescence analysis of PDI expression
Cells were cultured on cover slips and treated with H2O2 (200 pM) for 6h as
described earlier (Baty et al 2005; Seng et al 2007; Chen et al 2010). PDI
staining was performed using standard protocol as described previously (Wyles
et al 2004, Schultz-Norton et al 2006; Blagoveshchenskaya et al 2008). Briefly,
cells were fixed with 3% paraformaldehyde for 30min at room temperature,
followed by permeabilzation with 0.05% Triton X-100 in PBS for 10min. Cells
were then washed 3X 2 mL with PBS and incubated with blocking buffer (5%
BSA in PBS) for 1h. Cells were then incubated with rabbit anti-PDI (Cell
signaling, 1:200) and mouse anti-actin (Abeam, 1:100) antibody with blocking
buffer for 2h. After washing with PBS (3X 2 mL), cells were incubated with goat
anti-rabbit Alexa 488 and goat anti-mouse Alexa 568 (1:1000, Molecular Probes,
Canada) for 1h. For staining nuclei, 1.0 pM Hoechst 33342 stain was added and
further incubated for 5min. Cells were then washed 3X 2mL with PBS and
mounted on slides with fluoromount G (Southern Biotech) and examined by Zeiss
Axiovert

200M

inverted

fluorescence

microscope

equipped

with

UV/FITC/TRITC/DAPI filter cubes. The imaging was performed with an ECPIanNeofluar 40X oil objective. Images were analyzed with the aid of Northern
Exposure 6.0 image analysis software (Empix, Mississauga, ON) and ImageJ.

RFP-PDI immunofluorescence in cells under oxidative stress
BAECs or HTB126 cells BAEC were cultured on cover slips and oxidative
stress was induced using two oxidants: H2O2 and diamide as described above.
RFP-PDI was reduced using standard protocol as described previously (Raturi et
al 2005; Willems et al 2010). Following incubation with oxidants, cells were
washed with PBS (3X 2 mL) and incubated with RFP-PDI (1 pM) for 30min at
37°C in media. In some experiments, incubating with DTT (1 mM) reduced the
mixed disulfides between RFP-PDI and cell surface thiols. Next, cells were
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washed with PBS (3X 2 mL) and fixed with 3% paraformaldehyde for 20min at
room temperature. After fixation, cells were washed with PBS (3X 2 mL) and
incubated with blocking buffer (5% BSA in PBS) for 1h. Cells were then incubated
with mouse anti-actin (Calbiochem, 1:1000) antibody with blocking buffer for 2h.
After washing with PBS (3X 2 mL), cells were incubated with goat anti-mouse
Alexa 488 (1:1000, Molecular Probes, Canada) for 1h. For staining nuclei, 1.0 pM
Hoechst 33342 stain was added and further incubated for 5min. Cells were then
washed with PBS (3X 2 mL) and mounted on slides with fluoromount G
(Southern Biotech) and examined by inverted fluorescence microscope.
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3. Results

Oxidative Stress induction effects on cell viability
Oxidative stress induced cell death was assessed by trypan blue exclusion
assay.

BAECs and

HTB126

cells

were

incubated with the

indicated

concentrations of H2O2 and diamide to induce oxidative stress and then analyzed
for cell viability. The trypan blue exclusion assay of BAECs showed ~97% cells
were viable in controls; however the cell viability decreased to -94% and -92% in
20 pM and 200 pM H202-treated cells respectively (Figure 1A). The BAECs
treated with diamide and diamide-DTT had -96% and -95% viable cells
respectively (Figure 1A).
The trypan blue exclusion assay of HTB126 cells showed that ~94% cells
were viable in controls; however the cell viability decreased to -92% and -90% in
20 pM and 200 pM H202-treated cells respectively (Figure 1B). The HTB126
treated with diamide and diamide-DTT had -78% and -92% viable cells
respectively (Figure 1A). Consistent with previous results, the effect of diamide
on cell viability was reversed by DTT (Hill et al 2010). These results demonstrate
the concentrations of H202 and diamide used for thiol protein oxidation had slight
effect on cell viability.
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Figure 1: Effect of oxidant treatment on cell viability in BAEC and HTB126
cells. (A) BAECs and

(B) HTB126 cells were grown on coverslips and either

control mock treated for 10 min or H2C>2 (20 pM or 200 pM) treated with 10min.
The cells were then exposed to RFP-PDI (1 pM) for 30min. Similarly cells were
treated with diamide (0.2 mM) for 5 min. Diamide treated cells were exposed to
RFP-PDI (1 pM) for 30min and subsequently treated with DTT(1mM) for 10min
(diamide+DTT). Viability was assessed using trypan blue exclusion assay. The
results represent percentage of viable cells. Data is shown as mean ± standard
deviation (n=3).
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Oxidative stress effects on endogenous PDI levels
Previous studies have shown that H2O2 induced oxidative stress alters
expression of several cellular stress proteins and chaperones including PDI
(Curtis et al 2010; Lichtenfels et al 2012). Studies with retinal pigmented cells,
keratinocytes and lymphoid cells have shown oxidative stress induced
upregulation of thiol oxidoreductases and propose that increased expression is a
protective mechanism to protect cells from oxidative stress (Gauntt et al 1994;
Sachi et al 1995; Ejima et al 1999). However, with H2O2 stressed human LHCNM2 myoblasts it was shown that PDI is downregulated upon oxidative stress
(Baraibar et al 2011). Here, we investigated the effect of H202-induced oxidative
stress on endogenous PDI levels in BAECs and HTB126 cells. The
immunofluorescence data indicate that endogenous PDI was not significantly
affected by H202-induced oxidative stress in BAECs (Figure 2A, B). In contrast,
H2C>2-induced oxidative stress resulted in ~1.5-fold increase in endogenous PDI
in HTB126 cells compared to control (Figure 2C, D). These results indicate that
increased PDI expression may protect cancer cells under oxidative stress.

109

PDI-Green; Actin-Red; Nuclei-Blue

Control

\

B
150
v
0 — 120
SI

8 1 90
a) o

I"

1 o

106.6

60

ab
CL

30

110

PDI-Green; Actin-Red; Nuclei-Blue

Control

0)
o .—.

147.6

S £
0) o
1"

iX

Q
Q.

2W2

Figure 2: Endogenous PDI in oxidative stressed BAEC and HTB126 cells.
(A) BAECs were grown on coverslips and untreated (C) or treated with H2O2 for
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6h. The cells were then fixed with paraformaldehyde and incubated with rabbit
anti-PDI and mouse anti-actin antibody. Alexa Fluor 488 conjugated anti-rabbit
IgG and Alexa Fluor 568 conjugated anti-mouse IgG was used as secondary
antibody and nuclei were stained with Hoechst. The images were acquired using
40X oil immersion objective.
(B) The image data in Fig. 2A from ~25 cells/treatment were digitized with the aid
of ImageJ to convert the PDI fluorescence to average gray per unit area. The PDI
fluorescence is represented as % of control (C) average gray values. The data
shown are representative of two separate experiments with error bars showing
standard deviation.
(C) HTB126 cells were grown on coverslips and untreated (C) or treated with
H2O2 for 6h. The cells were then fixed with paraformaldehyde and incubated with
rabbit anti-PDI and mouse anti-actin antibody. Alexa Fluor 488 conjugated antirabbit IgG and Alexa Fluor 568 conjugated anti-mouse IgG was used as
secondary antibody and nuclei were stained with Hoechst. The images were
acquired using 40X oil immersion objective.
(D) The image data in Fig. 2C from -25 cells/treatment were digitized with the aid
of ImageJ to convert the PDI fluorescence to average gray per unit area. The PDI
fluorescence is represented as % of control (C) average gray values. The data
shown are representative of two separate experiments with error bars showing
standard deviation.
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RFP-PDI binding to cells treated with various oxidant species.
Protein-sulfenic acid resulting from reaction of cysteine with H2O2 is highly
unstable and is converted to P-S-S-(Cys) in presence of cysteine. Many proteins
are candidates for regulation by sulfenic acid formation such as nuclear factor 1,
NFkB-p50, GAPDH, Fos and c-Jun (Claiborne et al 1993; Yoshitake et al 1994;
Pineda-Molina et al 2001; Gallogly et al 2007).
To examine if RFP-PDI acts as a redox state sensor we probed normal
(BAECs) and cancer cells (HTB126) subjected to H202-mediated oxidative stress
with RFP-PDI. Here, we used two concentrations of H202: 20 pM and 200 pM to
induce oxidative stress (Baty et al 2005). Exposure of BAECs to 20 pM and
200 pM H202 elevated -3.3 fold (Figure 3A-IV, 3B) and -9.2 fold (Figure 3A-VI,
3B) in RFP-PDI fluorescence. In contrast, HTB126 cells exposed to 20 pM and
200 pM H202 elevated -6.2 fold (Figure 3C-IV, 3D) and -14.5 fold (Figure 3C-VI,
3D) in RFP-PDI fluorescence. These results indicate increased RFP-PDI
fluorescence in cells under oxidative stress compared to control cells.
In order to further confirm the increase in RFP-PDI fluorescence with cells
under oxidative stress, we used a different oxidant, diamide that oxidizes
intracellular GSH to GSSG and increase mixed disulfides between protein and
GSH (PSSG) or protein and CSH (PSSC) (Schuppe et al 1992; Chen et al 1999;
Chai et al 2003; Hansen et al 2009). Induction of oxidative stress by diamide
markedly increased RFP-PDI fluorescence by -13.7 fold (Figure 3A-VIII, 3B) and
-14.8 fold (Figure 3C-VIII, 3D) in BAECs and HTB126 cells respectively.
Interestingly, diamide treated cells exposed to RFP-PDI followed by DTT was
associated with a significant reduction in the RFP-PDI fluorescence signal in both
BAECs (Figure 3A-X, 3B) and HTB126 cells (Figure 3C-X, 3D). These results
indicate that RFP-PDI construct acts as cell surface oxidative stress sensor.
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Figure 3: RFP-PDI binding to cells treated with various oxidant species.
(A) BAECs were grown on coverslips and either control mock treated for 10 min
or H2O2 (20 pM or 200 jjM) treated with 10min. The cells were then exposed to
RFP-PDI (1 |jM) for 30min. Similarly cells were treated with diamide (0.2 mM) for
5 min. Diamide treated cells were exposed to RFP-PDI (1 pM) for 30min and
subsequently treated with DTT(1mM) for 10min (diamide+DTT). After fixation,
cells were immunostained with mouse anti-actin antibody followed by Alexa Fluor
488 conjugated anti-mouse IgG (Green). Nuclei (blue) were stained with Hoechst
33342. The images were acquired using 40X oil immersion objective.
(B) The image data in Fig. 3A from ~50 cells/treatment were digitized with the aid
of ImageJ to convert the RFP-PDI fluorescence to average gray per unit area.
The RFP-PDI fluorescence is represented as % of control (C) average gray
values. The data shown are representative of three separate experiments with
error bars showing standard deviation.
(C) HTB126 were grown on coverslips and either control mock treated for 10 min
or H2O2 (20 pM or 200 pM) treated with 10min. The cells were then exposed to
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RFP-PDI (1 pM) for 30min. Similarly cells were treated with diamide (0.2 mM) for
5 min. Diamide treated cells were exposed to RFP-PDI (1 |jM) for 30min and
subsequently treated with DTT(1mM) for 10min (diamide+DTT). After fixation,
cells were immunostained with mouse anti-actin antibody followed by Alexa Fluor
488 conjugated anti-mouse IgG (Green). Nuclei (blue) were stained with Hoechst
33342. The images were acquired using 40X oil immersion objective.
(D) The image data in Fig. 3C from -50 cells/treatment were digitized with the aid
of ImageJ to convert the RFP-PDI fluorescence to average gray per unit area.
The RFP-PDI fluorescence is represented as % of control (C) average gray
values. The data shown are representative of three separate experiments with
error bars showing standard deviation.
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4. Discussion
In the current study, using a red fluorescence protein-PDI construct
(RFP-PDI), we demonstrated increased association of exogenous RFP-PDI with
cells under oxidative stress. The observation that more RFP-PDI is associated
with cells under oxidative stress indicates that PDI is able to sense the cell
surface redox state. Our data show that RFP-PDI construct does not interact with
cell surface under normal conditions in both endothelial cells (BAECs) (Figure
3A-II, 3B) and cancer cells (HTB126) (Figure 3C-II, 3D). But, when cells were
exposed to oxidants like H2O2 or diamide, we observed a significant elevation in
RFP-PDI fluorescence. The H202 (20 pM or 200 pM) induced oxidative stress
elevated RFP-PDI fluorescence in both normal (Figure 3A-IV, VI; 3B) and cancer
cells (Figure 3C-IV, VI; 3D) by -9.2 fold and -14.5 fold respectively.
Intra-cellularly, diamide increases protein glutathiolation via depleting GSH
and therefore resulting in GSSG or PSSG directly via sulfenylhydrazine
intermediate (Kosower et al 1995; Hill et al 2007). By extension, diamide
mediated intracellular GSH depletion should translate to the formation of
extracellular protein cysteinylation. Our data show an increase in surface RFPPDI fluorescence in both BAECs and HTB126 by -13.7 fold (Figure 3A-VIII, 3B)
and -14.8 fold (Figure 3C-VIII, 3D) respectively. In contrast, the reduction of
protein mixed disulfides with DTT resulted significant reduction in RFP-PDI
fluorescence both BAECs (Figure 3A-X, 3B) and HTB126 cells (Figure 3C-X, 3D).
Thus, the elevation in RFP-PDI fluorescence in cells under oxidative stress is due
to formation of covalent mixed disulfides between RFP-PDI and cell surface
thiols.
The proposed mechanism for thiol reduction (degluthathionylation) by a
domain of PDI is similar to that of glutaredoxin (Grx) dithiol mechanism that
involves mixed disulfides between PDI-protein substrate as shown in (Scheme 1)
(Peltoniemi et al 2006; Hatahet et al 2009). The mechanism involves the active
site cysteine executing the nucleophilic substitution thus initiating formation of
mixed disulfides between PDI and substrate protein carrying a disulfide bond.
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Another free active site cysteine undergoes deprotonation and interacts with
S-atom yielding oxidized enzyme and reduced protein substrate. The oxidized
PDI is reduced via interaction with two GSH molecules.
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Schemel: Proposed degluthathionylation catalytic mechanism by PDI.
Our experimental data show elevation in RFP-PDI fluorescence due to
extracellular protein cysteinylation under oxidative stress and reversal of mixed
disulfide between RFP-PDI and protein thiols by DTT treatment. This suggest
that mixed disulfides between RFP-PDI and protein thiols are not resolved by the
second active site cysteine of PDI.
The reduction of mixed disulfides and glutathionylated proteins by monothiol
mechanism was previously described in case of Grx (Kalinina et al 2008). This
mechanism involves interaction of N-terminal Cys residue of glutaredoxin with
GSH residue of mixed disulfide protein-SSG to form an intermediate Grx-S-SG,
which is then reduced using GSH. We propose that PDI mediated thiol reduction
could occur by monothiol mechanism via a-domain active site of PDI with Cys
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residue of P-S-S (Cys) to form an intermediate PDI-S-S-Protein (Scheme 2). The
reduction of PDI-S-S-Protein depends on the extracellular reductants. This is
exactly what we observed, loss of RFP-PDI fluorescence with DTT treatment
supporting the proposed mechanism that PDI-S-S-Protein reduction depend on
extracellular reductants.

s+

Protein-S-S-Cys

SH
HS-Cys
S-S-Protein
SH
Depend on external reductant
or DTT
V

SH
+

Protein-SH

SH
Scheme 2: Proposed scheme for PDI mediated catalytic reduction of PSSC.
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We also report -1.5-fold increase in endogenous PDI under conditions of
H2O2 mediated oxidative stress (Figure 2C, D). Thus, increase in expression of
endogenous PDI suggest that more PDI could leak out to cell surface to maintain
cell surface redox balance as previously reported (Jiang etal 1999).
In summary, the present study demonstrates RFP-PDI construct as a cell
surface oxidative stress sensor. From protein sensor point of view, the increase
in RFP-PDI fluorescence with oxidative stress is good. On the other hand, from
physiological point of view the increased association of RFP-PDI to cell surface
would mean attenuation/inhibition of thiol-dependent signaling pathways. In future
studies, the RFP-PDI probe could be potentially utilized in

in-vivo

studies to

monitor oxidative stress.
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CHAPTER-5
Endoplasmic reticulum stress-mediated inhibition of
NSMase2 elevates plasma membrane cholesterol in
endothelial cells

Published as original in Biochimica et Biophysica Acta 1821 (2012) 313-323.
123

1. Introduction
Dysfunction of endothelium is a common factor in the pathogenesis of many
cardiovascular diseases such as hypertension, coronary artery disease, diabetes,
chronic heart failure, peripheral artery disease and chronic renal failure (Cai et al
2000; Heitzer et al 2001). Previous studies in humans have shown that
endothelial dysfunction is an early step in the development of atherosclerosis
(Poredos et al 2002; Davignon et al 2004). Endothelial dysfunction is
characterized by imbalance between vasodilation and vasoconstriction (Vane et
al 1990; Masaki et al 1995). A central feature of endothelial dysfunction is
reduced nitric oxide (NO) generated by endothelial nitric oxide synthase (eNOS),
increased oxidative stress and hypercholesterolemia (Nedeljkovic et al 2002;
Kawano et al 2002). Increased oxidative and nitrosative stress also play a
significant role in the pathogenesis of endothelial dysfunction (Ohara et al 1993;
Keaney et al 1995; Pacher et al 2005; Eizirik et al 2008 and Civelek et al 2009).
ROS generating enzymes like NADPH oxidase (NOX2) and eNOS localize
to plasma membrane lipid rafts in endothelial cells. Superoxide anion produced
under oxidative stress and NO produced from eNOS interacts to form
peroxynitrite (ONOO ) that attacks several biomolecules causing endothelial
dysfunction. Peroxinitrite promotes tyrosine nitration in proteins and thus
considered as a marker for nitrating species in cells (Halliwell et al 1997; Eiserich
et al 1998; Pacher et al 2005).
Endoplasmic reticulum (ER) stress leads to increase in unfolded/misfolded
proteins in the ER lumen thus disrupting ER homeostasis. ER stress activates
unfolded protein response (UPR), an early event in progression of endothelial
dysfunction. Recent evidences indicate that ER stress accompanied by
dysregulated cholesterol metabolism raises cellular cholesterol levels (Haze et al
1999; Ye et al 2000; Werstuck et al 2001; Lee et al 2004; Ji et al 2006 and
Colgan et al 2007).
Golgi residing Site-1 protease (S1P) and Site-2 protease (S2P) cleave and
activate activating transcription factor 6 (ATF6) in response to ER stress. ATF6
activates genes responsible for ER protein folding and trafficking, thus involved in
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restoration of ER homeostasis (Lee et al 2004 and Colgan et al 2007). Sterol
Regulatory

Element

Binding

Proteins

(SREBPs)

are

membrane bound

transcription factors that regulate cholesterol synthesis in cells (Sakakura et al
2001; Edwards et al 2000). S1P and S2P of Golgi also cleave and activate
SREBP-2 to activate transcription of target genes required for synthesis and
uptake of cholesterol.
Neutral Sphingomyelianse 2 (NSMase2) is a caveolae residing plasma
membrane protein with Mg2+-dependent enzyme activity. NSMase catalyze the
hydrolysis of sphingomyelin to ceramide and phosphocholine. Ceramide is
involved in various cell signal transduction pathways such as cell differentiation,
cell proliferation, apoptosis and regulation of sterol homeostasis (Chatterjee et al
1999).
It is well established that NSMase2 regulates cellular cholesterol
homeostasis. NSMase maintains cholesterol balance in cell by translocation of
excess cholesterol from plasma membrane to ER (Liza et al 2003). Previous
studies have shown that mammalian cells treated with NSMase2 downregulates
cholesterol synthesis and upregulates cholesterol esterification (Slotte et al 1988;
Gupta et al 1991; Stein et al 1992; Ohvo-Rekila et al 2002; Lei et al 2007). Other
studies have shown that extracellular NSMase treatment produces a factor that
prevents the nuclear entry of SREBP-2 by inhibiting its proteolytic processing
(Nohturfft et al 1999). Recent studies in neuronal cells have shown that oxidative
stress resistance increased sphingomyelin and cholesterol levels accompanied
by decrease in NSMase activity (Clement et al 2009). However, data obtained
with cancer cells show that oxidative stress results in increased NSMase2 activity
(Matmati et al 2008; Yoshimura et al 2008).
The objectives of this study are 1- To determine if ER stress increase
plasma membrane cholesterol content in cells. 2- The effect of ER stress on
plasma membrane resident protein NSMase2 and cholesterol content in cells.
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2. Experimental Methods

Cell culture and treatment
Bovine aortic endothelial cells (BAEC) were obtained from Coriell Research
Repository. The cells were maintained in F-12 complete medium (ATCC)
supplemented with 10%FBS (Invitrogen), 100 pg/mL Streptomycin, and
100 U/mL Penicillin (GIBCO). Cells from passages five to ten were used for all
studies. All cells were maintained in a humidified incubator at 37 °C with 5% C02
and 95% air. In most of the experiments the cells were treated with Tm
(10 pg/mL) or Pm (500 pM) for 24h unless otherwise stated. Cells that were mock
treated with culture medium at the corresponding times were taken as control.

Monitoring cell viability
Cell viability was determined by trypan blue dye exclusion assay. Cells were
grown to 80% confluence in 6-well plates and treated with Tm (10 pg/mL) or Pm
(500 pM) for 24 h as described before. After incubation, the media was removed
and cells were trypsinized. The cell viability was assessed by mixing aliquots of
cell suspensions (100 pi) with an equal volume of 0.4% Trypan blue solution
(Gibco, Canada) for 2 min. Cells were visualized under a light microscope to
determine the percentage of cells that picked up the Trypan blue dye.
NSMase2 Overexpression
BAEC were grown in 24-well glass bottom plates (4 *104 cells/well, MatTek
Corp) and transiently transfected with 5 pg of the pCMV-SPORT6 NSMase2
expression plasmid (IRAV 90-H-1 (SO# 98041), Product #6399438, Open
Biosystems) using 100 pL of the Lipofectamine LTX transfection reagent
(Invitrogen) according to the manufacturer's instructions. The transfection was
carried out for 24h until 80% of the cells were transfected. The overexpression of
NSMase2 in cells was assessed by indirect immunofluorescence.
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NSMase2 Knockdown
RNA interference approach was employed for knockdown of NSMase2.
Three targets were selected with the following sequence:
1-678: Sense: 5-CAGUGAAUGGAAGGGUACAGGUCCU-3',
Antisense: 5'-AGGACCUGU ACCCUUCCAUUCACUG-3';
2-1637: Sense: 5'-UUGAGAUACAG CGCUCCCUUUGAGG-3',
Antisense: 5'-CCUCAAAGGGAGCGCUGUAUCUCAA-3';
3-2120: Sense: 5'-UUCAGCAGCUCUUUGCGUCCCUUCU-3',
Antisense: 5'-AGAAGGGACGCAAAGAGCUG CUGAA-3'.
siRNA was transfected into BAECs by using oligofectamine according to
the manufacturer's instructions. BAEC were cultured in 35 mm plates and
incubated with 375 pmol of siRNA and oligofectamine reagent in serum free
media. After 4 hour incubation, the growth medium with 3X serum was added
without removing the transfection mixture and further incubated for 24h.
Knockdown of NSMase2 was assessed by indirect immunofluorescence.

Epifluorescence

estimation

of

plasma

membrane

and

intracellular

cholesterol
Plasma membrane cholesterol was estimated with the GFP construct of
perfringolysin-O-domain-4 (PFO-D4-GFP) (Miersch et al 2008, Ohno-lwashita et
al 2010). BAEC were cultured on cover slips and stained with PFOD4-GFP
(750 nM) for 30min at room temperature in the dark. Cells were washed 3X 2 mL
with PBS. The cells were then fixed with 3% paraformaldehyde for 1h at room
temperature. After fixation, cells were washed 3X 2 mL with PBS and incubated
with propidium iodide (1 mg/mL) for 15min to stain the nuclei and once again
washed 3X 2mL with PBS and imaged. Intracellular non-esterified cholesterol
was estimated with filipin (Blanchette-Mackie et al 1988). For filipin staining,
BAEC grown on coverslips were fixed with 3% paraformaldehyde for 1h at room
temperature. After fixation cells were washed 3X 2 mL with PBS and incubated
with 0.05 mg/mL of filipin in PBS with 10% fetal bovine serum for 2h in the dark.
Cells were washed 3X 2 mL with PBS and further incubated with propidium
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iodide (1 mg/mL) for 15min to stain the nuclei. Cells were then washed 3X 2 mL
with PBS and imaged. The epifluorescence-capable microscope used in these
studies was a Zeiss Axiovert 200M inverted fluorescence microscope equipped
with UV/FITC/TRITC/DAPI filter cubes. The imaging was performed with an
ECPIan-Neofluar 40X oil objective. Images were analyzed with the aid of
Northern Exposure 6.0 image analysis software (Empix, Mississauga, ON) and
ImageJ. The filipin staining in Figure 4A was done by Ryan McLarty.

Immunofluorescence
Cells were cultured on coverslips and treated with Tm (10pg/mL) or Pm
(500 pM) for 24h as described before. NSMase2 staining was performed as
described previously (Tani et al 2007, Milhas et al 2010). Cells were fixed with
3% paraformaldehyde for 1h at room temperature, followed by permeabilzation
with 0.5% Triton X-100 in PBS for 5min. Cells were then washed 3X 2 mL with
PBS and incubated with blocking buffer (5% BSA in PBS) for 1h. Cells were then
incubated with anti-N02-Tyr (Abeam, 1:200) and anti-NSMase2 (Santa Cruz,
1:100) antibody with blocking buffer for 2h. After washing with PBS (3X 2 mL),
cells were incubated with goat anti-rabbit Alexa 488 and goat anti-mouse Alexa
568 (1:1000, Molecular Probes, Canada) for 1h. For staining nuclei, 1.0 pM
Hoechst 33342 stain was added and further incubated for 5min. Cells were then
washed 3X 2 mL with PBS and mounted on slides with fluoromount G (Southern
Biotech) and examined by inverted fluorescence microscope.

Immunoprecipitation of NSMase2
Isolation of plasma membranes from cells was performed as previously
described (Koizumi et al 1976). To the isolated plasma membrane, 10 volumes of
0.1% Triton X-100, 10 mM Tris/HCI (pH 7.5), 0.2 mM MgCh and protease
inhibitor cocktail were added and sonicated for 30s at 4°C. The concentration of
Triton X-100 was then raised to 1.0% and incubated overnight at 4°C. The
membrane fractions were then centrifuged for 10 min at 30,000g. The
supernatant after centrifugation was pre-cleared with Protein G beads (GE
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Healthcare) for 1h at 4°C and used for immunoprecipitation (IP) experiments. To
the supernatant rabbit anti-NSMase2 antibody (1:25, Santa Cruz Biotechnology)
was added and incubated for 90min at 4°C. Protein G beads was added to the
supernatants and the mixture was incubated at 4°C for 2h. The beads were spun
down by centrifugation (400g for 5min) and washed once with wash buffer
(20 mM Tris HCI pH 7.5 and 0.2% Triton-X 100). Following centrifugation, elution
buffer (20 mM Tris HCI pH 7.5, 0.2% Triton-X 100 and 4% SDS) was added to
beads and incubated for 15min. The beads were then centrifuged at 400g for
5min to collect the eluted protein and analyzed for NSMase2 by western
immunoblots.

Detection of ROS in BAECs
ROS production in BAECs was estimated as described in image-iT™
(Molecular Probes, I36007) according to the manufacturer's instructions. Briefly,
BAECs were cultured on cover slips and treated with or without Tm (10 pg/mL) or
Pm (500 pM) for 24 h. After treatment, cells were washed gently with warm
Hank's balanced salt solution (CaCI2 (1.26 mM), MgCI2 (0.493 mM), MgS04.7H20
(0.407 mM), KCI (5.33 mM), KH2P04 (0.441 mM), NaHC03 (4.17 mM), NaCI
(137.9 mM), Na2HP04 (0.338 mM), Glucose (5.56 mM)). Cells were incubated at
37 °C for 30min with 25 pM of 5-(and-6)-carboxy- 2',7'-dichlorodihydrofluorescein
diacetate (carboxy-H2DCFDA) solution in 5% C02 humidified incubator. Cells
were further incubated with 1.0 pM Hoechst 33342 stain for 5min to stain the
nuclei. Cover slips were washed 3x with warm Hank's balanced salt solution and
imaged immediately (Zeiss Axiovert 200 M) using excitation/emission maxima of
495 nm/529 nm for dichlorofluorescein (DCF) and 350 nm/461 nm for Hoechst
33342 stain.

Statistics
The error bars represent mean ± S.D. The data was analyzed with a paired,
two-tailed Student's t-test and a value of p<0.001 was considered significant
(indicated by * in figures).
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3. Results

ER Stress induction effects on cell viability
ER stress induced cell death was assessed by trypan blue exclusion assay.
Cells were incubated with the indicated concentrations of palmitate (Pm) and
tunicamycin (Tm) to induce ER stress for 24h and then analyzed for cell viability.
The trypan blue exclusion assay showed that ~94% cells were viable in the
controls, however the viability of Tm and Pm-treated cells decreased by 3% and
8% with respect to control cells (Figure 1). These results demonstrate minimal
effect of ER stress on cell viability and these viable cells were used for
subsequent experiments.
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Figure 1: Cell Viability in ER stressed BAEC.
BAECs were treated with Tm (10 |jg/mL) or Pm (0.5 mM) for 24h
as described before. Viability was assessed using Trypan blue exclusion assay.
The results represent percentage of viable cells. Data is shown as mean ± S.D
(n=3).
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ER stress elevates both intracellular and plasma membrane cholesterols
Previous studies in human aortic smooth muscle cells and hepatocytes
have demonstrated that ER stress activates SREBPs. The activation of SREBPs
is associated with upregulation of cholesterol biosynthesis and elevation in
intracellular cholesterol (Werstuck et al 2001; Lee et al 2004; Ji et al 2006;
Colgan et al 2007). In the current study, we extended these findings to BAEC and
utilized the well-characterized ER stressors Tm and Pm. The ER stress induced
by Tm and Pm inhibit protein glycosylation and lipid dynamics that compromise
ER membrane integrity, respectively (Zinszner et al 1998; Kharroub et al 2004).
Filipin was used to fluorescently probe for non-esterified intracellular cholesterol
(Blanchette-Mackie et al 1988) and perfringolysin-O-domain 4-GFP construct
(PFO-D4-GFP) as a probe for PM cholesterol (Miersch et al 2008; Ohno-lwashita
et al 2010).
In agreement with previous studies, exposure to either Tm or Pm yielded ~3
to ~3.2-fold elevations in the filipin fluorescence at the perinuclear/ER regions of
the cell (Figure 2A, B) a clear indication of intracellular accumulation of
cholesterol upon induction of ER stress. For the first time, we report that ER
stressors increase PM cholesterol as evidenced by ~2.4 to ~2.9-fold increase in
the fluorescence of PFO-D4-GFP (Figure 2C, D).
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Figure 2: Intracellular and plasma membrane cholesterol content is
increased in ER-stressed BAEC.
(A) BAECs were grown on coverslips and either control mock treated for 24h (C
24h) or Pm (0.5 mM) treated for 24h (Pm 24h) or Tm (10 pg/mL) treated for 24h ,
(Tm 24h). The cells were then fixed and stained with filipin (intracellular nonesterified cholesterol) and propidium iodide (nuclear stain) and imaged.
(B) The image data in Fig. 2A from -20 cells/treatment were digitized with the aid
of ImageJ to convert the filipin fluorescence to average gray per unit area. The
filipin fluorescence is represented as % of control (C 24h) average gray values.
The data shown are representative of 3 separate experiments with error bars
showing S.D.; * p < 0.001, two-tailed t-test.
(C) BAECs were grown on coverslips and either control mock treated for 24h (C
24h) or Pm (0.5 mM) treated for 24 h (Pm 24h) or Tm (10 Mg/ml_) treated for 24h
(Tm 24h). The cells were then stained with PFOD4-GFP (PM non-esterified
cholesterol), fixed and stained with propidium iodide (nuclear stain) and imaged.
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(D) The image data in Fig. 2C from -20 cells/treatment were digitized with the aid
of ImageJ to convert the filipin fluorescence to average gray per unit area. The
PFOD4-GFP fluorescence is represented as % of control (C 24h) average gray
values. The data shown are representative of 3 separate experiments with error
bars showing S.D.; * p < 0.001, two-tailed t-test.
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Neutral sphingomyelinase 2 in BAEC is modified by reactive oxygen and
reactive nitrogen species during ER stress
Plasma membrane-resident NSMase2 is one of the key enzymes implicated
in the regulation of cellular cholesterol homeostasis (Slotte et al 1988; Stein et al
1992; Stein et al 1992; Clement et al 2009). We next sought to determine if
NSMase2 in BAECs is modified by ER stress. It is well known that reactive
oxygen species (ROS) are produced upon the onset of ER stress (Yeh et al
2004; Santos et al 2009; Li et al 2010; Yoon et al 2010). Here, we confirmed this
with the oxidative fluorogenic probe carboxy-H2DCF, where a -2.3 to -2.6- fold
increase in intracellular ROS was detected 24 h post-treatment with either Pm or
Tm (Figure 3A).
To examine whether NSMase2 was modified by reactive nitrogen
compounds during ER stress, the immunoprecipitated NSMase2 from either Pm
or Tm-treated BAEC (24h) was subjected to western blot analysis with antinitrotyrosine antibodies. These data showed that ER stress resulted in a ~3-fold
increase in NSMase2 nitration relative to untreated controls (Figure 3B, C). As
further confirmatory evidence, we determined tyrosine nitration of NSMase2 by
immunofluorescence. We report -1.2 and -1.4 fold fluorescence of NSMase2
(Figure 4 A, B) and -1.9 and -1.2 fold increase in fluorescence of nitrotyrosine
staining compared to controls (Figure 4C,D).
These results indicate that both nitrosative and oxidative stresses play a
role in the modification of proteins, including NSMase2, upon the onset of ER
stress.
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Figure 3. Evidence of RONS production in BAEC.
BAEC were cultured on cover slips and mock control treated for 24h (C 24h) or
palmitate (0.5 mM) treated for 24h (Pm 24h) or tunicamycin (10 M9/mL) treated
for 24h (Tm24h). Cells were incubated at 37°C for 30min with 25 |jM carboxyH2DCFDA solution in 5% CO2 humidified incubator and imaged immediately
using excitation/emission maxima of 495nm/529nm for the oxidation product of
carboxy-H2DCFDA.
(A) Carboxy-H2DCFDA image data from -100 cells/treatment were digitized with
the aid of ImageJ to convert the carboxy-h^DCFDA fluorescence to average gray
per unit area. The carboxy-HaDCFDA fluorescence is represented as % of control
(C 24h) of average gray values. The data shown is representative of 2 separate
experiments with error bars showing S.D.; * p<0.001, two-tailed t-test.

(B)

Anti-nitrotyrosine (upper) and anti-NSMase2 (lower) immunoblots of

NSMase2 immunoprecipitated from the plasma membranes of variously treated
BAEC (5 X105 cells/1Ocm culture plate): Confluent control cells before (Lane 1)
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and after 24h mock treatment (Lane 2); palmitate (0.5 mM), treated for 24h (Lane
3) or tunicamycin (Lane 4) treated for 24h (Lane 4) probed with anti-nitrotyrosine
antibodies.
(C) The band density of anti-nitrotyrosine blots in Figure 5B: confluent control
cells (C Oh); mock control treated for 24h (C 24h); palmitate (0.5 mM) treated for
24h (Pm 24h) or tunicamycin (10 pg/mL) treated for 24h (Tm 24h) estimated by
ImageJ software and presented relative to % of control. The data shown is
representative of 3 separate experiments with error bars showing S.D.; *
p<0.001, two-tailed t-test.

137

NSMasez-Green; Nuclei-Blue

o
S0) =•
o 300
c O 200

s

|— 100

C 24h

Pm 24h

Tm 24h

Pm24h

NO,-Tyr-Red

Tm24h

400
u

!=• 300
Si
o2 co

= O 200

fc o
*7
S®
n —

o
z
C24h

Pm 24h

Tm 24h

198

100

o >
Pm24h

Tm24h

Figure 4. NSMase2 tyrosine nitration in BAECs.
(A) BAEC were cultured on cover slips and mock control treated for 24h (C 24h)
or palmitate (0.5 mM) treated for 24h (Pm 24h) or tunicamycin (10pg/mL) treated
for 24h (Tm 24h). The cells were then fixed and stained with anti-NSMase2, antiN02-Tyr and Hoechst (nuclear staining).
(B) The image data in Fig. 4A were digitized with the aid of ImageJ to convert the
NSMase2 fluorescence to average gray per unit area. The NSMase2
fluorescence is represented as % of control (C) average gray values. The data
shown are representative of 2 separate experiments with error bars showing S.D.
(C) BAEC were cultured on cover slips and mock control treated for 24h (C 24h)
or palmitate (0.5 mM) treated for 24h (Pm 24h) or tunicamycin (10 pg/mL) treated
for 24h (Tm 24h). N02-Tyr staining in red is shown.
(D) The image data in Fig. 4C were digitized with the aid of ImageJ to convert the
N02-Tyr fluorescence to average gray per unit area. The N02-Tyr fluorescence is
represented as % of control (C) average gray values. The data shown are
representative of 2 separate experiments with error bars showing S.D.
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The effects of NSMase2 over-expression or knock down on cholesterol
content in BAECs
In the current study, we observed that ER stress increases ROS and
modifies NSMase2, which has been previously suggested to lead to elevated
cellular cholesterol (Stein et al 1992; Liza et al 2003). To further support the key
role of NSMase2 in ER stress-mediated increases in plasma membrane
cholesterol, NSMase2 in BAEC was altered by expression plasmid and RNA
interference (RNAi) techniques.
The epifluorescence data indicate that intracellular and plasma membrane
cholesterol contents were not significantly affected by NSMase2 over expression
(OE) (Figure 5A, B, C, D). In contrast, the Knock down (KD) of NSMase2 resulted
in a striking ~2.8-fold increase in intracellular and ~1.7-fold increase in PM
cholesterol (Figure 5A, B, C, D). These results indicate that inhibition of
NSMase2 can result in build up of plasma cholesterol.
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Figure 5: The effects of NSMase2 over-expression or knock down on
cholesterol content in BAEC.
(A) BAEC control cells after (C 24h) or NSMase2 over expressed (OE), or
NSMase2 knocked down (KD) cells were grown on coverslips for 24h and
fixed/stained with filipin (intracellular non-esterified cholesterol) and propidium
iodide (nuclear staining) and imaged.
(B) The image data in Figure 4A from ~20 cells/treatment were digitized with the
aid of ImageJ to convert the filipin fluorescence to average gray per unit area.
The filipin fluorescence is represented as % of control (C 24h) of average gray
values. The data shown is representative of 3 separate experiments with error
bars showing S.D.; * p<0.001, two-tailed t-test.
(C) BAEC control cells after (C 24h) or NSMase2 over expressed (OE), or
NSMase2 knocked down (KD) cells were grown on coverslips for 24h and stained
with PFOD4-GFP (plasma membrane non-esterified cholesterol), fixed

and

stained with propidium iodide (nuclear staining) and imaged.
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(D) The image data in Figure 4C from -20 cells/treatment were digitized with the
aid of ImageJ to convert the PFOD4-GFP fluorescence to average gray per unit
area. The PFOD4-GFP fluorescence is represented as % of control (C 24h) of
average gray values. The data shown is representative of 3 separate
experiments with error bars showing S.D.; * p<0.001, two-tailed t-test.
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4. Discussion
A previous study from our lab has demonstrated an inverse relationship
between PM cholesterol levels and NO-diffusion and NO-signaling (Miersch et al
2008). In that study, plasma membrane cholesterol levels were manipulated with
cyclodextrin and fibroblasts from sterol transport-defective Niemann-Pick type C1
were used as model system for elevated plasma membrane. The aim of this
study is to investigate the conditions responsible for elevation of plasma
membrane cholesterol levels in normal cells. Recent studies have shown that
cholesterol biosynthesis was upregulated in ER-stressed hepatocytes and aortic
smooth muscle cells (Werstuck et al 2001; Kim et al 2005; Colgan et al 2007).
However, these studies did not extend to the effect of ER stress on plasma
membrane.
The epifluorescence data with filipin as the intracellular cholesterol probe
indicated that induction of ER stress by either Pm or Tm in BAEC increased
intracellular cholesterol by ~3-fold (Figure 2A, B). These results are consistent
with results observed with hepatocytes and smooth muscle cells using a different
ER stressor (homocysteine) (Werstuck et al 2001; Kim et al 2005; Colgan et al
2007), strongly suggests that cellular cholesterol upregulation is a general, ER
stress-related, phenomenon. The epifluorescence data with PFO-D4-GFP shows
that ER stress did significantly elevate plasma membrane cholesterol (Figure 2A,
B).
To identify the mechanism by which ER stress leads to elevation in
cholesterol biosynthesis, we focused on NSMase2 that has been implicated in
regulation of plasma membrane cholesterol levels (Liza et al 2003). It is well
established that NSMases are localized to discrete sphingolipid-cholesterol-rich
lipid rafts/ caveolar microdomains in plasma membrane (Zhang et al 2010).
Elevated cholesterol in the plasma membrane activates NSMase2 that directs
translocation of excess cholesterol to ER followed by esterification (Slotte et al
1988).
Several reports have revealed association between oxidative stress and ER
stress. It is widely accepted now that reactive oxygen species (ROS) are
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produced upon the onset of ER stress (Yeh et al 2004; Santos et al 2009; Li et al
2010; Yoon et al 2010). Intracellular ROS in BAECs increased by -2.3 to -2.6fold upon ER stress (Figure 3A).
The most important source of ROS in endothelium appears to be the
NADPH oxidase.

A recent study (Li et al 2010) has shown that the plasma

membrane resident, superoxide generating enzyme, NADPH oxidase (NOX2) is
significantly upregulated by ER stress. The fact that NOX and eNOS, are both
located in the plasma membrane suggests that their products will readily react to
generate peroxynitrite. Protein tyrosine nitration and inhibition of the protein
function mediated by peroxynitrite is previously reported (Surmeli et al 2010). The
formation of peroxynitrite could favor nitration of tyrosine containing proteins that
are localized in plasma membrane lipid-rafts. Our results indicate that under
conditions of ER stress, there is a -3-fold increase in tyrosine nitration of
NSMase2 (Figure 3B, C). The data with immunofluorescence also show increase
in tyrosine-nitration of NSMase2 (Figure 4C, D). Therefore, these lines of
evidence strongly suggest that reactive nitrogen compounds modify NSMase2.
Under normal conditions active NSMase2 yields phosphocholine and
ceramide from sphingomyelin. The removal of the sphingomyelin from the
cholesterol-sphingomyelin complex leads to the accumulation of free plasma
membrane cholesterol that is translocated to the ER. Thus maintaining
cholesterol homeostasis under normal conditions. RONS produced during ER
stress inactivate a significant fraction of NSMase2 resulting in less free
cholesterol and ceramide. Lower ceramide also means that the inhibitory control
on SREBP is removed, thus upregulating both intracellular and membrane
cholesterols. To further test our hypothesis that the ER stress-mediated inhibition
of NSMase2 can lead to elevations of both cellular and PM cholesterol levels, we
over-expressed and knocked down NSMase2 in BAEC. The results with
NSMase2 knock down show statistically significant elevations in both intracellular
and plasma membrane cholesterols (Figure. 5A, B, C, D). However, the
immunofluorescence data with NSMase2 over expression has shown statistically
insignificant lowering in intracellular cholesterol (Figure. 5A, B, C, D). Taken
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together, these studies clearly indicate that inhibition of NSMase results in
increased cellular cholesterol levels.
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CHAPTER-6

Exploring the role of AZD6140 on P2Y12-Cholesterol raft
interactions in platelets
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1. Introduction
ADP plays an important role in platelet aggregation via activating two major
ADP receptors on platelets P2Y1 and P2Y12 (Jasper et al 2002). P2Y12 is a Gprotein coupled receptor (GPCR), which initiates signaling via the inhibition of
adenylate cyclase and activation of PI3K (Dorsam et a/2004). P2Y12 signaling is
indispensable for ADP-induced complete platelet aggregation and for the
stabilization of aggregates (Gachet et al 2001). The human P2Y12 receptor is
342 amino acid protein comprised of seven-transmembrane helices (Cavallari et
al 2007) that is predominantly expressed in platelets.
P2Y12 is a plasma membrane cholesterol raft-resident protein (Savi et
al 2006). Cholesterol (or lipid) rafts are specialized microdomains within the
plasma membrane and serve as a scaffold for a variety of signaling molecules
like the GPCRs. A variety of GPCRs are known to localize in lipid rafts, including
EDG-1 receptor (endothelial differentiation gene-1), adenosine A1 receptors, a1adrenergic receptor and bradykinin receptor B2 (De Weerd et al 1997;
Schwencke et al 1999; Igarashi et al 2000; Lasley et al 2000; Fujita et al 2001).
Recent studies indicate that these GPCR signaling molecules must form
clustered and oligomeric structures on plasma membrane cholesterol rafts for
biological properties of the receptor such as signaling, ligand binding and
regulation induced by agonist (Rocheville et al 1999; 2000).
The ability of the P2Y12 receptor to couple to Gai protein in ADPmediated platelet activation is highly dependent on localization of the receptors in
cholesterol (or lipid) rafts in platelets (Quinton et al 2005). Furthermore, agents
that disrupt the clustering or dimerization of raft resident proteins can partition
them out of lipid rafts thereby attenuating their signaling pathways (Cunningham
et al 2003; Higuchi et al 2003; Sabourin et al 2002).
In fact, the free thiol-containing, active metabolite (act-met) of the
antithrombotic drug clopidogrel is postulated to act by disrupting P2Y12 oligomer
formation and was recently shown to induce the removal of P2Y12 from
cholesterol rafts (Pereillo et al 2002; Savi et al 2006). These studies that were
conducted on P2Y12 expressed in human embryonic kidney (HEK293) cells
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showed that act-met was able to reduce disulfide-linked oligomers of P2Y12.
Once reduced the P2Y12 monomers were unable to interact with cholesterol rafts
and were partitioned out of the rafts.
One aspect of this study is very curious: Pereillo et at (2002) have
determined that the act-met thiol is very reactive. However, clopidogrel-act-met
thiol would not be expected to remain reduced and unconjugated in the relatively
oxidizing and protein rich environment of the plasma. This raises the possibility
that clopidogrel-act-met-mediated disruption of P2Y12 clustering on cholesterol
rafts does not require thiol-disulfide exchange as postulated by Savi et al (2006)
but is due instead to conformational changes induced by oxidized (disulfidelinked) clopidogrel-act-met binding to P2Y12.
We therefore hypothesized that ticagelor (AZD6140) a reversible high
affinity P2Y12 antagonist (Kim et al 2011) devoid of free thiols, could also inhibit
ADP-mediated signaling by disrupting P2Y12 clustering on cholesterol rafts. It is
well established that platelets of type-2 diabetic (T2D) patients are hyper
reactive, and display increased adhesion and aggregation as compared to normal
platelets (Vinik et al 2001, Kajita et al 2001, Gabbianelli et al 2003, Redondo et al
2005, Signorello et al 2007). Therefore, it is important to test if AZD6140
functions in a similar manner to disrupt P2Y12 oligomers in T2D and normal
platelets. Another goal is to compare the effect of AZD6140 on ADP dependent
platelet aggregation in vitro in normal and T2D platelets and also to assess the
reversibility of the effect of AZD6140 on P2Y12 receptor oligomerization and
aggregation.

147

2. Experimental Methods

Subject Selection
Healthy human subjects (n=10), ages 25-70 years were chosen to
participate in the study only if they showed no overt symptoms of disease and
were taking no medication. None of the patients smoked or had a history of
alcohol abuse. Human subjects (n=25), ages 35-70 with newly diagnosed type 2
diabetes are chosen for the study from the clinic of Dr. Rabih Nour, consultant
endocrinologist, 100-1390 Walker Rd, Windsor, ON. Individuals were selected
who were subsequently managed with metformin and lifestyle intervention. The
Research Ethics Boards at University of Windsor approved all experimental
protocols.

Blood collection and isolation of platelets
Whole blood was collected from healthy volunteers and T2D patients into
blood collection tubes containing ACD (VWR). Isolation of platelets was
performed using standard protocol as described previously (Miersch et al 2007).
Platelets were fluorescently labeled with 60 pM BODIPY® FL N-(2-aminoethyl)
maleimide (Molecular Probes, Canada). After 30 min incubation, labelledplatelets were harvested by washing twice with HEPES-ACD buffer to remove the
excess dye and were reintroduced into blood.

Construction of and Protein Immobilization in flow chambers:
Construction of and protein immobilization in flow chambers was performed
as described previously (Kaur et al 2010). The flow chamber consists of Teflon
holder with matching holes on two sides and was adhered to a glass coverslip
(1.5cm) using polydimethylsiloxane (PDMS) plus curing agent (10:1). Teflon
tubing (2 cm) was inserted through the holes of Teflon holder followed by filling
the mold with PDMS plus curing agent (10:1). After incubation at 60 °C for 6h, the
teflon tubing was pulled through the holes to create cylindrical tubes. PDC-32G
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(Harrick Plasma, USA) plasma cleaner was used to generate silanol groups on
PDMS surface of flow chamber (Miyaki et al 2007).
Following plasma oxidation, the flow chamber was amine-derivatized. The center
of the flow chamber was coated with 5 pi of 2% aminopropyltrimethoxysilane
(APTMES) (Sigma, Canada) for 10 min to generate an amine terminated surface
layer. The bi-functional amine directed reagent disuccinimidylsuberate (DSS,
0.5pl of 0.5mM) (Pierce, USA) was then added to the APTMES ring followed by
Type I fibrinogen from bovine plasma (1 \i\ of 5 pM) (Sigma, Canada) and
incubated for 15 min. DSS covalently couples fibrinogen via its free amines to the
amine-terminated inner surface of the flow chamber. The reaction was stopped
by passing through 10 mL of 0.15 M Tris-HCI, pH 8.0 at a flow rate of 2 ml/min.
Platelet aggregation in flow chambers:
The platelets from normal and T2D subjects were isolated, fluorescently
labeled with BODIPY® FL N-(2-aminoethyl) maleimide and reintroduced into the
whole blood. The isolated blood was divided into two aliquots. One aliquot served
as a control whereas the second aliquot was exposed to AZD6140 to a final
concentration of 30 |^M (concentration as suggested by Astrazeneca) and
incubated for 1h with gentle agitation. ADP-induced platelet adhesion was
monitored in real-time using inverted fluorescence microscope (Zeiss Axiovert
200M) set with FITC filter cube. Images were captured every 20s interval (5X
objective) using a CCD camera (Hitachi KP-F140F). Micropumps were used for
mixing the blood sample containing the fluorescently labeled platelets (0.95
mL/min) with the platelet activator ADP 20 |jM final concentration (400 |jM, 0.95
mL/min) at a t-junction before the blood enters the flow chamber. Image analysis
was performed using Northern Eclipse 6.0 (Empix, Mississauga, ON) and ImageJ
(NIH) software.
The reversibility of AZD6140 was tested as follows: After a 1hr incubation
period with 30 ^iM of AZD6140, the platelets were isolated and re-suspended in
platelet free blood. The solutions used for isolation of platelets and the platelet
free blood used to re-suspend the platelets did not contain any AZD6140, thus
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ensuring that the drug was washed out during these procedures.
The effect of AZD6140 on platelet adhesion in clopidogrel treated subjects
was tested as follows: The platelets from clopidogrel-pretreated subjects were
isolated and fluorescently labeled. The labeled platelets were reintroduced into
the whole blood and divided into two aliquots. One aliquot served as control
whereas the second aliquot was exposed to AZD6140 to a final concentration of
30

and incubated

for 1h, ADP stimulated aggregation was assessed as

described above.
Cholesterol content in normal and T2D platelets
The cholesterol content in platelets from normal and T2D subjects was analyzed
by flow cytometry as described previously (Waheed et al 2001). The platelets
were isolated and resuspended in Hepes buffered saline pH 7.0 at a
concentration of 108 platelets/mL. The platelets were then treated with different
concentrations of GFP-PFO-D4 (0-500 nM) for 30 min. After incubation, platelets
were washed 3X with Hepes buffered saline (pH 7.0) and centrifuged at 500g for
5 min. The platelets were then resuspended in Hepes buffered saline and
analyzed on a Cytomics FC500 flow cytometer (Beckman Coulter, USA).
Isolation of lipid raft fractions and western blotting
Plasma membrane lipid rafts were isolated by sucrose density gradient
fractionation as previously described (Dorahy et al 1996; Quinton et al 2005; Savi
et al 2006). Briefly, platelets were solubilized in pre-cooled Triton X-100 lysis
buffer (0.5% Triton X-100/150 mM NaCI/25 mM Hepes, pH 7.0 containing
protease inhibitor cocktail). All subsequent steps were performed with precooled
solutions at 4°C. An equal volume of 80% sucrose in HBS was then added to
platelet lysate to adjust final concentration of sucrose to 40%. The lysate (final
volume of 1 ml at 40% sucrose) was placed at bottom of ultracentrifuge tube.
Successive volumes of 30% (1.5 mL) and 5% (0.75 mL) sucrose were layered
upon the 40% homogenate.
After centrifugation at 200,000xg in Beckman coulter, for 18h at 4°C in a
MLA-80 fixed angle rotor, eight equal fractions were taken, starting from the top
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of the gradient. The protein concentration in each fraction was determined by
bicinchoninic acid (BCA) assay. Twenty micrograms of each protein sample was
resolved on SDS-PAGE gel and transferred onto polyvinylidene fluoride (PVDF)
membranes.
The membrane was blocked in 5% nonfat dry milk in Tris-buffered
saline/Tween (TBST; 20 mM Tris, 140 mM NaCI, 0.1% Tween 20) for 1 h. The
membranes were incubated with anti-rabbit P2Y12 (1:200; Almone labs) or antimouse CD36 (1:1000; Abeam) for 2h at RT. After 3X washes with TBST, the
membranes were probed with horseradish peroxidase-conjugated anti-rabbit and
anti-mouse secondary antibodies (1:2000; Abeam), repectively for 1h at RT. The
membranes were washed 3X in TBST and bands were visualized by using
enhanced chemiluminescence reagent (Pierce, USA).
For isolation of lipid rafts from AZD6140-treated samples: AZD6140 was
added to the blood samples to the final concentration of 30 m.M. All subsequent
solutions used in the isolation of the platelets and their plasma membranes as
well the solutions employed in the sucrose density centrifugation experiments
contained 30 ^M AZD6140 in order to ensure that the AZD6140 effects on P2Y12
receptor were not reversed due the dilution of the drug during P2Y12 isolation.
For AZD6140-reversibility: The AZD6140 treated blood sample was divided into 2
aliquots. Platelets from one aliquot were isolated and suspended in buffer not
containing AZD6140 and incubated at 37°C for 1h.

The platelets were then

isolated from both the blood and buffer and analyzed for P2Y12 oligomerization
and raft association.
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3. Results

The effect of AZD6140 on P2Y12 receptor oligomers in human platelets
Initial characterization of P2Y12 receptor lipid-raft association was
determined by platelet lysis in Triton X-100 buffer followed by sucrose density
fractionation. Analysis of the gradient fractions for P2Y12 receptor was performed
by immunoblotting. Platelet P2Y12 was found in sucrose density gradient
fractions 3-6 both in samples obtained from normal subjects (Figure 1A). These
fractions also contained the platelet plasma membrane raft marker CD36
indicating that we were isolating the correct fractions (Figure 1B).
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Figure 1: Localization of P2Y12 oligomers in lipid rafts of human platelets.
Platelet plasma membrane lipid rafts were obtained by sucrose density gradient
ultracentrifugation as described in experimental methods. The gradient fractions
were then separated by SDS-PAGE under non-reducing conditions followed by
(A) anti-P2Y12 (B) anti-CD36 immunoblotting. The data shown are representative
of ten different experiments.
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To investigate whether AZD6140 antagonizes the P2Y12 receptor by
dissociating oligomers, the P2Y12 receptor oligomeric status was studied in both
normal and T2D platelets. P2Y12 receptor was in oligomeric form and highly
concentrated in the gradient fractions 3-6 in normal subjects (n=10, Figure 2A).
Similar results were obtained with T2D subjects (n=20, Figure 2C). After
treatment with AZD6140, the P2Y12 receptor oligomers were disrupted to dimers
and monomers. Of the 10 normal platelets samples analyzed, ~30% of the
P2Y12 oligomers were converted to apparent dimers plus monomer (Figure 2B,
Figure 3). The response of the T2D platelet samples to AZD6140 exposure was
drastically different than normals. T2D platelet (n=20) exposure to AZD 6140 (30
pM) resulted in >50% conversion of the P2Y12 oligomers to mainly dimers
(Figure 2D, Figure 3).
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Figure 2: The effect of AZD6140 on P2Y12 receptor oligomers in platelets.
Platelets from normal and T2D subjects were treated with AZD6140 (30 jaM) or
vehicle. Platelets were then solubilized in Triton X-100 lysis buffer followed by
sucrose density fractionation as described in methods. The centrifuged gradient
was divided into eight equal fractions and protein concentrations were
determined for each fraction. The aliquots containing equal quantities of protein
were subjected to SDS-PAGE under non-reducing conditions followed by antiP2Y12 immunoblotting. The figure is representative of P2Y12 oligomeric state
with (A) no AZD6140 (B) AZD6140 (30 \M) in normal subjects (n=10) and (C) no
AZD6140 (D) AZD6140 (30 fxM) from T2D subjects (n=20).
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Figure 3: Composite immunobiot data of P2Y12 receptor oligomer state in
platelets.
Western immunobiot densities of bands corresponding to P2Y12 oligomers
(~220KDa), dimers (~100KDa) and monomers (~50KDa) from normal (n=10,
white bars) and T2D (n=20, pink bars) platelets subsequent to AZD6140
treatment with anti-P2Y12 antibodies. Densitometry was performed using Image
J software for the blots and the error bars represent standard deviation.
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The reversibility of AZD6140 on P2Y12 receptor oligomers in human
platelets
It is well documented that GPCR clustering or oligomerization is essential
for the biological properties of the receptor. However, no studies to date have
demonstrated the effect of AZD6140 reversibility on P2Y12 receptor. Therefore,
we examined reversibility of AZD6140 with respect to P2Y12 receptor oligomers
in normal and T2D subjects. To this end, blood samples were treated with 30
AZD6140 for 1h, The platelets were isolated and suspended in buffer with no
drug. Platelet P2Y12 receptor from these subjects were isolated by sucrose
gradient centrifugation and quantified by immunobloting.
As illustrated in Figure 4A. upon removal of reversible agent from platelets,
the P2Y12 receptor regains oligomer forms. The quantification of P2Y12
oligomers after western blotting show ~50% and ~80% P2Y12 oligomers from
normal and T2D respectively (Figure 4B).
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Figure 4: Reversibility of AZD6140 on P2Y12 oligomers in platelets.
Platelets from normal and T2D subjects were treated with AZD6140 (30 h,M).
After 1h, platelets were isolation and resuspended in buffer not containing
AZD6140 and further incubated for 1h. Platelets were then solubilized in Triton
X-100 lysis buffer followed by sucrose density fractionation as described in
methods. The centrifuged gradient was divided into eight equal fractions and
protein concentrations were determined for each fraction. The aliquots containing
equal quantities of protein were subjected to SDS-PAGE under non-reducing
conditions followed by anti-P2Y12 immunoblotting. The figure is representative of
reversibility of AZD6140 on P2Y12 oligomers (A) normal subjects (left) and T2D
subjects (right). The data shown are representative of two independent
experiments.
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(B) Composite immunobiot data: Western immunobiot densities of bands
corresponding to P2Y12 oligomers from normal (n=2, white bars) and T2D (n=2,
pink bars). Densitometry was performed using Image J software for the blots and
the error bars represent standard deviation.
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Plasma membrane cholesterol content in normal and T2D platelets
In an effort to determine if the differential effects of AZD6140 on P2Y12
oligomers were related to platelet plasma membrane cholesterol concentration,
intact normal (n=4) and T2D (n=4) platelets were titrated with the cholesterol
specific probe perfringolysin-O-domain 4-GFP construct (PFO-D4-GFP). In
previous studies with model membranes, the relative mol% of cholesterol in
plasma membranes was related to the apparent PFO-D4-GFP:cholesterol
dissociation constant via the following relationship
Chol-mol% 1/ Choi Mol% 2= 0.86 eA0.123 (KD apparent 2^Kd Apparent l)- EC|1.
The PFO-D4-GFP affinity for intact normal and T2D platelets was
determined by exposing the isolated platelets to varying amounts of PFO-D4GFP and determining the % of platelets that were labeled at a given
concentration of PFO-D4-GFP by flow cytometry. The apparent KdS estimated
from a fit of the fluorescence saturation data (Figure 5) were 300 nM (KD apparent

2)

and 32 nM (KD apparent 1) for normal and T2D platelets respectively. Inserting these
values into Eq 1, T2D-platelets had ~3-fold larger mol% of cholesterol in
comparison to non-diabetic. Based on these results, the P2Y12 oligomer-stability
appeared to be inversely proportional to the plasma membrane cholesterol
content.
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Figure 5: Platelet plasma membrane cholesterol concentrations.
Isolated platelets from normal and T2D subjects were treated with different
concentrations of GFP-PFO-D4 (0-500nM) for 30min. Platelets were washed, resuspended in Hepes buffer saline and analyzed by flow cytometer. For each
sample, 10000 platelets were measured. The apparent Kps estimated from a fit of
the fluorescence saturation data for normal (white bars) and T2D (grey bars)
platelets are shown. The data presented is representative of four separate
experiments with error bars showing standard deviation.
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AZD6140 inhibits ADP induced platelet adhesion
The effect of AZD6140 on ADP-induced platelet adhesion was assessed in
fibrinogen coated flow chambers. The time dependent increase in the number of
platelets adhered was monitored. In these studies, the inhibition of platelet
adhesion in the presence of AZD6140 and the reversibility of drug was compared
to no AZD6140-treated controls. The number of platelets adhered to fibrinogen
coated flow chambers at 120s are shown in normal subjects (Figure 6) and T2D
subjects (Figure 7). In case of normal platelets, AZD6140 inhibited the initial rates
of aggregation by ~30-fold and decreased the total number of adhered platelets
by -96% (Figure 8A, Tables 1, 2). Whereas, with T2D platelets the initial rates
were inhibited by ~2.5-fold but the number of platelets adhered decreased by
75% upon AZD6140 exposure (Figure 8B, Tables 1, 2).
The reversibility of the drug's action on platelet adhesion show with normal
samples -50% of the initial rates and -50% of the total platelets adhered after
washout. Similar results were obtained with the T2D platelets where -60 % of
the initial rates and 50% of the platelets adhered post-washout (Figure 8, Tables

1,2).
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Figure 6: The effect of AZD6140 on platelet adhesion in Normal subjects
ADP-induced platelet adhesion on fibrinogen coated flow chambers perfused with
whole blood containing fluorescently labeled platelets. Representive images of
platelet adhesion from no AZD6140 (Top panel), AZD6140 (middle panel) and
reversibility of AZD6140 on platelet adhesion (bottom panel) are shown. Results
are representative of six different experiments. All experiments were done at
37°C.

Images were captured on Zeiss Axiovert 200 microscope using 5X

objective at 20s intervals. Northern Eclipse software (Empix, Canada) was used
for image capture and quantification of adhered platelets.
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Figure 7: The effect of AZD6140 on platelet aggregation in T2D subjects
ADP-induced platelet adhesion on fibrinogen coated flow chamber perfused with
whole blood containing fluorescently labeled platelets. Representive images of
platelet adhesion from no AZD6140 (Top panel), AZD6140 (middle panel) and
reversibility of AZD6140 on platelet adhesion (bottom panel) are shown. Results
are representative of six different experiments. All experiments were done at
37°C.

Images were captured on Zeiss Axiovert 200 microscope using 5X

objective at 20s intervals. Northern Eclipse software (Empix, Canada) was used
for image capture and quantification of adhered platelets.
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29±15
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15+5
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Table 2
n=6
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Max # of platelets bound (@ 120 sec)
NO AZD6140

+AZD 6140

AZD6140 Reversibility

Normal

3000±400

124±78

1700±102

T2D

17641402

440±175

941±112

Figure 8: Kinetics of ADP-induced platelet adhesion to fibrinogen coated
flow chambers
ADP-induced platelet adhesion on fibrinogen coated flow chamber perfused with
whole blood containing fluorescently labeled platelets. Graphs (A) and (B) show
platelets from normal and T2D subjects respectively adhered to fibrinogen over
time . Platelet adherence in no AZD6140 (white circles), +AZD6140 (red circles)
and reversibility of AZD6140 (yellow circles) is shown. The data presented are
representative of 6 separate experiments with error bars showing S.D.
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Table 1 shows the initial rates of platelet adhesion in normal and T2D subjects.
The entire image date from 20s interval was used for obtaining binding data.
Results represent mean ± S.D. from at least six independent experiments. The
initial rates were calculated from the kinetic plots of the platelet adhesion data.
Table 2 shows the maximum number of platelets attached to fibrinogen after 120
sec from normal and T2D subjects respectively. The number of platelets adhered
in control, AZD6140 pretreated and reversibility of AZD6140 are shown. Results
are expressed as number of platelets adhered ± S.D. from six independent
experiments.
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The effects of AZD6140 in clopidogrel-pretreated patients
The effect of AZD6140 on inhibition of ADP-induced platelet aggregation
and P2Y12 oligomers was assessed in clopidogrel-pretreated subjects. The
platelets from clopidogrel-pretreated subjects were exposed to AZD6140 to a
final concentration of 30

and platelet adhesion was assessed in flow

chambers. Interestingly, the platelets of clopidogrel-treated subjects were still
sensitive to ADP-induced aggregation (Figure 9A,B) suggesting further blockade
of P2Y12 receptor by AZD6140.
P2Y12 oligomer profiles on a limited number of subjects on clopidogrel
treatment were also determined as a function of AZD6140. The P2Y12 oligomers
were already disrupted in clopidogrel-treated subjects (Figure 9C-A) to mainly
dimers and some trimers. The early sucrose density fractions the oligomers were
intact. Upon introduction of AZD6140, P2Y12 were disrupted to mainly dimers in
all fractions (Figure 9C-B).
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Figure 9: The effect of AZD6140 on platelet aggregation in clopidogrel
treated T2D subject
(A) ADP-induced platelet adhesion on a PDMS coated with fibrinogen in flow
chamber perfused with whole blood containing fluorescently labeled platelets.
Images of platelet adhesion from no AZD6140 (Top panel) and AZD6140 (bottom
panel) are shown. Experiments were done at 37°C and images were captured on
Zeiss Axiovert 200 microscope using 5X objective at 20s intervals. Northern
Eclipse software (Empix, Canada) was used for image capture and quantification
of adhered platelets. (B) Kinetic plots obtained from representative raw images
from plavix-pretreated subject at 120s. ADP (20 pM) mediated aggregation of
platelets in whole blood, in the absence (red filled circles) or presence of
AZD6140 (30 pM) (open circles). (C) The effects of in vitro exposure to AZD6140
on the oligomerization status of the platelet ADP receptor P2Y12 were monitored
in human platelets from T2D on clopidogrel. (A) on clopidogrel (B) AZD6140 on
plavix.
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4. Discussion
The present study investigates the effect of AZD6140 treatment on the
platelet P2Y12 receptor and platelet responses mediated by this receptor. The
platelet P2Y12 receptor is principally localized to plasma membrane lipid rafts
and is mainly in oligomeric form (Figure 1, 2A & 2C). Previous studies had
reported that the irreversible P2Y12 receptor antagonist clopidogrel (act-met)
acts by disrupting P2Y12 receptor oligomers into monomers (Savi et al 2006). It
is postulated that formation of disulfide bond between thiol group of clopidogrel
(act-met) and extracellular cysteines of P2Y12 receptor induce the removal of
P2Y12 oligomers from cholesterol rafts. In both normal and T2D platelets,
AZD6140 resulted in disruption of P2Y12 oligomers to dimers and monomers
(Figure 2B&2D). The data presented here strongly support the hypothesis that
AZD6140 devoid of free thiols can also inhibit ADP-mediated signaling by
disrupting P2Y12 clustering on cholesterol rafts.
Curiously, our study indicates that effects of AZD6140 on P2Y12 oligomers
differs depending on whether the platelets are from normal or T2D from diabetic
subjects. In the case of normal platelets, AZD6140-mediated disruption resulted
in conversion of only -30% of the P2Y12 oligomers to dimers plus monomer. In
contrast, >50% of the P2Y12 oligomers were disrupted to dimers in T2D platelets
(Figure 3). The different responses obtained can be explained by the differences
in plasma membrane cholesterol content. In support of this we have shown here
and in previous studies that T2D platelets have ~3-fold higher levels of
cholesterol than those from normal individuals (Miersch et al 2007). As
cholesterol concentrations increase in T2D, cholesterol interacts with P2Y12 at
the dimmer interface weakening the dimer-dimer interactions. As a result, when
plasma membrane cholesterol is elevated, as in the case of the T2D platelet,
AZD6140 is able to disrupt the oligomers more easily than in normal platelets.
Previous studies have reported the reversible binding of AZD6140 to the
P2Y12 receptor. We investigated the reversibility of the drug on platelet function
and oligomeric status of the receptor. The initial rates of aggregation were
inhibited by ~30-fold and -2.5-fold in normal and T2D respectively (Figure 8,
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Tables 1, 2). Furthermore, the assessment of the reversibility of AZD6140 had
that shown ~50% and ~60 % of the initial rates in normal and T2D were retained
after the AZD washout. One possible explanation of these data is that although
our blot data (Figure 4) suggest that the P2Y12 tetramer is reformed after
removal of the drug, its conformation after exposure to AZD6140 might be
different from that of the native receptor.
Consistent with previous results (Storey et al 2007) we also observed that
platelets of clopidogrel treated subjects were still sensitive to AZD6140 and retain
the ability to adhere. The blockade of P2Y12 receptors by AZD6140 is supported
by additional ADP-induced platelet adhesion (Figure 9 A, B). The P2Y12
oligomers were already disrupted in clopidogrel (act-met) treated subjects, further
exposure to AZD6140 resulted in receptor dimers in all fractions (Figure 9C). In
summary, we have demonstrated the AZD6140 treatment results in P2Y12
oligomer dissociation. The differential effect of AZD6140 in normal and T2D
platelets correlates to the differences in platelet cholesterol levels.
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CHAPTER-7
Conclusions
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Nitric oxide is a gaseous signaling molecule that plays a key role in various
cellular processes such as smooth muscle cell relaxation, neurotransmission,
immune response and platelet aggregation. S-nitrosothiols are important
mediators of NO signaling, that increase the short half-life of NO and in general
exert similar physiological effects as that of NO. Protein disulfide isomerase is a
multifunctional enzyme that catalyzes isomerization, reduction and oxidation of
protein disulfides; several studies have also reported its role in S-nitrosation and
denitrosation. PDI localized to cell surface (csPDI) mediates release of NO from
S-nitrosothiols, reduces disulfide bonds as well as mediate entry of virus and
bacteria. The work presented here deals with various aspects of nitric oxide,
thiols, S-nitrosothiols and PDI under physiological and pathophysiological
conditions.
In Chapter 2, we demonstrate that sinapinic acid has the ability to
denitrosate S-nitrosothiols at pH 7.0 resulting in generating a free thiol and
denitrate plus denitrosates at pH 8 and 8.5. In addition, we also shown that
sinapinic acid degrades S-nitrosothiols, but it does not reduce disulfide bridges.
Furthermore, the fact that sinapinic acid produced nearly identical

S-

nitrosoprotein patterns/density, in comparison to ascorbate, in the biotin switch
analysis of RAW 264.7 cells and S-nitroso-BSA. Sinapinic acid detects basal
protein S-nitrosothiols identical to that of ascorbate from RAW 264.7 cells
indicating that sinapinic acid can readily replace ascorbate in the analysis of the
S-nitrosoproteome.
In Chapter 3, the key role of PDI in hypoxic vasodilation is demonstrated. Our
results show nitrite supporting S-nitrosation of PDI under normoxia but not under
hypoxia. In addition, this study also indicates that in RBCs, PDI can interact with
hemoglobin, as well as with the anion transporter (band 3) and the glucose
transporter (Glutl). Also, PDI has more affinity for RBC surface under
oxygenated conditions than under deoxygenated conditions, the exact apposite
was found for soluble S-nitrosated PDI. Our data support the hypothesis that PDI
can act as an acceptor of NO-equivalents from a variety of NOx-modified RBC
resident proteins such as Hb-(S)NO, SNO-AE1, SNO-Glut1 under normoxia. The
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RBC-surface PDI is then dislodged from the RBC surface under hypoxia to
shuttle NO-equivalents from RBC to its surroundings.
In Chapter 4, we show increased association of RFP-PDI with cells upon
oxidative stress. We further demonstrate that mixed disulfides are formed
between RFP-PDI and cell surface thiols that are susceptible to DTT. Our data
also show increase in endogenous PDI levels with oxidative stress that may
enhance cell surface association and control redox balance of surface thiols.
Taken together, our data indicate that RFP-PDI acts as cell surface oxidative
stress sensor.
Previous studies from our lab have shown that plasma membrane cholesterol
affects nitric oxide diffusion and signaling. In Chapter 5, we investigated if ER
stress resulting in unfolded protein response affects plasma membrane
cholesterol levels in normal cells. We show that induction of ER stress in
endothelial cells elevates intracellular and plasma membrane cholesterol. The
main findings of this study are that under conditions of ER stress, neutral
spingomylinase (NSMase2) the key enzyme in the control of plasma membrane
cholesterol levels was dysfunctional as a result of nitration of its tyrosine
residues. To further highlight the role of NSMase2, we showed that over
expression of the enzyme under conditions of ER stress could attenuate
cholesterol accumulation. On the contrary, inhibition of NSMase2 elevated
plasma membrane cholesterol. This study implicates the key role of NSMase2 in
ER stress-mediated increases in plasma membrane cholesterol.
In Chapter 6, the mode of action of AZD6140 on P2Y12 receptor is established.
The finding

herein show that AZD6140 devoid of free thiols inhibits ADP-

mediated signaling by disrupting P2Y12 clustering on cholesterol rafts. The
significance of this study is that it demonstrates the differential effect of AZD6140
in normal and T2D subjects and correlates to the differences in cholesterol levels
of platelets. Taken together, the studies confirm that AZD6140 yields reversible
and greater inhibition of platelet aggregation.

173

Future Directions:

Hypoxic Vasodilation: Recent studies have shown that H2S reacts with Snitrosothiols to form thionitrous acid (HSNO) that can freely diffuse the cell
membrane and transnitrosate hemoglobin. Studying S-nitrosation of RBC
membrane proteins and PDI mediated by HSNO would be important to determine
if H2S mediated signaling is a 02-dependent process and also raises the
possibility of cross talk between two.

NSMase2 and plasma membrane cholesterol: NSMase expression levels and
activity in cancer cells is largely unknown. Increased cholesterol levels were
shown associated with progression of cancer. Therefore, it would be interesting
to study the NSMase expression and activity in normal versus cancer cells and
correlate with plasma membrane cholesterol levels.

RFP-PDI oxidative stress sensor: Future directions include utilizing the RFPPDI probe in in-vivo studies to monitor oxidative stress. These studies would give
us overall indication of cell surface redox state and oxidative stress affect on thiol
dependent cell signaling pathways.
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